

## GENERAL INFORMATION

**03**COMMITTEES AND  
WELCOME**8**

CONGRESS INFORMATION

**12**

CONGRESS CENTRE LAYOUT

**14**

TRANSPORT INFORMATION

**17**

STAND UP FOR EPILEPSY

**18**

HISTORICAL EXHIBITION

## SCIENTIFIC PROGRAMME

**24**SCIENTIFIC PROGRAMME  
INFORMATION**28**

FULL WEEK TIMETABLE

**30**

SUNDAY 30TH SEPTEMBER

**38**

MONDAY 1ST OCTOBER

**48**

TUESDAY 2ND OCTOBER

**60**

WEDNESDAY 3RD OCTOBER

**70**

THURSDAY 4TH OCTOBER

## POSTERS

**85**

MONDAY 1ST OCTOBER

**111**

TUESDAY 2ND OCTOBER

**137**

WEDNESDAY 3RD OCTOBER

## OTHER INFORMATION

**166**

BURSARIES

**167**

SPEAKERS LIST

**182**LIST OF EXHIBITORS  
AND FLOORPLAN

# GENERAL INFORMATION

## INTERNATIONAL ORGANISING COMMITTEE

### CO-CHAIRS

MEIR BIALER  
*(ISRAEL)*

PHILIP SMITH  
*(UK)*

### MEMBERS

NORMAN DELANTY  
*(IRELAND)*

ALLA GUEKHT  
*(RUSSIA)*

REETTA KÄLVIÄINEN  
*(FINLAND)*

GEORGE KOSTOPOULOS  
*(GREECE)*

KRISTINA MALMGREN  
*(SWEDEN)*

SIMON SHORVON  
*(UK)*

TORBJÖRN TOMSON  
*(SWEDEN)*

## SCIENTIFIC ADVISORY COMMITTEE

### CHAIR

SIMON SHORVON  
*(UK)*

### MEMBERS

MEIR BIALER  
*(ISRAEL)*

JOHN DUNCAN  
*(UK)*

SVEIN JOHANNESSEN  
*(NORWAY)*

WOLFGANG LÖSCHER  
*(GERMANY)*

KRISTINA MALMGREN  
*(SWEDEN)*

PHILIP SMITH  
*(UK)*

TORBJÖRN TOMSON  
*(SWEDEN)*

# WELCOME

Dear Colleagues,

On behalf of the International Organising Committee, we welcome you to the ILAE's 10th European Congress on Epileptology (ECE).

The ECE London 2012 congress has all the ingredients of a landmark event in the epilepsy calendar. The programme will cover cutting-edge research in the field of epilepsy through presentations from the leaders in the field, including lectures by world-renowned scientists on topics at the interfaces of epilepsy. The year 2012 is the centenary of the introduction of phenobarbital for the treatment of epilepsy, and the congress will strongly focus on drug therapy. The schedule will also feature a coordinated clinical teaching programme designed to inform and improve specialist clinical practice.

Four main themes run through the programme: basic science of epilepsy; imaging and surgery; clinical epileptology and neuropsychiatry; and clinical pharmacology and drug therapy. In all themes, paediatric issues will be considered alongside those of adult epileptology. There will also be a strong emphasis on high quality poster presentations.

This promises to be an exceptional congress. London is one of the world's great cities and the congress follows shortly after the 2012 Olympic Games, with the Olympic stadium near the congress centre. There will be an Olympic feel, and we plan a number of Olympic style events. The congress, like the Olympic Games and like London itself, aims to inspire, and will be a venue where you can enjoy and learn.

With warm regards,



Philip Smith  
Co-Chair  
International Organising Committee



Meir Bialer  
Co-Chair  
International Organising Committee

Dear Colleagues,

As President of the International League Against Epilepsy, it is my pleasure to welcome you to London for the 10th European Congress on Epileptology.

The European Congress on Epileptology has grown considerably in stature in recent years to become a staple in the calendars of epileptologists and neurologists across Europe, and indeed, the world. The next five days will bring you the very best in cutting-edge epilepsy research, lectures from world-renowned scientists, as well as many exciting features which are new to the congress.

London itself needs little introduction, being one of the world's leading centres of culture, commerce, fashion and trade. Over 14 million people call the UK capital their home, making it noisy, exciting, and never, ever dull. With so many sights and sounds to pique the interest of the wandering epileptologist, there is something to suit every taste and background.

In this Congress, we will recognize the long standing contributions of several European chapters founded many years ago. We will celebrate the host chapter, UK, founded more than 100 years ago; the Netherlands, founded 75 years ago; and the chapters from France, Israel, Italy, Sweden and Switzerland with over 50 years of service to people with epilepsy in their countries. Indeed, it is a great opportunity to commemorate country wide efforts by many individuals selflessly volunteering and collaborating to improve the quality of life for all persons with epilepsy regardless of gender and age, through education, training, and research.

I trust that your experience will be nothing less than invaluable, enlightening and unforgettable!

With warm regards,



Solomon L. Moshé



# Download the 10th ECE mobile app (free)

## Free WiFi is available in the Boulevard of ICC London ExCeL.



Congress App supported by:



Join the Conversation - Are you on Twitter?

To join the online conversation you can follow the Epilepsy Congress on Twitter by following @EpilepsyCongres. The official hashtag (#) for the 10th European Congress on Epileptology on Twitter is #ece2012

### ICC LONDON EXCEL

One Western Gateway  
Royal Victoria Dock  
London  
E16 1XL  
UK

Tel: +44 (0)20 7069 5000  
Fax: +44 (0)20 7069 4747  
Web: [www.excel-london.co.uk](http://www.excel-london.co.uk)  
DLR stop: Prince Regent



## CONGRESS INFORMATION

### REGISTRATION

The Registration Area is located in the East Boulevard of ICC London ExCeL. Congress bags should be collected on-site in the Registration Area upon exchange of the voucher.

Please note that name badges must be worn at all times.

### EXHIBITION AREA

The Exhibition Area is situated in the Capital Hall on Level 0 of ICC London ExCeL.

Exhibition opening times are listed below on the Facilities Timetable Overview.

### FACILITIES TIMETABLE OVERVIEW

	SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY
REGISTRATION	07:30 - 19:00	07:00 - 18:00	07:00 - 18:00	07:00 - 18:00	07:00 - 13:30
COFFEE BREAKS	-	11:00 - 11:30 16:00 - 16:30	11:00 - 11:30 16:00 - 16:30	11:00 - 11:30 16:00 - 16:30	10:30 - 11:00
LUNCH	-	13:00 - 14:30	13:00 - 14:30	13:00 - 14:30	-
POSTERS	-	10:00 - 17:00	10:00 - 17:00	10:00 - 17:00	-
EXHIBITION	-	09:00 - 17:00	09:00 - 17:00	09:00 - 17:00	09:00 - 12:00
SPEAKERS' ROOM	08:00 - 19:00	07:00 - 18:00	07:00 - 18:00	07:00 - 18:00	07:00 - 15:00

### LUNCHES & COFFEE BREAKS

Lunches and coffee breaks will be served in the Exhibition Area on Monday - Thursday morning.

### LANGUAGE

The official language of the congress is English; please note that translation facilities will not be provided.

### CERTIFICATES OF ATTENDANCE

Certificates of Attendance can be collected from the registration desk from Tuesday 2nd October onwards during registration opening hours.

### CONGRESS SECRETARIAT

Members of the Congress Secretariat may be contacted at anytime at the Registration Area. For queries arising after the congress, please contact:

10th ECE London 2012  
 ILAE Congress Secretariat  
 7 Priory Hall  
 Stillorgan  
 Dublin 18  
 Ireland  
 Tel +353 1 2056720  
 Fax +353 1 2056156  
 Email london@epilepsycongress.org

### CONGRESS BAGS



The congress bags were sourced from Township Patterns, which is a unique social enterprise producing eco-friendly conference bags. The range is made by fair-trade women's cooperatives in the townships of South Africa. Each item sold brings economic development and opportunity to the women and their communities.

---

## CLOAKROOM

---

A cloakroom for coats and luggage is located on Level 0 of ICC London ExCeL.

---

## INTERNET CENTRE

---

The Internet Centre is located by the Poster Area in the Capital Hall on Level 0 of ICC London ExCeL.

---

## LIABILITY AND INSURANCE

---

The International League Against Epilepsy (ILAE) and its agents do not accept any liability whatsoever for death, personal injury, accidents, theft, loss or damage to persons, property or belongings of participants or accompanying persons, either before, during or following the congress, tours or their stay in London. It is therefore recommended that participants arrange their own personal health, accident and travel insurance.

---

## CME ACCREDITATION

---

The 10th European Congress on Epileptology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Please visit [www.uems.net](http://www.uems.net) for further information.

The 10th ECE is designated for up to 21 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, please see the details on the AMA website, [www.ama-assn.org](http://www.ama-assn.org), for further details.

The statement of accreditation will be incorporated into the attendance certificates issued to fully registered delegates during the congress. Please contact the Congress Secretariat in the Registration Area if you require further information on the issuance of CME accreditation.

---

## BURSARIES

---

74 abstracts have been selected for bursaries by the Scientific Advisory Committee.

The bursaries, covering flights, accommodation and registration are provided by the ILAE Commission on European Affairs. The list of awardees is available on page 166.

---

## WELCOME CEREMONY AND RECEPTION

---

All delegates are invited to attend the Welcome Ceremony which will begin at 18:30 on Sunday 30th September in the Auditorium. This will be followed by a Welcome Reception open to all participants.

A highlight of the Welcome Ceremony is the showing of a documentary video giving an impressionistic, and at times irreverent, view of the ECE programme and of London. The video was recorded during an ILAE UK Chapter scientific meeting and meeting of the ECE Scientific Advisory Committee (SAC).

Interviews were recorded with students working in the field of epilepsy in London, senior members of the UK chapter, attendees at the scientific meeting and SAC members – with some added footage supplied by Monty Python amongst others – to all of whom we express our thanks. The video was produced by Beata Romanowski and Simon Shorvon.

---

## SPEAKERS' ROOM





---

The Speakers' Room is located on the Level 2 Mezzanine of ICC London ExCeL. Opening times are listed on the Facilities Timetable Overview.

Facilities to review and amend presentations are available to all speakers and technical assistance will also be provided in this room.

Please note that all speakers should submit their final PowerPoint presentations to the desk in the Speakers' Room no less than 3 hours in advance of their session. Speakers at early morning sessions are required to submit their material no later than 17:00 on the evening before their session is scheduled.

CONGRESS CENTRE LAYOUT



## LONDON TRANSPORT INFORMATION

### LONDON UNDERGROUND

Or 'the Tube' as it is universally known, is normally the quickest and easiest way of getting around London. London is served by 12 Tube lines. Underground trains on all lines run every few minutes between 05:30 and 00:30 from Monday to Saturday, and between 07:30 and 23:30 on Sundays.

### DOCKLANDS LIGHT RAILWAY

The Docklands Light Railway (DLR) is a light-rail public transport metro for the redeveloped Docklands area of eastern London. The DLR is separate from the London Underground. The two systems are, however, integrated wherever they meet, and share a single ticketing system. The DLR appears on the London Underground's Tube map.

### LONDON BUSES

London buses are a quick, convenient and cheap way to travel around; they also offer plenty of sightseeing opportunities en route. The Central London bus guide will be sufficient to navigate the bus system; this map is available from travel information centres.



East London Tube Map

### TRANSPORT TO ICC LONDON EXCEL

By underground, the Jubilee line is recommended as the quickest route from Central London. Take the Tube to the Canning Town station, and then change on to a DLR train to the Prince Regent for ExCel station. Public bus services 147 and 241 depart from bay B of Canning Town station to Custom House (access to the venue is via the DLR footbridge).

Additionally, a fully signposted walking route is provided from the main exit of Canning Town bus station for anyone who wishes to complete their journey to the venue by foot. Blue directional signs guide you to the main west entrance of ExCel London. The walk takes approximately 12-15 minutes.

### TAXIS

London cabs are available at the taxi ranks, located at the west and east entrances. Fares are charged on a meter basis at the end of the journey. Please refer to the congress centre plan to locate the taxi rank.

## LONDON TRANSPORT INFORMATION

### OYSTER CARDS



Delegates may find the Oyster Card is a useful way to purchase transport fares. Oyster is a plastic smartcard which can be used instead of paper tickets. Oyster is the cheapest way to pay for single journeys on bus, Tube, tram, DLR, London Overground and most National Rail services in London.

- 01| Purchase an Oyster Card when you arrive in London (airport, train or any Underground station). Load it with some credit and touch in and touch out. Note that the fare deducted from the card will then be much cheaper than individually priced tickets. In fact, the vast majority of Londoners use Oyster Cards every day.
- 02| For people staying more than five days in London and who will use public transport every day, you can use the 7 Day Travel Card (this can also be loaded onto an Oyster Card).

\*\*\* Remember to 'touch-off' with your Oyster Card on arrival at your destination\*\*\*

### CABLE CAR OVER THE THAMES



Running between North Greenwich and the Royal Docks, and with a journey time of less than 10 minutes, the cable car provides a fun journey over the river Thames. Please note that Oyster Cards can be used on the cable cars.

## STAND UP FOR EPILEPSY - PHOTOGRAPHY EXHIBITION



The ILAE, through the Taskforce on Sports and Epilepsy, will be launching an exciting and innovative new photography exhibition during the congress; Stand Up For Epilepsy. The collection features people with epilepsy alongside some of the biggest names from the sporting world. The collection will be on display in the lobby area of Level 3 for the duration of the congress and is free to all congress delegates.



## HISTORICAL EXHIBITION

### THE BEGINNING OF THE END OF THE FALLING SICKNESS: EPILEPSY AND ITS TREATMENT IN LONDON 1860 - 1910

'Few persons can have been long familiar with the streets of any great European city without having observed, more or less frequently, a desolate wretch writhing on the ground, foaming at the mouth, hissing between the teeth, lacerating the tongue by frenzied clappings, drawing up all




The consultant staff of the National Hospital for the Paralysed and Epileptic in 1886

the limbs convulsively, and then, perhaps smitten into rigidity, as if suddenly petrified. They have been told it was an epileptic patient, and have passed on ... Is it credible that none [no institution] exists for the cure or alleviation of the epileptic and paralytic ?'

This was written in the Daily Telegraph (the London newspaper) on November 2nd 1859, reporting the foundation of the 'National Hospital for the Paralysed and Epileptic' at Queen Square, and is the starting point of this historical exhibition, prepared for the 10th European Congress on Epileptology.

The inclusion of a historical exhibition is a new ECE feature, and one which it is to be hoped will be repeated in subsequent years. This exhibition is composed of about 70 original items – books, photos, letters and drawings of historical importance - relating to the development of epileptology in London between the years 1860 - 1910. The exhibits are drawn from the historical archives and libraries at Queen Square and other London institutions. A free 64 page catalogue of the exhibition is also available to all delegates. The exhibit and the catalogue were compiled and prepared by Simon Shorvon and Louise Shepherd.

The title of the exhibition is a reference to Oswei Temkin's famous book on the history of epilepsy (The Falling Sickness). The last chapter of his book was called 'The End of the Falling Sickness', and referred to the period starting around 1860, for it was from then, for the next half-century, that epilepsy shed its skin of pre-scientific superstition and emerged in as what is recognisable as its modern form. This was the 'Age of Hughlings Jackson', as Temkin put it, and London was a major



Sir William Gowers

centre for this transformation. It was there that a number of physicians and surgeons changed the conceptual basis of epilepsy, that the first effective drug treatment of epilepsy was discovered, that the first hospital was established specifically for the treatment of epilepsy, that the cortical localization of epileptic activity was demonstrated, and that the first surgical operation for epilepsy was carried out. Through these activities, furthermore, epilepsy rose from a condition of general obscurity to become the hierophant of brain disease, and a central concern of neurology, of medicine, and of neuroscientific thought.



John Hughlings Jackson

The small exhibition and catalogue are designed to illustrate the evolution of the concepts and treatment of epilepsy in London in this most dynamic period in the history of epileptology, with sections on: Epilepsy in 1860, the foundation of the National Hospital for the Paralysed and Epileptic, pioneering early physicians, John Hughlings Jackson (1835-1911), Sir David Ferrier (1843-1928), Sir William Gowers (1845-1915), Sir Victor Horsley (1857-1916), William Aldren Turner (1864-1945) and the London connections to the ILAE and EPILEPSIA, the National Society for the Employment of Epileptics and the Chalfont Centre, bromides and other medicinal therapies of the period.

Simon Shorvon

[The Historical Exhibition is located on Level 1 in front of Hall B.](#)

# SCIENTIFIC PROGRAMME

SUNDAY 30TH SEPTEMBER

MONDAY 1ST OCTOBER

TUESDAY 2ND OCTOBER

WEDNESDAY 3RD OCTOBER

THURSDAY 4TH OCTOBER

SESSIONS, SYMPOSIA

SPECIAL LECTURES

DEBATES, ECE FORUMS,

OLYMPIAD, COURSE

Dear Colleagues,

The Scientific Advisory Committee (SAC) has worked hard to make an exceptional programme for the 10th ECE London 2012. Our focus has been on the sometimes contrasting objectives of including the most innovative and cutting edge research and science (our primary goal), covering as broad a range of epilepsy topics as possible, and providing a high quality teaching experience to improve epilepsy management in the clinic. We have wanted to make the programme both instructive and entertaining, and thus to inspire our colleagues and to raise the profile of European epilepsy so that it is recognised as primus inter pares.

To these ends, we have constructed a full and high quality programme of around 300 presentations. There are in total 4 main sessions (plenary themes), 6 special symposia, 42 sessions, 31 ECE forums, 9 sponsored symposia, 3 debates, 15 platform sessions and 3 "how to do it" sessions.

There are number of features:

- Plenary themes, with associated platform and poster sessions, of: basic and translational science, neuroimaging and surgery, clinical epileptology and neuropsychiatry, and clinical pharmacology and drug therapy.
- Nobel Lecture Series - lectures by a Nobel laureate/ Fields medallist
- Debates - entertaining debates on controversial issues
- ECE Forums - interactive sessions with an informal atmosphere
- Epilepsy Course – a coordinated advanced course on the 'Causes of epilepsy'
- Epilepsy Olympiad - an epilepsy tournament for competing national chapters
- Chairs' Symposium - entitled 'The borderland of epilepsy'
- '100 barbiturate years' - a special symposium to celebrate the centenary of the discovery of the antiepileptic action of phenobarbital
- Starred poster presentations

- A documentary film session
- An historical exhibit entitled: The beginning of the end of the falling sickness: epilepsy and its treatment in London 1860-1910

The programme itself is "colour-coded" into 8 categories as a quick guide to help navigation.

The London 2012 Olympics finished a few weeks ago, with some events held in the congress centre. We will continue the Olympic theme at the congress. This will include the Epilepsy Olympiad and an exhibition of photos from the ILAE's Stand Up For Epilepsy project.

Finally, there is London, an extraordinary city fully worth exploring. As Dr Johnson, the famous essayist and moralist, remarked in 1777: "No Sir, when a man is tired of London, he is tired of life; for there is in London all that life can afford". This is still true today and we hope you will, at the London 2012 Congress, have a refreshing, instructive and entertaining time.

With best wishes,



Simon

Simon Shorvon

Simon Shorvon  
Chair,  
Scientific Advisory Committee

## SCIENTIFIC PROGRAMME INFORMATION

### SESSIONS AND SPECIAL SYMPOSIA

The scientific sessions form the main part of the congress. These sessions were selected from the large number proposed by ILAE members, and are chosen to represent the best of European and global epileptology. There is a different plenary theme each day - basic and translational science, neuroimaging and surgery, clinical pharmacology and drug therapy, and clinical epileptology and neuropsychiatry - and plenty of other sessions covering the full range of epileptology.

Two special symposia are also taking place. The Chairs' Symposium explores "The borderland of epilepsy", a title based of course on Gowers classic treatise of 1907, and features a number of interesting aspects at the periphery of epilepsy. "One hundred barbiturate years" celebrates the discovery of the antiepileptic effect of phenobarbital, made in 1907. This drug has had a profound effect on the course of epilepsy therapy and has changed the lives of many. This symposium considers the legacy of the barbiturates, their past and their future.

Other sessions include three 'How to do' sessions devoted to drug therapy, a session concerned with advocacy and what the professionals need to know to improve healthcare and research, a documentary film session on the theme of epilepsy, a prize symposium and a neurobiology symposium prepared by the ILAE Commission on Neurobiology.

### NOBEL PRIZE AND FIELDS MEDAL LECTURES

We are delighted to announce that Professor Sir Peter Mansfield, Nobel Prize laureate for medicine in 2003, will lecture on MRI The Early years (Tuesday 2nd October) and Professor Sir William Timothy Gowers, Fields Medallist in 1998 will lecture on Open Access and Open Science (Monday 1st October). The intention of the Scientific Advisory Committee is to provide inspiration for our young colleagues to excel in research. Alfred Nobel himself had epilepsy, so one would like to think that he would have approved of this idea. Epilepsy has yet to have its own Nobel laureate but we all hope that by bringing the top minds in science to our congress, the meeting will play a small part in motivating and inspiring our researchers. These lectures should be a highlight of each day.

### EPILEPSY COURSE - THE CAUSES OF EPILEPSY

On Thursday 4th October, the last day of the congress, the ILAE UK Chapter is hosting a major epilepsy course on "The causes of epilepsy". The event runs all day from 07:30 - 18:30, giving delegates the option to come and go. As well as 20-minute talks, each with 10 minutes for questions, there will be a guest lecture on "genetic mechanisms in epilepsy" and an epilepsy-themed Clinico-Pathological Conference. We shall encourage audience questions and interaction.

The event is aimed principally at epilepsy specialists, and is open to all conference delegates. Please see pages 76-77 for the full programme for this event.

*Note: No additional registration or payment required for full congress delegates.*

### ECE FORUMS

The ECE Forums are another innovation in the scientific programme of the congress. They are sessions in which the selected topics can be explored and discussed in a workshop style. The topics were selected 'bottom-up' from proposals made by members worldwide, and are a potpourri of subjects which generally focus on cutting-edge or controversial aspects of epilepsy work. The sessions are intended to be creative with an emphasis on interaction and informality. A total of 31 forums are being held and all are freely open to all conference delegates.

### EPILEPSY OLYMPIAD



Inspired by the spirit of the London Olympics, an 'Epilepsy Olympiad' will be another feature of the London 2012 congress. The Olympiad takes the form of an epilepsy knock-out quiz, and the competitors are 20 or so national teams, each with 4 members selected by their national ILAE chapter. The competition will take place in three sessions held over three days.

In the first session, on Monday 1st October (11:30 - 12:30, Hall B), all teams compete in the group round of the competition, taking the form of a series of multiple choice questions. The 8 top-scoring teams from this round will then enter the knockout rounds, with the

format based on the famous British television show 'University Challenge' in which 2 teams at a time compete against each other, with starter questions awarded to the team that gets to the buzzer first, and then bonus questions.

The quarter-finals will be held on Tuesday 2nd October (14:30 – 16:00, Hall B) and the 4 top-scoring teams then proceed to the semi-final round. On Wednesday 3rd October (16:30 – 18:00, Hall B), the two semi-finals to select 2 finalists, and then the final round will be held. The questions have been prepared by Simon Shorvon and Phil Smith. Some are serious, many are difficult and some are more light-hearted – but all are on the topic of 'Epilepsy'.

Some questions will be historical and some contemporary, and there will be music and picture questions too. The rounds are open to audience participation, with the audience providing raucous support of their national team. The Olympiad should provide some fun and entertainment, but should also be a great learning experience!

---

## ECE DEBATES

---

The ECE debates are a new feature of the congress. The debates will be provocative and thought-provoking, and we hope also entertaining. The audience will be invited to question the debaters and to vote in some of these sessions; the sessions should be enjoyable but also have a serious point. One of the debates – the Michael Debate – is a special session arranged by the Michael Foundation, which is celebrating its 50th Anniversary.

---

## LECTURES AT THE INTERFACE

---

Special lectures covering topics at the interface of epilepsy and other scientific disciplines were invited, to broaden the scope of epilepsy, by celebrated figures in their fields.

---

## PRIZE SYMPOSIUM

---

The awardees of the the four most prestigious prizes in epileptology in 2012 will present their work during the Symposium of Excellence in Epileptology (14:30 - 16:00, Tuesday 2nd October).

The European Epileptology Award, which has been awarded to Christian Elger, is a biannual award for an outstanding contribution to European epileptology.

The Morris-Coole Epilepsia Prize was inaugurated 5 years ago, as an annual prize awarded to the lead researcher who, in the opinion of the judging panel, published an outstanding

paper in Epilepsia in the previous calendar year. The goal of the prize is to inspire young researchers to devote a career in research into the basic scientific or clinical problems of epilepsy. It is now funded by the ILAE, with the insignia presented by the Morris-Coole Trust. The 2012 prize has been awarded to Sebastian Schuchmann, who will present his work on "Respiratory alkalosis in children with febrile seizures" during the symposium.

Lectures will also be given by Tom Panayiotopoulos, winner of the British Branch - Excellence in Epilepsy Award 2012 and Pasquale Striano, winner of the 2012 CEA Young Investigator Award.

---

## AWARDS

---

We would like to congratulate the following awardees:

- Christian Elger - 2012 European Epileptology Award
- Tom Panayiotopoulos - 2012 British Branch Excellence in Epilepsy Award
- Sebastian Schuchmann - 2012 Morris-Coole Epilepsia Prize
- Ann Little - 2012 CEA Service Award
- Alla Guekht - 2012 CEA Education Award
- Pasquale Striano - 2012 CEA Young Investigator Award

---

## PLATFORM AND POSTER PRESENTATIONS

---

60 of the best abstracts have been selected by the Scientific Advisory Committee for oral presentation. They will be presented in platform sessions.

Special attention has also been given to poster presentation during the congress. Guided poster tours will be held on Monday - Wednesday at lunchtime, giving an opportunity to all authors to present their work and for delegates to ask questions.

A number of posters which have been selected by the Scientific Advisory Committee based on the quality of the work will also be shown to the audience during the morning and afternoon coffee breaks.

PROGRAMME AT A GLANCE

SCIENTIFIC PROGRAMME

	Sunday 30th September	Monday 1st October	
07.30-08.00		Sessions 07.45-09.00	
08.00-08.30	European Chapter Convention	"How to do it" course 07.45-09.00	
08.30-09.00		Eisai Symposium	
09.00-09.30		Set up	Chairs' Symposium 09.00-11.00
09.30-10.00			
10.00-10.30		Coffee Break and Best Posters	
10.30-11.00			ECE Forums 11.30 - 13.00
11.00-11.30		Debate 11.30-12.30	
11.30-12.00			Olympiad 11.30-12.30
12.00-12.30		Platform Sessions 11.30-12.30	
12.30-13.00			Lunch / Posters 12.30-14.00
13.00-13.30	The Fields Medal Lecture 13.30-14.30		
13.30-14.00		Sessions 13.30-15.00	
14.00-14.30	Neurobiology Symposium 13.30-15.00		
14.30-15.00		Neuro Sigma Symposium 13.30-15.00	
15.00-15.30	Sessions 15.00-16.30		
15.30-16.00		Sessions 14.30-16.00	
16.00-16.30	100 barbiturate years 14.30-16.00		
16.30-17.00		Coffee Break and Best Posters	
17.00-17.30	ViroPharma Symposium 16.30-18.00		
17.30-18.00		Eisai Symposium 16.30-18.00	
18.00-18.30	Welcome Ceremony 18.30-19.30		
18.30-19.00		GlaxoSmithKline Symposium 18.30-20.00	
19.00-19.30	Reception 19.30-20.30		
19.30-20.00			
20.00-20.30			

	Tuesday 2nd October	Wednesday 3rd October	Thursday 4th Oct
	Sessions 07.45-09.00	Sessions 07.45-09.00	
	"How to do it" course 07.45-09.00	"How to do it" course 07.45-09.00	
	Elekta Symposium	EGI Symposium	
	Set up	Set up	ECE Forums
	ECE Forums 09.00-10.30	ECE Forum 09.30-11.00	ECE Forums
	Coffee Break	Coffee Break and Best Posters	ECE Forums
	Debate 11.30-12.30	Platform Sessions 11.30-12.30	Platform Sessions 11.30-12.30
	The Nobel Prize Lecture 13.30-14.30	Lectures at the Interface 13.30-14.30	ECE Forums
	Olympiad 14.30 - 16.00	Prize Symposium 14.30-16.00	Sessions 16.30-18.00
	Sessions 14.30-16.30		
		UCB Pharma Symposium 16.30-18.00	Sessions 16.30-18.00
	Coffee Break and Best Posters		
		Olympiad Final 16.30-18.00	Olympiad Final 16.30-18.00

SCIENTIFIC PROGRAMME

## SCIENTIFIC PROGRAMME

SUNDAY 30<sup>TH</sup> SEPTEMBER

	Auditorium 2000 pax	Hall C 400 pax	Hall D 420 pax
09.30-10.00			
10.00-10.30			
10.30-11.00			Febrile Infection Related Epilepsy Syndrome (FIRES)
11.00-11.30			
11.30-12.00		HCN channels as targets for antiepileptic and antiepileptogenic therapies	Neurobiological substrates of epileptic zones
12.00-12.30			
12.30-13.00			
13.00-13.30			
13.30-14.00	Epilepsy surgery in childhood - What can be achieved?		Can imaging differentiate between seizure focus in, and spread to the frontal lobes?
14.00-14.30		NeuroSigma Symposium	
14.30-15.00			
15.00-15.30		Are antiepileptic drugs harmful to developing brain?	Electroclinical manifestations elicited by intracerebral electric stimulation of motor cortex and motor seizures
15.30-16.00			
16.00-16.30			
16.30-17.00	ViroPharma Symposium		
17.00-17.30			
17.30-18.00			
18.00-18.30			
18.30-19.00	Welcome Ceremony		
19.00-19.30			
19.30-20.00	Reception		
20.00-20.30			

	Hall E 385 pax	Hall F 385 pax	Hall G 340 pax		
08.00-08.30					
08.30-09.00					
09.00-09.30		European Chapter Convention			
09.30-10.00					
10.00-10.30					
10.30-11.00					
11.00-11.30					
11.30-12.00	The blood-brain barrier hypothesis in drug resistant epilepsy			Interneurons	
12.00-12.30					
12.30-13.00					
13.00-13.30					
13.30-14.00	Epilepsy and consciousness	Is MEG the only investigation we need prior to surgery?	Neurobiology symposium		
14.00-14.30					
14.30-15.00					
15.00-15.30	Emotion and social cognition in epilepsy	Ictal video-EEG characteristics of absence seizures in various epileptic syndromes	Advances in seizure control by targeting novel channels and receptors		
15.30-16.00					
16.00-16.30					

PHARM

PAED

**ECE Forum:** FEBRILE INFECTION RELATED EPILEPSY SYNDROME (FIRES): CLINICAL PRESENTATION, PATHOPHYSIOLOGICAL MECHANISMS AND TREATMENT STRATEGIES

10:00 - 11:30, Hall D

Chair: *F. Vigevano (Italy)*

*N. Specchio (Italy), R. Nabbout (France), E. Trinko (Austria)*

BASIC

**ECE Forum:** NEUROBIOLOGICAL SUBSTRATES OF EPILEPTIC ZONES

11:30 - 13:00, Hall D

Chairs: *J. Jefferys (UK), P. Jiruska (UK)*

Does understanding of neurobiological substrates of epileptic zones matter from clinical perspective?

- *P. Marusic (Czech Republic)*

Interictal spikes as markers of ictogenesis: implications of location and mechanisms of generation - *M. de Curtis (Italy)*

High-frequency oscillations as an electrophysiological marker of pathological reorganization in the epileptic brain - *R.J. Staba (USA)*

Ictogenesis: macroseizures vs. microseizures? - *M. Stead (USA)*

BASIC

**ECE Forum:** INTERNEURONES!

11:30 - 13:00, Hall G

Chairs: *R. Köhling (Germany), A. Trevelyan (UK)*

*M. Walker (UK), A. Trevelyan (UK), M. Avoli (Canada), E. Aronica (Netherlands), F. Wendling (France),*

*K. Kaila (Finland), R. Köhling (Germany)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

BASIC PHARM

**ECE Forum:** HCN CHANNELS IN EPILEPSY:

EVIDENCE FROM ANIMAL MODELS AND HUMAN GENETICS

11:30 - 13:00, Hall C

Chair: *N. Poolos (USA)**N. Poolos (USA), M. Shah (UK), J. DiFrancesco (Italy)*

BASIC PHARM

**ECE Forum:** BLOOD-BRAIN BARRIER DYSFUNCTION IN EPILEPSY: MECHANISMS AND DIAGNOSTIC TOOLS

11:30 - 13:00, Hall E

Chair: *N. Marchi (USA)**T. Granata (Italy), M. Koepp (UK), M. Natoli - Lerner (France), H. Potschka (Germany), A. Vezzani (Italy), D. Janigro (USA), P. Fabene (Italy)*

PSYCH NPh&amp;Im

**Session:** CAN IMAGING DIFFERENTIATE BETWEEN SEIZURE FOCUS IN, AND SPREAD TO THE FRONTAL LOBES?

13:30 - 15:00, Hall D

Chairs: *M. Koepp (UK), T. O'Brien (Australia)*Frontal lobe (dys)functions in JME - *C. Vollmar (UK)*Consequences of TLE for frontal lobe functions - *P. Boon (Belgium)*Seizure-focus or spread of activity: fronto-temporal connectivity in FLE - *M. Centeno (UK)*

BASIC PSYCH

**Session:** EPILEPSY AND CONSCIOUSNESS

13:30 - 15:00, Hall E

Chairs: *M. Mula (Italy), A. E Cavanna (UK)*Epilepsy and the global workspace theory of consciousness - *F. Bartolomei (France)*Alterations of consciousness during focal and generalized seizures - *S. Seri (UK)*The default-mode network and consciousness in epilepsy - *K. Detyniecki (USA)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

SURG PAED PHARM

**Session:** EPILEPSY SURGERY IN CHILDHOOD - WHAT CAN BE ACHIEVED?

13:30 - 15:00, Auditorium

Chairs: *B. Rydenhag (Sweden), B. Dalla Bernardina (Italy)*The scope of childhood epilepsy surgery – What and when to refer - *T. Polster (Germany)*Neurodevelopmental outcomes – Realistic expectations? - *H. Cross (UK)*What can we expect with medication – Is there an optimal time for withdrawal? - *K.P.J. Braun (Netherlands)*

BASIC

**Session:** NEUROBIOLOGY SYMPOSIUM

13:30 - 15:00, Hall G

Chair: *A. Nehlig (France), A.M. Vezzani (Italy)*West Syndrome/ IS - *A. Galanopoulou (USA)*Tuberous sclerosis - *A. Galanopoulou (USA)*Dravet Syndrome - *M. Mantegazza (Italy)*Progressive myoclonus epilepsy, EPM1 - *A. E. Lehesjoki (Finland)*

SURG PSYCH NPh&amp;Im

**Session:** IS MEG THE ONLY INVESTIGATION WE NEED PRIOR TO SURGERY?

13:30 - 15:00, Hall F

Chairs: *F. Rugg-Gunn (UK), J. Engel (USA)*Replacing intracranial EEG recordings with MEG - *S. Rampp (Germany)*Replacing the sodium amytal test and cognitive fMRI for the evaluation of language and memory function with MEG - *F. Rugg-Gunn (UK)*Current practice, gaps and opportunities in pre-surgical evaluation - *K. Hamandi (UK)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

**Satellite Symposium: NEUROSIGMA: TRIGEMINAL NERVE STIMULATION FOR TREATMENT OF EPILEPSY AND NEUROPSYCHIATRIC DISORDERS**

14.00 - 15.00, Hall C

Chair: *CM DeGiorgio (USA)*

TNS background: results from neuro-anatomic, animal and PET studies – *CM DeGiorgio (USA)*

Clinical trials of eTNS for drug resistant epilepsy – *CM DeGiorgio (USA)*

Clinical trials of eTNS for depression and PTSD – *IA Cook (USA)*

The NeuroSigma eTNS System: Patient perspectives, device function, availability – *CP Kealey (USA)*

GENET BASIC

**Session: ADVANCES IN SEIZURE CONTROL BY TARGETING NOVEL CHANNELS AND RECEPTORS**

15:00 - 16:30, Hall G

Chairs: *D. Henshall (Ireland), U. Heinemann (Germany)*

Targeting acquired Ca<sup>2+</sup>-channelopathies in epilepsies - *A.J. Becker (Germany)*

Targeting P2X7 receptors for seizure control - *D.C. Henshall (Ireland)*

Targeting NPY receptors in epileptogenesis - *M. Kokaia (Sweden)*

NRSF-dependent HCN1 channelopathy in temporal lobe epilepsy - *C. Bernard (France)*

BASIC PAED PHARM

**Session: ARE ANTIEPILEPTIC DRUGS HARMFUL TO DEVELOPING BRAIN?**

15:00 - 16:30, Hall C

Chairs: *H. Kubova (Czech Republic), F. Jensen (USA)*

Critical periods of vulnerability for the developing nervous system: evidence from humans and rodent models - *G.L. Holmes (USA)*

Are antiepileptic drugs neurotoxic during early postnatal development? - *C. Ikonomidou (USA)*

Long-term consequences of early exposure to antiepileptic drugs - *A. Nehlig (France)*

Do antiepileptic drugs affect normal postnatal development and brain excitability? - *H. Kubova (Czech Republic)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

SURG NPh&Im

**Session: ELECTROCLINICAL MANIFESTATIONS ELICITED BY INTRACEREBRAL ELECTRIC STIMULATION OF MOTOR CORTEX AND MOTOR SEIZURES**

15:00 - 16:30, Hall D

Chairs: *B. Diehl (UK), S. Lhatoo (USA)*

Extraoperative cortical stimulation of the motor cortex in patients with epilepsy, practical considerations - *S. Kovac (UK)*

Stimulation of the primary motor cortex and pathophysiology of clonic seizures in humans - *H.M. Hamer (Germany)*

Electroclinical manifestations of stimulation of the premotor, supplementary motor cortex and cingulum - *P. Kahane (France)*

What can brain stimulation and physiology teach us about the healthy motor system? - *M. Husain (UK)*

BASIC PSYCH NPh&Im OTHER

**Session: EMOTION AND SOCIAL COGNITION IN EPILEPSY**

15:00 - 16:30, Hall E

Chairs: *E. Gaily (Finland), H. Jokeit (Switzerland)*

Emotional body language during epileptic seizures - *C. Baumgartner (Austria)*

Recognition of facial emotions in temporal lobe epilepsy - *S. Meletti (Italy)*

Social cognition in patients with temporal lobe epilepsy - *H. Jokeit (Switzerland)*

PAED NPh&Im OTHER

**Session: ICTAL VIDEO-EEG CHARACTERISTICS OF ABSENCE SEIZURES IN VARIOUS EPILEPTIC SYNDROMES**

15:00 - 16:30, Hall F

Chairs: *N. Fejerman (Argentina), C. Dravet (France)*

Ictal video-EEG characteristics of absence seizures in absence epilepsies - *G. Capovilla (Italy)*

Ictal video-EEG characteristics of absence seizures in coexistence with myoclonic seizures - *A. Covanis (Greece)*

Ictal video-EEG characteristics of absence seizures in coexistence with generalized tonic-clonic seizures - *M. Koutroumanidis (UK)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

.....  
**Satellite Symposium:** – VIROPHARMA: WHAT HAPPENS WHEN A CHILD HAS A PROLONGED ACUTE CONVULSIVE SEIZURE IN THE COMMUNITY?

16.30 -18.00, Auditorium

Chair: *L Lagae (Belgium)*

'Time is brain' – Rescue medication for children with prolonged convulsive seizures – *A Arzimanoglou (France)*

PERFECT – What is it, why it is needed and what can we learn from it? – *L Lagae (Belgium)*

Clinical care – Physician insights into current clinical practice across Europe – *H Cross (UK)*

Administering rescue medication – Application of policies and legal frameworks – *A Arzimanoglou (France)*

.....

OPENING CEREMONY

18.30 -19.30, Auditorium

.....

WELCOME RECEPTION

19.30 -20.30, Auditorium Lobby



MONDAY 1<sup>ST</sup> OCTOBER

	Auditorium	Hall B 1000 pax	Hall C 400 pax	Hall D 420 pax
07.30-08.00				
08.00-08.30	Epigenetics and epileptogenesis	Assessing the effectiveness of interventions for epilepsy	Eisai Symposium	Automated image analysis in epilepsy
08.30-09.00				
09.00-09.30	The borderland of epilepsy in 2012			
09.30-10.00				Trans-border Epilepsies Program in EU : How and why to apply ?
10.00-10.30				
10.30-11.00				
11.00-11.30	Coffee Break and Best Posters			
11.30-12.00	Debate	Olympiad	Genetics 1	Basic Science 1
12.00-12.30				
12.30-13.00	Lunch and posters			
13.00-13.30				
13.30-14.00	The Fields Medal Lecture			
14.00-14.30				
14.30-15.00	100 barbiturate years	Are there common pathophysiological mechanisms for epilepsy and depression?	Evolving genetics of malformations of cortical development	Addressing treatment gaps in North America & Europe
15.00-15.30				
15.30-16.00				
16.00-16.30	Coffee Break and Best Posters			
16.30-17.00	Eisai Symposium			
17.00-17.30				
17.30-18.00				
18.00-18.30	GlaxoSmithKline Symposium			
18.30-19.00				
19.00-19.30				
19.30-20.00				

	Hall E 385 pax	Hall F 385 pax	Hall G 340 pax
07.30-08.00			
08.00-08.30	Consciousness and emotional qualia during a seizure	Can we predict and overcome drug-resistance?	How to do it course 1
08.30-09.00			
09.00-09.30			
09.30-10.00	The horror of falls: revisiting epileptic drop attacks	SCORE: Standardised Computer-based Organised Reporting of EEG	
10.00-10.30			
10.30-11.00			
11.00-11.30			Coffee Break and Best Posters
11.30-12.00	Clinical Epileptology	Neuropsychiatry	Antiepileptic Drugs
12.00-12.30			
12.30-13.00	Lunch and posters		
13.00-13.30			
13.30-14.00			
14.00-14.30			
14.30-15.00	Stress and epilepsy	Long term outcome in children with CSWS-ESES	
15.00-15.30			
15.30-16.00			
16.00-16.30	Coffee Break and Best Posters		

N'Ph&amp;Im

PHARM

BASIC

Session: CAN WE PREDICT AND OVERCOME DRUG-RESISTANCE?

07:45 - 09:00, Hall F

Chairs: *N. Delanty (Ireland), P. Mareš (Czech Republic)*Imaging multi-drug transporter function in animal models of epilepsy - *J.P. Bankstahl (Germany)*Imaging drug-sensitivity and resistance in humans - *M. Feldmann (UK)*Inhibition of P-gp: overcoming drug-resistance - *W. Löscher (Germany)*

PSYCH

Session: CONSCIOUSNESS AND EMOTIONAL QUALIA DURING A SEIZURE

07:45 - 09:00, Hall E

Chairs: *C. Özkara (Turkey), G. Singh (India)*Consciousness beyond epilepsy: the quality of the unperceivable - *M. Mula (Italy)*

What do we know about the neural correlates of altered consciousness during seizures?

- *A. Eugenio Cavanna (UK)*Impairments of extended consciousness in epilepsy - *A. Zeman (UK)*

N'Ph&amp;Im

PHARM

Session: ASSESSING THE EFFECTIVENESS OF INTERVENTIONS FOR EPILEPSY:

IS OUR APPROACH FIT FOR PURPOSE?

07:45 - 09:00, Hall B

Chairs: *A. Guekht (Russian Federation), T. Marson (UK)*Assessing clinical effectiveness at NICE - *M. Baker (UK)*Clinical and cost effectiveness of antiepileptic drugs - *E. Perucca (Italy)*Clinical and cost effectiveness of diagnostic interventions for epilepsy - *P. Ryvlin (France)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

N'Ph&amp;Im SURG

**Session:** AUTOMATED IMAGE ANALYSIS IN EPILEPSY – READY FOR THE BEDSIDE?

07:45 - 09:00, Hall D

Chairs: *J. Gotman (Canada), N. Focke (Germany)*

Standardized voxel based maps and their application for temporal lobe epilepsy - *L. Bonilha (USA)*  
 MRI postprocessing techniques in the presurgical evaluation of epilepsy patients - *H.-J. Huppertz (Switzerland)*  
 Personalized imaging: PET and region-based MRI in the presurgical assessment - *A. Hammers (France)*

PSYCH BASIC GENET

**Session:** EPIGENETICS AND EPILEPTOGENESIS

07:45 - 09:00, Auditorium

Chairs: *I. Blümcke (Germany), H. Lerche (Germany)*

The methylation hypothesis in epileptogenesis - *K. Kobow (Germany)*  
 Differential methylation patterns define status epilepticus and epileptic tolerance - *S. Miller-Delaney (Ireland)*  
 Epigenetic regulation of memory - *A. Fischer (Germany)*

N'Ph&amp;Im PHARM OTHER

**HOW TO DO IT COURSE 1**

07:45 - 09:00, Hall G

Chairs: *D. Schmidt (Germany), C. Elger (Germany)*

How to diagnose epileptic vs non epileptic events - *C. Elger (Germany)*  
 How to use EEG and MRI in epilepsy – *M. Seeck (Switzerland)*  
 How to start drug therapy - *D. Schmidt (Germany)*

**Satellite Symposium:** EISAI EUROPE LTD.: MANAGING SEIZURES, MANAGING MOOD?

08:00 - 09:00, Hall C

Chair: *E. Trinka (Austria)*

Epilepsy and the burden of mood disorders - *E. Trinka (Austria)*  
 Faculty debate: "We should treat mood over seizures in patients with epilepsy"  
 For - *M. Kerr (UK)*  
 Against - *P. Ryvlin (France)*  
 Can we manage mood while managing seizures? - *E. Trinka (Austria)*  
 Interactive discussion - All

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

OTHER

**ECE Forum:** TRANS-BORDER EPILEPSY PROGRAMME IN THE EU – HOW AND WHY TO APPLY?

09:00 - 10:30, Hall D

Chair: *B. Steinhoff (Germany)*

Introduction - *B. Steinhoff (Germany)*  
 Trans border Epilepsy programme: Where we were and how we lived the vision - *E. Hirsch (France)*  
 Trans-border epilepsy surgery: Practical issues and how to overcome them - *M.P. Valenti (France)*  
 Trans border epilepsy programme: Highlights of scientific exchange - *A.M. Staack (Germany)*  
 Trans border Epilepsy Programme: The outlook and perspectives - *E. Hirsch (France)*  
 Conclusion - *B. Steinhoff (Germany)*

OTHER

**ECE Forum:** THE HORROR OF FALLS: REVISITING EPILEPTIC DROP ATTACKS

09:00 - 10:30, Hall E

Chair: *A. Palmmini (Brazil)*

Introduction & presentation of the Forum - *A. Palmmini (Brazil)*  
 Mechanisms of epileptic falls - *P. Kahane (France)*  
 Drop attacks in generalized epileptic syndromes – What to look for? - *H. Oguni (Japan)*  
 Medication, or neuromodulation? - *A. Palmmini (Brazil)*

N'Ph&amp;Im

**ECE Forum:** SCORE: STANDARDISED COMPUTER-BASED ORGANISED REPORTING OF EEG

07:45 - 09:00, Hall F

Chair: *S. Beniczky (Denmark)*

*S. Beniczky (Denmark), H. Aurlien (Norway), M. Neufeld (Israel), M. Fabricius (Denmark),  
 G. Rubboli (Italy), R. Pressler (UK)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

PSYCH PAED OTHER PHARM

### Chairs Symposium: THE BORDERLAND OF EPILEPSY IN 2012

09:00 - 11:00, Auditorium

Chairs: *M. Bialer (Israel), P. Smith (UK)*

The Startle Syndromes: physiology and treatment - *M.A.J. Tijssen (Netherlands)*

The Parasomnias: mechanisms and treatment - *P. Tinuper (Italy)*

"Migralepsy": an overlap syndrome of children and adults - *D. Kasteleijn-Nolst Trenité (Netherlands)*

Syncope: risk of sudden death - *P. O'Callaghan (UK)*

Why are AEDs effective in treating non-epileptic conditions? - *M. Bialer (Israel)*

PHARM

### Debate: WHEN THERE IS CLASS I EVIDENCE FROM A RANDOMIZED TRIAL, PHYSICIANS SHOULD ALWAYS TREAT BASED ON THE RESULTS

11:30 - 12:30, Auditorium

Chairs: *F. Vigeveno (Italy), J. Duncan (UK)*

Yes - *J. French (USA)*

No - *T. Marson (UK)*

GENET PAED OTHER

### Platform Session - GENETICS 1

11:30 - 12:30, Hall C

Chairs: *N. Delanty (Ireland), E. Cvetkovska (Macedonia)*

Identification of novel syntaxin binding protein 1 (STXBP1) mutations in patients with severe early onset epileptic encephalopathies (EOEE) - *T. Djémié (Belgium)*

Screening for SYNGAP1 mutations in patients with non-syndromic ID and Epilepsy with Myoclonic Absences or Myoclonic Astatic Epilepsy - *R.S. Møller (Denmark)*

Mutations in CDKL5 as a cause of early onset epilepsy - *M. Gos (Poland)*

PRRT2 mutations are the major cause of benign familial infantile seizures (BFIS) - *Y. Weber (Germany)*

### EPILEPSY OLYMPIAD



11:30 - 12:30, Hall B

Chairs: *P. Smith (UK), R. Thomas (UK), R. Tallis (UK)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

### THE FIELDS MEDAL LECTURE

13:30 - 14:30, Auditorium

Chair: *R. Tallis (UK)*

Introduction - *R. Tallis (UK)*

Open Access and Open Science - *Professor Sir Timothy Gowers (UK)*

BASIC

### Platform Session - BASIC SCIENCE 1

11:30 - 12:30, Hall C

Chairs: *C. Bernard (France), M. Kokaia (Sweden)*

Seizure-induced brain-born inflammation and blood-brain barrier damage are counteracted by ANAK-INRA in the isolated guinea pig brain preparation - *L. Librizzi (Italy)*

Severe functional defects of the Kv7.2 channel caused by mutations associated with epileptic encephalopathies - *S. Maljevic (Germany)*

Complement C3 upregulation contributes to a sustained inflammatory response and perpetuation of seizure foci in a pilocarpine model of temporal lobe epilepsy - *I. Kharatishvili (Australia)*

GABAergic interneurons lead to the epileptogenesis: Interneuron pathology associated with ARX mutation - *M. Itoh (Japan)*

OTHER PAED PSYCH

### Platform Session - CLINICAL EPILEPTOLOGY

11:30 - 12:30, Hall E

Chairs: *A. Rossetti (Switzerland), R. Mameniskiene (Lithuania)*

Neurological and neuroimaging outcomes of childhood status epilepticus: a 10-year cohort study - *S. Pujar (UK)*

Assessment of Status epilepticus and Seizures in Neurological Intensive Care Unit in Salzburg, Austria - *J. Dobsberger (Austria)*

Middle Short Gyrus of the Insula Implicated in Speech Production: Intracerebral electric Stimulation of patients with epilepsy - *A. Afif (France)*

Aspects of ictal consciousness in patients with Epilepsy, Non-epileptic Attack Disorder (NEAD) and dual diagnosis - *A.E. Cavanna (UK)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

BASIC PSYCH

Platform Session – NEUROPSYCHIATRY

11:30 - 12:30, Hall F

Chairs: *S. Koch Stoecker (Germany), S. Danielsson (Sweden)*Postictal psychosis in temporal lobe epilepsy - risk factors and postsurgical outcome - *R.A. Cleary (UK)*Psychiatric Comorbidity In Children Before And After Temporal Lobe Epilepsy Surgery - *A. Michoulas1 (Canada)*How Sodium Valproate causes language delay and autism - a molecular study - *R. Moldrich (Australia)*

Prevalence and associates of suicidal behavior in frequent treatment-resistant focal seizures:

The ASERT study - *A. Kanner (USA)*

PHARM

Platform Session - ANTIEPILEPTIC DRUGS

11:30 - 12:30, Hall G

Chairs: *F. Onat (Turkey), J. Mifsud (Malta)*

Analysis of efficiency and safety of oxcarbazepine depending on patient's age and forms of epilepsy -

*A.A. Kholin (Russian Federation)*Discontinuation of antiepileptic drugs in pregnancy; a UK population based study in The Health Improvement Network primary care database - *S.L. Man (UK)*

Tolerability and Safety of Zonisamide in Elderly Patients with Partial Epilepsy: Results of a Pooled

Analysis - *E. Trinko (Austria)*Long-Term Treatment with Adjunctive Lacosamide for Partial-Onset Seizures: An Analysis of Results from Patients Exposed Only to Approved Doses - *N. DCruz (USA)*

PHARM

## 100 BARBITURATE YEARS

14:30 - 16:00, Auditorium

Chairs: *E. Perucca (Italy), E. Reynolds (UK)*How phenobarbital revolutionized the drug treatment of epilepsy - *S. Shorvon (UK)*How phenobarbital chemical structure affected the development of subsequent new AEDs - *M. Bialer (Israel)*How theories evolved concerning the mechanism of action of barbiturates - *W. Löscher (Germany)*The current position of phenobarbital in epilepsy and its future - *M. Brodie (UK)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

PHARM

Session: ADDRESSING TREATMENT GAPS IN NORTH AMERICA & EUROPE

14:30 - 16:00, Hall D

Chair: *H. Cross (UK)*Treatment gaps in North America - *N. Jette (Canada)*Addressing the treatment gap in underserved populations: American Indians - *K. Parko (USA)*

Addressing the treatment gap at source in 2011: the Georgian GCAE demonstration project

- *N. Okujava (Georgia)*

Drug treatment across Europe: Prescription patterns and the gap in drug availability -

*C. Johannessen (Norway)*

BASIC PSYCH

Session: ARE THERE COMMON PATHOPHYSIOLOGICAL MECHANISMS FOR EPILEPSY AND DEPRESSION?

14:30 - 16:00, Hall B

Chairs: *K. Malmgren (Sweden), A. Depaulis (France)*The role of inflammation in epilepsy - *R. Nabbout (France)*The role of inflammation in depression - *B.E. Leonard (Ireland)*The role of brain plasticity in epilepsy - *M. Kokaia (France)*The role of brain plasticity in depression - *G. Kempermann (Germany)*

OTHER PAED BASIC GENET

Session: EVOLVING GENETICS OF MALFORMATIONS OF CORTICAL DEVELOPMENT

14:30 - 16:00, Hall C

Chairs: *P. Van Bogaert (Belgium), C. Marini (Italy)*Malformations of cortical development: clinical and genetic overview - *R. Guerrini (Italy)*

Spectrum of neuronal migration disorders associated to mutations of the tubuline genes

- *J. Chelly (France)*Insights from the studies of copy number variations (CNVs) - *C.G.F. De Kovel (Netherlands)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

PSYCH

BASIC

**Session:** STRESS AND EPILEPSY

14:30 - 16:00, Hall E - Chair: *D. O'Brien (Ireland), N. Delanty (Ireland)*

Stress and human disease - *N. Delanty (Ireland)*

Stress and epilepsy - mechanisms - *M. Joels (Netherlands)*

Stress and epilepsy – clinical practice - *M. Privitera (USA)*

OTHER

PAED

PSYCH

**Session:** LONG TERM OUTCOME IN CHILDREN WITH CSWS-ESES

14:30 - 16:00, Hall F - Chairs: *C. A. Tassinari (Italy), E. Hirsch (France)*

Neuronal network in children with CSWS-ESES - *U. Stephani (Germany)*

Slow sleep and learning - *R. Huber (Switzerland)*

Penelope Syndrome or ESES - *C. A. Tassinari (Italy)*

**Satellite Symposium:** EISAI EUROPE LTD.: THE EVOLVING THERAPEUTIC LANDSCAPE IN EPILEPSY

16:30 - 18:00, Auditorium - Chair: *J Duncan (United Kingdom)*

Introduction – *J Duncan (United Kingdom)*

Individualised decision-making in epilepsy monotherapy - *E. Trinka (Austria)*

Emerging data informing monotherapy options: zonisamide and other agents - *M. Baulac (France)*

AMPA receptors: a new target in the treatment of epilepsy - *M Rogawski (USA)*

Phase III data for perampanel - *B Steinhoff (Germany)*

Panel discussion - *All*

**Satellite Symposium** – GLAXOSMITHKLINE: MAKING EVIDENCE-BASED DECISIONS IN PARTIAL EPILEPSY TREATMENT

18.30 - 20:00, Auditorium - Chair: *JW Sander (UK)*

Burden of epilepsy – *H Hamer (Germany)*

Optimising patient care in partial epilepsy: what are the challenges? – *JP Leach (UK)*

Exploring clinical experience with retigabine through patient case studies in partial epilepsy - *W Van Paesschen (Belgium)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY



TUESDAY 2<sup>ND</sup> OCTOBER

	Auditorium 2000 pax	Hall B 1000 pax	Hall C 400 pax	Hall D 420 pax
07.30-08.00				
08.00-08.30	What is a seizure?	Nocturnal Frontal lobe epilepsy and non-REM parasomnias - variations on	Elekta Symposium	Communication challenges in the epilepsy clinic
08.30-09.00				
09.00-09.30	Why do new antiepileptic drugs not deliver and what to do about it?	Interplay between epilepsy and psychiatry		
09.30-10.00				
10.00-10.30				
10.30-11.00				
11.00-11.30	Coffee Break and Best Posters			
11.30-12.00	Gene Therapy for Epilepsy	Are the mechanisms of action of antiepileptic drugs relevant to the treatment of epilepsy?	Clinical Pharmacology	Genetics 2
12.00-12.30				
12.30-13.00	Lunch and posters			
13.00-13.30				
13.30-14.00	The Nobel Prize Lecture			
14.00-14.30	Symposium of Excellence in epileptology	Olympiad	Epileptic encephalopathies: Can we make a difference?	The long term outcome of epilepsy surgery
14.30-15.00				
15.00-15.30				
15.30-16.00	Coffee Break and Best Posters			
16.00-16.30	UCB Pharma Symposium			
16.30-17.00				
17.00-17.30				
17.30-18.00				

	Hall E 385 pax	Hall F 385 pax	Hall G 340 pax
07.30-08.00			
08.00-08.30	Classify this	Experimental strategies to modify or prevent epileptogenesis	How to do it course 2
08.30-09.00			
09.00-09.30	EpiNet, How to get the answer to nearly everything	Epilepsy & feature films	Epilepsy 12: Use of key performance indicators to assess quality of epilepsy care
09.30-10.00			
10.00-10.30			
10.30-11.00			
11.00-11.30	Neuropsychology	Surgical Treatment	Clinical Neurophysiology
11.30-12.00			
12.00-12.30	Lunch and posters		
12.30-13.00			
13.00-13.30	Changes in sexual function, affect and personality after epilepsy surgery	Genetic testing in the epilepsies: when and how to order genetic tests	What the professionals need to know to improve healthcare and research
13.30-14.00			
14.00-14.30			
14.30-15.00	Coffee Break and Best Posters		
15.00-15.30			
15.30-16.00			
16.00-16.30			

OTHER PAED SURG

## Session: CLASSIFY THIS

07:45 - 09:00, Hall E

Chairs: *A. Gil-Nagel (Spain)*, *R. Kälviäinen (Finland)*Epilepsy classification and non-lesional epilepsy surgery - *P. Ryvlin (France)*Identifying idiopathic generalized epilepsies - *A. Gil-Nagel (Spain)*Recognizing malformations of cortical development - *I. Blümcke (Germany)*

BASIC NPh&amp;Im

## Session: WHAT IS A SEIZURE?

07:45 - 09:00, Auditorium

Chairs: *G. Kramer (Switzerland)*, *V. Kimiskidis (Greece)*High frequency oscillations - *I. Fried (USA)*Single unit recordings - *S. Cash (USA)*Seizure prediction - *F. Mormann (Germany)*

PSYCH PHARM

## Session: COMMUNICATION CHALLENGES IN THE EPILEPSY CLINIC

07:45 - 09:00, Hall D

Chairs: *M. Reuber (UK)*, *H. Stefan (Germany)*Communication challenges in the epilepsy clinic - *S. Beyenburg (Luxembourg)*Using conversation analysis to improve clinical communication practice - *A. Perakyla (Finland)*Differentiating between epileptic and non-epileptic seizures - *C. Monzoni (UK)*Identifying anxiety in patients with epilepsy - *M. Schoendienst (Germany)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

## BASIC

**Session:** EXPERIMENTAL STRATEGIES TO MODIFY OR PREVENT EPILEPTOGENESIS

07:45 - 09:00, Hall F

Chairs: *R. Köhling (Germany), D. Kullman (UK)*

Anti-inflammatory strategies for seizure prevention - *A. Vezzani (Italy)*

Adenosine and neuromodulation as antiepileptogenic strategy - *D. Boison (USA)*

How should experimental studies on the prevention of epileptogenesis be designed? - *A. Pitkänen (Finland)*

## PHARM

**HOW TO DO IT COURSE 2**

07:45 - 09:00, Hall G

Chairs: *C. Elger (Germany), D. Schmidt (Germany)*

How to combine AEDs - *J. Sander (UK)*

How to adapt treatment to special needs - *M. Carreño (Spain)*

How and when to end therapy - *D. Schmidt (Germany)*

## OTHER

## NPh&amp;Im

**Session:** NOCTURNAL FRONTAL LOBE EPILEPSY AND NON-REM PARASOMNIAS - VARIATIONS ON THE SAME THEME?

07:45 - 09:00, Hall B - Chair: *Sofia Eriksson (United Kingdom)*

Differences between nocturnal frontal lobe epilepsy and non-REM parasomnias - *P. Tinuper (Italy)*

Non-REM sleep parasomnias: pitfalls for the epileptologist - *A. Kelemen (Hungary)*

REM sleep: focalizing and prognostic value in presurgical evaluation of epilepsy - *P. Gelisse (France)*

**Satellite Symposium:** – ELEKTA: ADVANCES IN CLINICAL APPLICATION OF MAGNETOENCEPHALOGRAPHY (MEG) FOR REFRACTORY EPILEPSY IN PAEDIATRIC AND ADULT PATIENTS

08.00 - 09.00, Hall C - Chair: *H Stefan (Germany)*

MEG in pre-surgical assessment of paediatric epilepsies – *S Seri (UK)*

Clinical applications of MEG in epilepsies – *H Stefan (Germany)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

## PHARM

## BASIC

**Main Session:** WHY DO NEW ANTIEPILEPTIC DRUGS NOT DELIVER AND WHAT TO DO ABOUT IT?

09:00 - 11:00, Auditorium

Chairs: *W. Löscher (Germany), E. Perucca (Italy)*

What has gone wrong in the past? Clinical - *M. Brodie (UK)*

What has gone wrong in the past? Preclinical - *S. White (USA)*

What to do about it? Preclinical - *W. Löscher (Germany)*

What to do about it? Clinical - *D. Schmidt (Germany)*

## PHARM

## OTHER

## PAED

## PSYCH

**Main Session:** INTERPLAY BETWEEN EPILEPSY AND PSYCHIATRY

09:00 - 11:00, Hall B

Chairs: *V. Komarek (Czech Republic), K. Malmgren (Sweden)*

The bilateral relationship between epilepsy and psychiatric disorders - *A.M. Kanner (USA)*

Is there a need for a separate classification of psychiatric disorders in epilepsy? - *S. Koch-Stoecker (Germany)*

Autism spectrum disorders, ADHD and epilepsy - *S. Danielsson (Sweden)*

Which epilepsy patients are at risk to develop psychiatric side effects from AED? - *M. Mula (Italy)*

## OTHER

**Special Session:** EPILEPSY AND DOCUMENTARY FILM MAKING

09:00 - 10:30, Hall F

Chairs: *S. Baxendale (UK), B. MacDonald (UK)*

Documentary Film Making - *B. MacDonald (UK)*

Introduction - *S. Anderson (UK)*

What's the time Mr Wolf? - Film Screening

Q&A

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

## OTHER

**ECE Forum:** COSTS OF EPILEPSY IN EUROPE: CURRENT STATUS AND THE WAY FORWARD

09:00 - 10:30, Hall G

Chair: *A. Guekht (Russian Federation)*Costs of epilepsy in Europe: EBC study and literature review - *E. Beghi (Italy)*Seizures and epilepsy: Major comorbidity of non-communicable diseases - *A. Guekht (Russian Federation)*Status Epilepticus: epidemiology and costs in Europe - *E. Trinka (Austria)*

## OTHER

**ECE Forum:** EPILEPSY AND FEATURE FILMS

10:30 - 11:30, Hall F

Chair: *S. Heiner (Germany)**G. Kramer (Switzerland), T. Meyer (Germany), F. Schmitt (Germany), S. Heiner (Germany)***Satellite Symposium:** DESITIN PHARMA LTD.: HOW TO IMPROVE ADHERENCE? THE IMPORTANCE OF GALENIC DRUG DEVELOPMENT

10:30 - 11:30, HALL C

Chair: *M. Koeppe (UK)*Adherence - A prerequisite for optimal antiepileptic drug therapy - *H. Stefan (Germany)*A tablet is not a tablet- small difference, big impact - *C. de Mey (Germany)*

## OTHER

**ECE Forum:** EPINET, HOW TO GET THE ANSWER TO NEARLY EVERYTHING

10:30 - 11:30, Hall E

Chairs: *P. Bergin (New Zealand), M. Richardson (UK)**P. Bergin (New Zealand) M. Richardson (UK)*

## OTHER

**ECE Forum:** EPILEPSY 12: USE OF KEY PERFORMANCE INDICATORS TO ASSESS QUALITY OF EPILEPSY CARE

10:30 - 11:30, Hall G

Chair: *L. Sander (UK)*Background - C. Ferrie (UK), Methodology - *C. Dunkley (UK)*Results - R. Chin (UK), Results - *R. Ranmal (UK)*What next - *W.P. Whitehouse (UK)*

## PHARM

## GENET

**Debate:** ARE THE MECHANISMS OF ACTION OF ANTIEPILEPTIC DRUGS RELEVANT TO THE TREATMENT OF EPILEPSY?

11:30 - 12:30, Hall B

Chairs: *P. Smith (UK), Fred Andermann (Canada)*Mechanisms of antiepileptic drug action are important in clinical practice - *G.J. Sills (UK)*Mechanisms of antiepileptic drug action are irrelevant in clinical practice - *E. Trinka (Austria)*

## PHARM

## BASIC

**Session:** GENE THERAPY FOR EPILEPSY

11:30 - 13:00, Auditorium

Chairs: *H. Potschka (Germany), M. Walker (UK)*Preventing epileptogenesis - *M. Simonato (Italy)*Targeting ion channels - *D. Kullmann (UK)*Novel viral vectors in epilepsy - *S. Gray (USA)*

## PHARM

Platform Session: CLINICAL PHARMACOLOGY AND THERAPEUTICS

11:30 - 12:30, Hall C

Chairs: *P. Patsalos (UK), P. Soares Da Silva (Portugal)*Antiepileptic drugs and lipid metabolism: valproate not so innocent? - *I.Y. Tan (Netherlands)*Does Carbamazepine affect the QT interval? - *T. Yadee (Thailand)*Changed Constitution without change in Brand Name - the Risk of Generics in Epilepsy - *VI. PATEL (Australia)*One year follow-up experience with eslicarbazepine acetate (Zebinix®) in a tertiary hospital in Oporto, Portugal - *F.D. Correia (Portugal)*

## PSYCH

Platform Session – NEUROPSYCHOLOGY

11:30 - 12:30, Hall E

Chairs: *S. Baxendale (UK), C. Helmstaedter (Germany)*Neuropsychological functioning in paediatric epilepsy syndromes - *A.F. Lopes (Portugal)*Neuropsychological function of patients with Unverricht-Lundborg disease - *M. Äikiä (Finland)*Evidence for cognitive deficits in untreated patients with newly diagnosed epilepsy - *J.A. Witt (Germany)*Cognitive function is impaired in patients with idiopathic generalised epilepsy and their unaffected family members - *F. Chowdhury (UK)*

## GENET

## PAED

Platform Session - GENETICS 2

11:30 - 12:30, Hall D

Chairs: *R. Kalviainen (Finland), J. Serratosa (Spain)*PRRT2 links infantile convulsions and paroxysmal dyskinesia with migraine - *R. Cloarec (France)*The familial epilepsy syndrome of Genetic Epilepsy with Febrile Seizures Plus: Syndrome evolution over seventeen years - *I.E. Scheffer (Australia)*Prospective study of POLG1 mutations presenting in children with intractable epilepsy-prevalence and clinical features - *J. Uusimaa (UK)*Inflammatory Process and Mesial Temporal Lobe Epilepsy with Epilepsy: the role of IL-1 - *J. Chaves (Portugal)*

## PAED

## SURG

Platform Session - SURGICAL TREATMENT

11:30 - 12:30, Hall F

Chairs: *A. Miserocchi (Italy), P. Kahane (France)*Seizure outcome ten years after resective epilepsy surgery - a population-based, prospective, longitudinal study - *A. Edelvik (Sweden)*Resective epilepsy surgery for malformations of cortical development in infancy and early childhood - *T. Otsuki (Japan)*Extratemporal epilepsy surgery in eloquent brain regions using functional neuronavigation and intra-operative MRI (iopMRI) - *K. Roessler (Germany)*Usefulness of Positron emission tomography in decision making for epilepsy surgery - *C. Rathore (India)*

## N'Ph&amp;Im

Platform Session - CLINICAL NEUROPHYSIOLOGY

11:30 - 12:30, Hall G

Chairs: *P. Larsson (Norway), S. Beznicky (Denmark)*EEG findings in 261 sequential patients with altered mental status presenting to the emergency department - *A.C. Grant (UK)*Is ECoG during epilepsy surgery for mesial temporal sclerosis of any use? - *J. Chan (Australia)*500 Implementation of Home Video-EEG-Telemetry at King's College Hospital (KCH), London - *F. Brunnhuber (UK)*The European EEG Database as a new Standard for long-term EEG Recordings in Epilepsy Patients - *A. Schulze-Bonhage (Germany)*

## THE NOBEL PRIZE LECTURE

13:30 - 14:30, Auditorium

Chair: *S. Shorvon (UK)*Introduction - *S. Shorvon (UK)*MRI – The early years - *Professor Sir Peter Mansfield (UK)*

PAED SURG

**Special Session: SYMPOSIUM OF EXCELLENCE IN EPILEPTOLOGY**

14:30 - 16:00, Auditorium

Chairs: *M. Bialer (Israel), S. Li (China)*Pharmacoresistance in Epilepsy: A Clinical View – European Epileptology Award - *C. Elger (Germany)*Respiratory alkalosis in children with febrile seizures - Epilepsia Morris-Cooile Prize - *S. Schuchmann (Germany)*From Hippocrates to the 'next generation sequencing era': a clinical perspective on epilepsy genetics – CEA Young Investigator Award - *P. Striano (Italy)*The significance of defining the type of epilepsy – ILAE British Branch Excellence in Epilepsy Award - *T. Panayiotopoulos (UK)***EPILEPSY OLYMPIAD**

14:30 - 16:00, Hall B

Chair: *P. Smith (UK)*

PSYCH SURG

**Session: CHANGES IN SEXUAL FUNCTION, AFFECT AND PERSONALITY AFTER EPILEPSY SURGERY**

14:30 - 16:00, Hall E

Chairs: *A. Schulze-Bonhage (Germany), I. Blatt (Israel)*Disturbances of sexual function - *A.M. Kanner (USA)*Disturbances of affect and behaviour - *S. Koch-Stoecker (Germany)*Epilepsy surgery should not be a form of psycho-surgery - *S. Shorvon (UK)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

OTHER

**Session: WHAT THE PROFESSIONALS NEED TO KNOW TO IMPROVE HEALTHCARE AND RESEARCH**

14:30 - 16:00, Hall G

Chairs: *E. Perucca (Italy), Mike Glynn (Ireland)*What is the best political agenda for epilepsy in Europe – *N. Deva, MEP, President of the International Committee on Human Dignity*Epilepsy in European health care agendas: cost vs. outcomes - *T. Tomson (Sweden)*Epilepsy in EU research agenda - *P. Cupers, DC Research & Innovation's Health Directorate*

PSYCH SURG

**Session: THE LONG TERM OUTCOME OF EPILEPSY SURGERY**

14:30 - 16:00, Hall D

Chair: *S. Wiebe (Canada)*The measure of success in epilepsy surgery - *S. Baxendale (UK)*Long term neuropsychological outcomes after epilepsy surgery in adults - *L. Andersson-Roswall (Sweden)*Long term outcome of epilepsy surgery; seizures, medication and mortality - *G. Bell (UK)*Psychosocial outcome of epilepsy surgery - *K. Malmgren (Sweden)*

PAED GENET OTHER

**Session: GENETIC TESTING IN THE EPILEPSIES: HOW AND WHEN TO ORDER GENETIC TESTS**

14:30 - 16:00, Hall F

Chairs: *J. Serratosa (Spain), S. Zuberi (UK)*Epileptic encephalopathies - *C. Marini (Italy)*Rare partial epilepsies - *R. Michelucci (Italy)*Whole exome sequencing or gene panel sequencing? - *A.E. Lehesjoki (Finland)*Common genetic epilepsies - *J.M. Serratosa (Spain)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

GENET

OTHER

BASIC

Session: EPILEPTIC ENCEPHALOPATHIES: CAN WE MAKE A DIFFERENCE?

14:30 - 16:00, Hall C

Chairs: *U. Kramer (Israel), C. Ferrie (UK)*

Epileptic encephalopathies with onset in infancy and childhood - *R. Guerrini (Italy)*

From molecular defect to epileptogenesis: do we have insights - *P. De Jonghe (Belgium)*

ESES in children with idiopathic and symptomatic focal epilepsies - *H. Cross (UK)*

Satellite Symposium: UCB PHARMA: MANAGING EPILEPSY: LEARNING FROM TODAY TO INFORM TOMORROW

16.30 - 18.00, Auditorium

Chair: *J Duncan (UK)*

Insights from patient data: the reality of living with epilepsy today - *P Ryvlin (France)*

Considerations for initial treatment: getting it right from the start - *M Brodie (UK)*

Considerations for combination therapy: real life data - *V Villanueva (Spain)*

Advancing treatment options for epilepsy: a future vision - *H Klitgaard (Belgium)*

Moderated Discussion

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY



WEDNESDAY 3<sup>RD</sup> OCTOBER

	Auditorium 2000 pax	Hall B 1000 pax	Hall C 400 pax	Hall D 420 pax
07.30-08.00				
08.00-08.30		It is not the size that matters - Challenges of neonatal seizures	<b>EGI Symposium</b>	Pre-surgical evaluation practices in children
08.30-09.00				
09.00-09.30				
09.30-10.00	Recent trends in AED clinical pharmacology	Neuroimaging and presurgical evaluation		
10.00-10.30				
10.30-11.00				
11.00-11.30			Coffee Break and Best Posters	
11.30-12.00	Functional MRI	Structural and Functional Imaging	Paediatric Epilepsy	The Michael debate: Present views of generalized ictogenesis
12.00-12.30				
12.30-13.00	Lunch and posters			
13.00-13.30				
13.30-14.00	Lectures at the Interface			
14.00-14.30				
14.30-15.00	Status Epilepticus: past, present, and future	Devices and epilepsy: the future?	Mechanistic approaches to treatment of seizure disorders with learning disability	Investigating undiagnosed epilepsies at transition to adult neurology and epilepsy services
15.00-15.30				
15.30-16.00				
16.00-16.30	Coffee Break and Best Posters			
16.30-17.00		Olympiad Final	Management of epilepsy in pregnancy	New genetics
17.00-17.30				
17.30-18.00				

	Hall E 385 pax	Hall F 385 pax	Hall G 340 pax
07.30-08.00	Hippocampal subfield pathology specifies surgical outcome in MTL-HS	Technical advances in epilepsy surgical problems	<b>How to do it course 3</b>
08.00-08.30			
08.30-09.00			
09.00-09.30			
09.30-10.00			New Classification of Status Epilepticus
10.00-10.30			
10.30-11.00			
11.00-11.30	Coffee Break and Best Posters		
11.30-12.00	Symptomatic Epilepsy	How to get a paper published - the view from the bench	Basic Science 2
12.00-12.30			
12.30-13.00	Lunch and posters		
13.00-13.30			
13.30-14.00			
14.00-14.30			
14.30-15.00	EEG-fMRI in epilepsy		
15.00-15.30			
15.30-16.00			
16.00-16.30	Coffee Break and Best Posters		
16.30-17.00	Metabolic epilepsies; recognition and treatment	Activation of innate immunity and toll-like receptors	
17.00-17.30			
17.30-18.00			

OTHER

BASIC

**Session:** HIPPOCAMPAL SUBFIELD PATHOLOGY SPECIFIES SURGICAL OUTCOME IN MTL-HS

07:45 - 09:00, Hall E

Chair: *R. Spreafico (Italy)*Epileptic networks in the temporal lobe - *F. Bartolomei (France)*Structural correlates of presurgical imaging findings in MTLE-HS - *R. Spreafico (Italy)*Proposal of an international classification system of hippocampal sclerosis - *I. Blümcke (Germany)*

SURG

**HOW TO DO IT COURSE 3**

07:45 - 09:00, Hall G

Chairs: *C. Elger (Germany), D. Schmidt (Germany)*How much presurgical diagnostics is necessary - *C. Elger (Germany)*How to use brain stimulation in Epilepsy - *P. Boon (Belgium)*How much have you learned? - *C. Elger (Germany)/D. Schmidt (Germany)*

N/Ph&amp;Im

SURG

**Session:** TECHNICAL ADVANCES IN EPILEPSY SURGICAL PROBLEMS

07:45 - 09:00, Hall F

Chairs: *A. McEvoy (UK), P. Chauvel (France)*Software developments facilitating the integration of multimodality imaging into operative neuronavigation systems - *C. Vollmar (UK)*Frame based and frameless stereo EEG - The use of the Renshaw robotic system - *A. Miserocchi (Italy)*Advantages and disadvantages of intraoperative MRI to an epilepsy surgery programme - *A. McEvoy (UK)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

PAED SURG NPh&Im

**Session:** PRE-SURGICAL EVALUATION PRACTICES IN CHILDREN: DO THEY REALLY DIFFER BETWEEN THE TWO SIDES OF THE ATLANTIC?

07:45 - 09:00, Hall D

Chairs: *O. Van Nieuwenhuizen (Netherlands), K. Garganis (Greece)*

Choosing the appropriate candidates on time - *A. Arzimanoglou (France)*

To implant or to resect? This is the first question - *P. Kahane (France)*

Grids, Stereo-EEG, both? These are other questions - *A. Alexopoulos (Greece)*

PAED NPh&Im

**Session:** IT IS NOT THE SIZE THAT MATTERS - CHALLENGES OF NEONATAL SEIZURES

07:45 - 09:00, Hall B

Chairs: *P. Plouin (France), R. Pressler (UK)*

Views of the neurophysiologist - *G. Boylan (Ireland)*

Views of the neonatologist - *L.S. De Vries (Netherlands)*

Views of the epileptologist - *R.M. Pressler (UK)*

**Satellite Symposium:** ELECTRICAL GEODESICS, INC.: CLINICAL APPLICATIONS OF ADVANCED EEG – DEVELOPMENTS IN EEG/FMRI AND HIGH RESOLUTION EEG FOR EPILEPSY

08.00 - 09.00, Hall C

Chair: *E Trinká (Austria)*

Functional imaging of epileptic networks – *S Vulliemoz (Switzerland)*

EEG source localization using dense array recordings – first experiences at the Bonn Epilepsy Center – *G Moeddel (Germany)*

What does EEG tell us about epileptic networks that fMRI cannot say- and vice versa? – *M Siniatchkin (Germany)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

PAED GENET OTHER BASIC

**Main Session:** RECENT TRENDS IN AED CLINICAL PHARMACOLOGY

09:00 - 11:00, Auditorium

Chairs: *S.I. Johannessen (Norway), M. Baulac (France)*

Genomics, kinetics and dynamics, making sense of the complexities - *M. Pirmohamed (UK)*

AED pharmacology in the unborn, newborn and mother, lessons from pregnancy registries - *T. Tomson (Sweden)*

Treatment issues in the peri-menopause - *G. Luef (Austria)*

Therapeutic drug monitoring (TDM) after 50 years: obsolete or still useful? - *S.I. Johannessen (Norway)*

SURG NPh&Im

**Main Session:** NEUROIMAGING AND PRESURGICAL EVALUATION

09:00 - 11:00, Hall B

Chairs: *M. Carreno (Spain), J. Duncan (UK)*

Beyond visual evaluation: automated assessments of MRI and PET - *N. Focke (Germany)*

Imaging electrical abnormalities: EEG-fMRI, MEG and ESI - *M. Guye (France)*

The role of fMRI to predict deficits after epilepsy surgery - *S. Bonelli (Austria)*

Linz/AT, Tractography and display of critical tracts - *G.P. Winston (UK)*

OTHER

**ECE Forum:** NEW CLASSIFICATION OF STATUS EPILEPTICUS

09:30 - 11:00, Hall G

Chairs: *I. Scheffer (Australia), H. Cock (UK)*

History of the classification of SE - *S. Shorvon (UK)*

How long do seizures last in adults? - *D. Lowenstein (USA)*

How long do seizures (including febrile seizures) last in children? - *S. Shinnar (USA)*

Proposal of a new classification - *E. Trinká (Austria)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

## OTHER

Special Session: HOW TO GET A PAPER PUBLISHED - THE VIEW FROM THE BENCH

11:30 - 12:30, Hall F

Chairs: *P. Schwartzkroin (USA), S. Shorvon (UK), A. Arzimanoglou (France), M. Reuber (UK)*Tips on getting a paper published - *P. Schwartzkroin (USA)*Open discussion - *P. Schwartzkroin (USA), S. Shorvon (UK), M. Reuber (UK), A. Arzimanoglou (France)*

NPh&amp;Im

GENET

OTHER

BASIC

Debate: THE MICHAEL DEBATE: PRESENT VIEWS OF GENERALIZED ICTOGENESIS

11:30 - 13:00, Hall F

Chairs: *N. Moshe (USA), J.M. Lopes Lima (Portugal)*Spontaneous absences in EEG-triggered fMRI - *F. Möller (Denmark)*Cortical and subcortical areas involved in IGEs - *M Koepp (UK) \**Lessons from reflex epileptic traits in IGE - *P. Wolf (Denmark)*"Generalized" seizures are really focal seizures - *B. Schmitz (Germany)*Animal data about generalized ictogenesis - *M. De Curtis (Italy) \**How can mutations determine ictogenesis in idiopathic epilepsies? - *O. Steinlein (Germany) \***\*Michael laureates*

NPh&amp;Im

PSYCH

SURG

Platform Session: FUNCTIONAL MRI

11:30 - 12:30, Auditorium

Chairs: *M. Guye (France), S. Bonelli (Austria)*Imaging memory in temporal lobe epilepsy: Reorganisation of memory function following anterior temporal lobe resection - results of a longitudinal fMRI study - *S. Bonelli (Austria)*Localization of the ictal onset zone using interictal EEG-fMRI in the pre-surgical evaluation of consecutive patients with refractory focal epilepsy - *S. Tousseyn (Belgium)*Mapping the irritative zone using simultaneous intracranial EEG-fMRI and comparison with post surgical outcome - *U. J. Chaudhary (UK)*Preoperative fMRI in temporal lobe epilepsy: assessment of language related areas - *F. Villani (Italy)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

## OTHER

Platform Session - SYMPTOMATIC EPILEPSY

11:30 - 12:30, Hall E

Chairs: *S. Papacostas (Cyprus), M. Neufeld (Israel)*VGKC antibodies in epilepsy: Diagnostic yield and therapeutic implications - *J. Lilleker (UK)*Epilepsy and other neurological manifestations associated with tuberous sclerosis complex - *P. Major (Canada)*Traumatic brain injury and subsequent risk of unprovoked seizures: a population-based case-control study - *B. Mahler (Sweden)*Epilepsy in primary cerebral tumours: interim results of the PERNO study (Project of Emilia Romagna Region on Neuro-Oncology) - *R. Michelucci (Italy)*

## PAED

Platform Session - PAEDIATRIC EPILEPSY

11:30 - 12:30, Hall C

Chairs: *M. Enzdeniene (Lithuania), U. Kramer (Israel)*Paroxysmal non-epileptic events in infants and toddlers: a semiology study - *L. Chen (China)*Epilepsy12 - UK Collaborative Clinical Audit of Health Care for Children and Young People with Suspected Epileptic Seizures - *C. Dunkley (UK)*Young adult ischemic stroke-related acute symptomatic and late seizures: risk factors -Ketogenic Diet as an Effective Alternative Therapy in Childhood Refractory Epilepsy: A Systematic Review - *A.K. Somale (India)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

## BASIC

## Platform Session - BASIC SCIENCE 2

11:30 - 12:30, Hall G

Chairs: *J. Kittler (UK), A. Nehlig (France)*

mTOR inhibition modulates epileptogenesis, seizures and depressive-like behavior in a genetic model of absence seizures and mild depression comorbidity: a role for inflammatory responses - *E. Russo (Italy)*

Developmental Changes in the Number of GABAergic Neurons of the Thalamic Reticular Nucleus in Absence Epilepsy Rats - *F. Onat (Turkey)*

The disease-modifying effect of carisbamate in the lithium-pilocarpine model of temporal lobe epilepsy translates into preserved cognitive functions - *J.-B. Faure (France)*

Sprouting mossy fibres innervate excitatory granule cells and inhibitory interneurons in the hippocampus of patients with temporal lobe epilepsy - *T.M. Freiman (Germany)*

## N'Ph/Im

## Platform Session – STRUCTURAL AND FUNCTIONAL IMAGING

11:30 - 12:30, Hall B

Chairs: *H. Huppertz (Switzerland), M. Carreno (Spain)*

Decreased functional frontal lobe connectivity is associated with cognitive impairment in pediatric frontal lobe epilepsy - *H. Braakman (Netherlands)*

Structural changes of the white matter in patients with juvenile myoclonic epilepsy - *C. Roth (Germany)*

Hippocampal subfield analysis in mesial temporal lobe epilepsy - *M. Deppe (Germany)*

Altered interactions within neural network supporting verbal working memory due to hippocampal sclerosis - *P. Campo (Spain)*

## OTHER

## LECTURES AT THE INTERFACE

13:30 - 14:30, Auditorium

Chair: *M. Walker (UK)*

The GABA receptor and its trafficking - *J. Kittler (UK)*

The interface between epilepsy and engineering - *M. Cook (Australia)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

## OTHER

## BASIC

## PHARM

## Session: STATUS EPILEPTICUS: PAST, PRESENT, AND FUTURE

14:30 - 16:00, Auditorium

Chairs: *E. Trinka (Austria), H. Cock (UK)*

GABAA receptor trafficking and the development of benzodiazepine pharmacoresistance during status epilepticus - *H. Goodkin (USA)*

AMPA receptor trafficking and the potential for new treatments for status epilepticus - *J. Kapur (USA)*

New drugs for the treatment of Status Epilepticus - *S. Shorvon (UK)*

## SURG

## N'Ph&amp;Im

## BASIC

## Session: DEVICES AND EPILEPSY: THE FUTURE?

14:30 - 16:00, Hall B

Chair: *M. Cook (Australia)*

Cortical stimulation - *P. Boon (Belgium)*

Deep brain stimulation as epilepsy therapy - *R. Fisher (USA)*

Seizure prediction and other novel management strategies - *M. Cook (Australia)*

Trigeminal Nerve Stimulation (eTNS) for Epilepsy: A novel therapy for epilepsy - *C. DeGiorgio (USA)*

## SURG

## N'Ph&amp;Im

## Session: EEG-FMRI IN EPILEPSY

14:30 - 16:00, Hall E

Chairs: *J. Duncan (UK), K. Garganis (Greece)*

Neuronal correlates of fMRI signals - *A. Shmuel (Canada)*

EEG-fMRI in generalized epilepsies - *H. Laufs (Germany)*

EEG-fMRI in the presurgical evaluation of epilepsy - Adults - *L. Lemieux (UK)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

OTHER GENET

**Session: INVESTIGATING UNDIAGNOSED EPILEPSIES AT TRANSITION TO ADULT NEUROLOGY AND EPILEPSY SERVICES**

14:30 - 16:00, Hall D

Chairs: *R. Wevers (Netherlands), N. Barucha (India)*Illustrative Case Presentations - *L. Nashef (UK)/ N. Moran (UK)/ Y. Rahman (UK)*Update on genetics and the role of CGH array in diagnosis of epilepsy - *N. Ghali (UK)*Investigation algorithm - *R. Nabbut (France)*

OTHER BASIC PHARM PAED GENET

**Session: MECHANISTIC APPROACHES TO TREATMENT OF SEIZURE DISORDERS WITH LEARNING DISABILITY**

14:30 - 16:00, Hall C

Chairs: *J. Jerney (Hungary), E. Brodtkorb (Norway)*The variety of seizure disorders associated with learning disability - *E. Brodtkorb (Norway)*The m-TOR mechanism: a new therapeutic approach in tuberous sclerosis - *P. Curatolo (Italy)*Dravet syndrome: seizure management across the ages - *A. Arzimanoglou (France)*Treatment of epilepsy in mitochondriopathies with POLG mutations - *B. Engelsen (Norway)*

BASIC

**Session: ACTIVATION OF INNATE IMMUNITY AND TOLL-LIKE RECEPTORS: KEY PLAYERS AT THE INTERSECTION BETWEEN INFECTION, INFLAMMATION AND EPILEPSY**

16:30 - 18:00, Hall F

Chairs: *A. Vezzani (Italy), H. Scharfman (USA)*Neonatal programming by neuroimmune challenge – long-term neurological sequelae - *Q. Pittman (Canada)*Toll-like receptor 4-mediated channelopathies and neuronal hyperexcitability - *C. Bernard (France)*Toll-like receptor signalling in epilepsy: the role of endogenous danger signals - *M. Maroso (Italy)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

BASIC GENET PAED

**Session: NEW GENETICS**

16:30 - 18:00, Hall D

Chairs: *P. De Jonghe (Belgium), S. Sisodiya (UK)*Individually rare, but collectively common - The paradox of rare diseases - *P. De Jonghe (Belgium)*Familial epilepsies - Advancing beyond the low-hanging fruits - *F. Zara (Italy)*Always read the instructions: what does the sequence tell us in epilepsy? - *I. Helbig (Germany)*Whole exome, whole genome: anything left? - *B. Koeleman (Netherlands)*

OTHER PAED GENET

**Session: METABOLIC EPILEPSIES; RECOGNITION AND TREATMENT**

16:30 - 18:00, Hall E

Chairs: *A. Evageliou (Greece), T. Martland (UK)*Metabolic epilepsies- clues to diagnosis - *N. Wolf (Netherlands)*Clinical spectrum of early onset epileptic encephalopathies of metabolic origin - *M. Kurian (UK)*GLUT-1 disorders-phenotypic spectrum & treatment - *J. Klepper (UK)*

PHARM PAED OTHER

**Session: MANAGEMENT OF EPILEPSY IN PREGNANCY**

16:30 - 18:00, Hall C

Chairs: *A. Sabers (Denmark), M. Marsh (UK)*Complications of pregnancy in women with epilepsy: summary of epidemiological data (including mortality trends) - *I. Borthen (Norway)*Prenatal diagnosis of malformations: an update - *A. Benachi (France)*Clinical management of pregnant women with epilepsy - *D. Battino (Italy)***OLYMPIAD FINAL**

16:30 - 18:00, Hall B

Chair: *P. Smith (UK)*Prize giving: *R. Tallis (UK)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

THURSDAY 4<sup>TH</sup> OCTOBER

	Hall C 400 pax	Hall D 420 pax	Hall E 385 pax	Hall F 385 pax
07.30-08.00	Common childhood epilepsies			
08.00-08.30				
08.30-09.00				
09.00-09.30	Surgical causes of epilepsy	Management of neuropsychiatric disorders in epilepsy	EMUs in Europe: towards optimised organisation and patients care	Weird epilepsies with unusual patients, strange seizures and EEGs
09.30-10.00				
10.00-10.30				
10.30-11.00	Coffee Break			
11.00-11.30	Medical causes of epilepsy	Prospective international EMU-based study of SUDEP risk factors	Epilepsy informatics and ontology	Rasmussen Encephalitis: we are far from achieving the goal
11.30-12.00				
12.00-12.30				
12.30-13.00				
13.00-13.30				
13.30-14.00	Genetic mechanisms	Hearts and Minds: epilepsy and cardiology special interest group	Management of epilepsy in elderly people	Do we really need a new Classification of Seizures and Epilepsies ?
14.00-14.30				
14.30-15.00				
15.00-15.30				
15.30-16.00	Genetic causes of epilepsy			
16.00-16.30				
16.30-17.00				
17.00-17.30	Special and severe situations			
17.30-18.00				
18.00-18.30				

	Hall G 340 pax	Hall H 100 pax	Hall J 100 pax
08.30-09.00			
09.00-09.30	Where is the seizure focus? Clues from EEG recordings	Perspectives of brain stimulation therapy in epilepsy	Usefulness of clinical electrophysiology in the ICU
09.30-10.00			
10.00-10.30			
10.30-11.00	Coffee Break		
11.00-11.30	Deep brain stimulation in epilepsy – when and where	Epileptogenic zone identification: toward a computer-assisted, quantified approach of intracranial signals	Oligoepilepsy - an official but phantom category?
11.30-12.00			
12.00-12.30			
12.30-13.00			
13.00-13.30			
13.30-14.00	Cognitive and behavioural outcome of patients affected by Dravet Syndrome	What can we learn about epilepsy using human brain tissue?	The children's hour- Presurgical fMRI paradigm selection for young children
14.00-14.30			
14.30-15.00			

N'Ph&amp;Im

PHARM

## ECE Forum: EMUS IN EUROPE: TOWARDS OPTIMISED ORGANISATION AND PATIENTS

## CARE

09:00 - 10:30, Hall E

Chairs: *P. Ryvlin (France), G. Rubboli (Italy)**A. Gil-Nagel (Spain), B.J. Steinhoff (Germany), G. Rubboli (Italy), E. Trinko (Austria), P. Ryvlin (France)*

N'Ph&amp;Im

OTHER

## ECE Forum: WEIRD EPILEPSIES WITH UNUSUAL PATIENTS, STRANGE SEIZURES AND EEGS

09:00 - 10:30, Hall F

Chair: *C. Özkara (Turkey)**C. Özkara (Turkey), P. Genton (France), A. Kelemen (Hungary), M.P. Canevini (Italy)*

BASIC

SURG

## ECE Forum: PERSPECTIVES OF BRAIN STIMULATION THERAPY IN EPILEPSY

09:00 - 10:30, Hall H

Chair: *A. Schulze-Bonhage (Germany)**J. Jefferys (UK), P. Boon (Belgium), M. Morrell (USA), A. Schulze-Bonhage (Germany)*

PSYCH

PHARM

## ECE Forum: MANAGEMENT OF NEUROPSYCHIATRIC DISORDERS IN EPILEPSY – INTEGRATING GLOBAL TREATMENT STANDARDS

09:00 - 10:30, Hall D

Chairs: *M. Kerr (UK), E. Krishnamoorthy (India)**M. Kerr (UK), F.M. Besag (UK), M. Mula (Italy), A. Kanner (USA), E. Krishnamoorthy (India)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

## NPh&amp;Im

**ECE Forum:** USEFULNESS OF CLINICAL ELECTROPHYSIOLOGY IN THE ICU

09:00 - 10:30, Hall J

Chairs: *A. Rossetti (Switzerland), A. Rabinstein (USA)**A. Rossetti (Switzerland), A. Rabinstein (USA)*

## NPh&amp;Im

**ECE Forum:** WHERE IS THE SEIZURE FOCUS? CLUES FROM EEG RECORDINGS

09:00 - 10:30, Hall G

Chair: *E. Papathanasiou (Greece)**E.S. Papathanasiou (Greece), I. Najm (USA), E.L. So (USA), D.L. Schomer (USA)*

## OTHER

**ECE Forum:** EPILEPSY INFORMATICS AND ONTOLOGY

11:00 - 12:30, Hall E

Chair: *S. Lhatoo (USA)*Classification and Consensus – The Informatics Imperative - *S. Lhatoo (USA)*The Present Impact of Ontology on 21st Century Medicine - *O. Bodenreider (USA)*A case for an epilepsy and seizure ontology – The Road Ahead - *A. Rector (UK)*The Possibilities – Practical Demonstrations of Sleep and Epilepsy Systems - *G. Zhang (USA)*The Possibilities – Practical Demonstrations of Sleep and Epilepsy Systems - *S. Sahoo (USA)*

## OTHER

**ECE Forum:** PROSPECTIVE INTERNATIONAL EMU-BASED STUDY OF SUDEP RISK FACTORS

11:00- 12:30, Hall D

Chair: *L. Nashef (UK)**P. Ryvlin (France), L. Bateman (USA), D. Hesdorffer (USA), E. Trinka (Austria), T. Tomson (Sweden)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

## PAED

## PHARM

**ECE Forum:** RASMUSSEN ENCEPHALITIS: WE ARE FAR FROM ACHIEVING THE GOAL

11:00 - 12:30, Hall F

Chair: *T. Granata (Italy)**H. Cross (UK), L. Fusco (Italy), C. Marras (Italy)*

## SURG

**ECE Forum:** DEEP BRAIN STIMULATION IN EPILEPSY - WHEN AND WHERE?

11:00 - 12:30, Hall G

Chair: *I. Rektor**I. Rektor (Czech Republic), P. Kahane (France), B. J. Steinhoff (Germany)*

## BASIC

**ECE Forum:** EPILEPTOGENIC ZONE IDENTIFICATION: TOWARD A COMPUTER-ASSISTED, QUANTIFIED APPROACH OF INTRACRANIAL SIGNALS

11:00 - 12:30, Hall H

Chair: *M. De Curtis (Italy)**F. Wendling (France), R. G. Andrzejak (Spain), O. David (France), V. Gnatkovsky (Italy)*

## PAED

## OTHER

**ECE Forum:** OLIGOEPILEPSY (OLE) - AN OFFICIAL BUT PHANTOM CATEGORY

11:00 - 12:30, Hall J

Chairs: *P. Rajna (Hungary), A. Fogarasi (Hungary)*Oligoepilepsy (OLE) - An Official but Phantom Category - *P. Rajna (Hungary)*Are there characteristics of childhood epilepsies predicting OLE for adulthood? - *A. Fogarasi (Hungary)*"Oligoepileptic outcome" of active epilepsies - *P. Halasz (Hungary)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

PSYCH

PAED

**ECE Forum: COGNITIVE AND BEHAVIOURAL OUTCOMES OF PATIENTS AFFECTED BY DRAVET SYNDROME**

13:30 - 15:00, Hall G

Chair: *C. Dravet (France)**B. Dalla Bernardina (Italy), D. Battaglia (Italy), R. Nabbout (France), L. Lagae (Belgium)*

PHARM

**ECE Forum: MANAGEMENT OF EPILEPSY IN ELDERLY PEOPLE**

13:30 - 15:00, Hall E

Chair: *T. Stepanyan (Georgia)**M. Brodie (UK), J. Pollard (USA)*

OTHER

**ECE Forum: DO WE REALLY NEED A NEW CLASSIFICATION OF SEIZURES AND EPILEPSIES?**

13:30 - 15:00, Hall F

Chair: *E. Hirsch (France)*Introduction - *E. Hirsch (France)*Pro with Video Cases Presentations - *S. Zuberi (UK)*Pro with Video Cases Presentations - *M.P. Valenti (France)*Cons with Video Cases Presentations - *P. Ryvlin (France)*Cons with Video Cases Presentations - *B.J. Steinhoff (Germany)*Questions-Answer - *E. Hirsch (France)*

OTHER

**ECE Forum: HEARTS AND MINDS: EPILEPSY AND CARDIOLOGY SPECIAL INTEREST GROUP**

13:30 - 15:00, Hall D

Chairs: *JP. Leach (UK), Paul Cooper (UK)**Malik Marek (UK), Markus Reuber (UK), Lina Nashef (UK)*

BASIC

**ECE Forum: WHAT CAN WE LEARN ABOUT EPILEPSY USING HUMAN BRAIN TISSUE?**

13:30 - 15:00, Hall H

Chair: *I. Pavlov (UK)*What we have learned about seizures from studies from pediatric epilepsy surgery patients? - *Gary W.**Mathern (USA)*Human epileptogenic oscillations in vitro: old friends and new acquaintances - *Mark Cunningham (UK)*Use of human tissue slices for drug discovery studies suitable for the treatment of pharmacoresistant epilepsies - *Uwe Heinemann (Germany)*Title to be confirmed - *Rüdiger Köhling (Germany)*

SURG

N'Ph&amp;Im

PAED

**ECE Forum: THE CHILDRENS HOUR - PRESURGICAL FMRI PARADIGM SELECTION FOR YOUNG CHILDREN AND/OR IMPAIRED POPULATIONS**

13:30 - 15:00, Hall J

Chairs: *B. Madison (USA), Louise Croft (UK)**B. Madison (USA), Louise Croft (UK), Kathrin Wagner (Germany), Christoph Helmstaedter (Germany)*

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

SURG

GENET

PAED

OTHER

## EPILEPSY COURSE - THE CAUSES OF EPILEPSY 07:30 - 18:30, HALL C - (OPEN TO ALL CONGRESS DELEGATES)

### COMMON CHILDHOOD EPILEPSIES

07:30 - 08:30

Chairs: *P. Smith (UK), Y. Wang (China)*Fever and fever-related epilepsies (including febrile seizures, GEFS+, etc) - *H. Cross (UK)*Benign childhood focal epilepsies (including Panayiotopoulos, Gastaut, and Rolandi) - *R. Guerrini (Italy)*

BREAK

### SURGICAL CAUSES OF EPILEPSY

09:00 - 10:30

Chairs: *P. Smith (UK), B. Jovic-Jakubi (Kuwait/Serbia)*Hippocampal sclerosis - Origins and imaging - *K. Malmgren (Sweden)*Cavernomas and AVMs - Diagnosis and prognosis - *R. Al-Shahi Salman (UK)*Head injury - Risks and medico-legal assessment - *J. Christensen (Denmark)*

10:30 - 11:00 - COFFEE BREAK

### MEDICAL CAUSES OF EPILEPSY

11:00 - 12:30

Chairs: *P. Smith (UK), V. Saxena (India)*Alcohol and drugs - Presentations, detection and management advice - *J.P. Leach (UK)*Brain infections - Encephalitis, HIV, and cysticercosis - *T. Solomon (UK)*utoimmune and inflammatory epilepsies - How to diagnose and whom to test - *R. Nabbut (France)*

BREAK

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY

### GENETIC MECHANISMS

13:15 - 14: 50

Chairs: *P. Smith (UK), T. Chepreganova - Changovska (Macedonia)*Keynote Invited Lecture - Genetic mechanisms in epilepsy: Why has progress been so slow? - *D. Greenberg (USA)*Complex single gene disorders including tuberous sclerosis, neurofibromatosis, progressive myoclonus epilepsies, etc - *N. Delanty (Ireland)*Mitochondrial disorders - Science and syndrome - *L. Bindoff (Norway)*

BREAK

### GENETIC CAUSES OF EPILEPSY

15:20 - 16:30

Chairs: *P. Smith (UK), K Mukhin (Russia)*Clinico-pathological conference - *I. Scheffer (Australia)**(presenter H. Cross (UK) / pathologist: T. Jacques (UK)*Cortical dysplasias - Science and syndrome - *G. Mathern (USA)*

BREAK

### SPECIAL AND SEVERE SITUATIONS

17:00 - 18:30

Chairs: *P. Smith (UK), A. Kapidzic (Bosnia)*Provoked and reflex seizures - Sleep, lights, stress and specific reflex epilepsies - *D. Kasteleijn-Nolst Trenité (Italy/ Netherlands)*Special and severe situations - *A. Covanis (Greece)*The causes of Status Epilepticus - *E. Trinka (Austria)*

18.30 CLOSE AND RETURN OF FEEDBACK FORMS

OTHER, AETIOLOGY, CLASSIFICATION

NEUROPHYSIOLOGY AND NEUROIMAGING

GENETICS

EPILEPSY SURGERY

BASIC SCIENCE

PSYCHIATRY AND PSYCHOLOGY

PAEDIATRIC EPILEPTOLOGY

MEDICAL THERAPY AND PHARMACOLOGY



Keep things simple with Zonegran® once-daily monotherapy

## ZONEGRAN® – A POSITIVE STEP TOWARDS...

- + Effective seizure control in monotherapy and as adjunctive treatment<sup>1</sup>
- + Once daily dosing for monotherapy<sup>1</sup>
- + Not affecting the combined contraceptive pill<sup>1</sup>
- + Minimal interactions with other AEDs<sup>2</sup>
- + A favourable tolerability profile<sup>3</sup>

For use as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy<sup>1</sup>

**Zonegran® V (zonisamide)** Please refer to the SPC before prescribing. **Presentation:** Hard capsules 25 mg, 50 mg, 100 mg zonisamide. **Indications:** Adjunctive therapy in adult patients with partial seizures, with or without secondary generalisation and monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. **Dose and administration: Adults: Adjunctive therapy:** Starting dose is 50 mg in two divided doses. After one week, increase to 100 mg daily. Then increase at one weekly intervals in 100mg increments. Can be taken once or twice daily after titration. In renal or hepatic impairment and patients not receiving CYP3A4-inducing agents consider two weekly intervals. **Monotherapy:** Starting dose is 100 mg once a day. After two weeks, increase to 200 mg once a day. Then increase at two-weekly intervals in 100mg increments. Withdraw gradually. **Elderly and patients with renal or hepatic impairment:** Caution. Not recommended in severe hepatic impairment. **Children and adolescents under 18 years:** Not recommended. **Contra-indications:** Hypersensitivity to zonisamide, sulphonamide or any excipient. **Pregnancy:** Do not use during pregnancy unless potential benefits justify the risks. Women of childbearing potential must use contraception during treatment and for one-month after discontinuation. **Lactation:** Excreted into breast milk. Either discontinue Zonegran or stop breast-feeding. **Warnings and Precautions:** Serious rashes occur, including cases of Stevens-Johnson syndrome. Contains a sulphonamide group which is associated with serious immune based adverse reactions. Closely supervise and consider discontinuation in patients with unexplained rash. Cases of agranulocytosis, thrombocytopenia, leukopenia, aplastic anaemia, pancytopenia and leucocytosis have been reported. Monitor for signs of suicidal ideation and behaviours and consider appropriate treatment. Use with caution in patients with risk factors for nephrolithiasis, including prior stone formation, family history of nephrolithiasis and hypercalcaemia. Evaluate and monitor serum bicarbonate levels in patients who are at risk of metabolic acidosis. If metabolic acidosis develops and persists, consider reducing Zonegran dose, discontinuing Zonegran treatment or adding alkali treatment with Zonegran as osteopenia may develop. Use with caution in patients treated with carbonic anhydrase inhibitors, e.g. topiramate. Decreased sweating, elevated body temperature and heat stroke have been reported. Patients should maintain hydration and avoid excessive temperatures. Monitor pancreatic lipase and amylase levels in patients taking Zonegran who develop clinical signs and symptoms of pancreatitis, consider discontinuation. In cases of severe muscle pain/weakness with or without fever, assess markers of muscle damage and consider discontinuation. Zonegran 100 mg capsules contain E10. Caution in patients less than 40 kg. In patients with weight loss consider dietary supplement, increased food intake or discontinuation. **Drug interactions:** No clinically relevant pharmacokinetic effects on carbamazepine, lamotrigine, phenytoin, sodium valproate, oral contraceptives (ethinylestradiol or nonhormone). Insufficient data with carbonic anhydrase inhibitors, e.g. topiramate. Zonegran was not affected by lamotrigine or CYP3A4 inhibitors. Caution with drugs which are P-gp substrates. Avoid concomitant administration with drugs causing urolithiasis. Zonisamide is metabolised partly by CYP3A4, N-acetyl-transferases and conjugation with glucuronic acid, therefore caution with substances that can induce or inhibit these enzymes. **Side effects:** Most common adverse reactions in controlled adjunctive-therapy studies were somnolence, dizziness and anorexia. Refer to SPC for all side effects. Vary common effects (≥1/10), anorexia,

agitation, irritability, confusional state, depression, ataxia, dizziness, memory impairment, somnolence, diplopia, decreased bicarbonate. Common effects (≥1/100, <1/10): ecchymosis, hypersensitivity, affect lability, anxiety, insomnia, psychotic disorder, bradyphrenia, disturbance in attention, nystagmus, paraesthesia, speech disorder, tremor, abdominal pain, constipation, diarrhoea, dyspepsia, nausea, rash, pruritis, alopecia, nephrolithiasis, fatigue, influenza-like illness, pyrexia, oedema peripheral, weight decreased. Serious effects: pneumonia, suicidal attempt, convulsion, cholecystitis, calculus urinary, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms. The most common adverse reactions in a randomised, controlled monotherapy trial comparing zonisamide with carbamazepine prolonged release were decreased bicarbonate, decreased appetite, and decreased weight. Vary common effects (≥1/100, <1/10): decreased appetite, agitation, depression, insomnia, mood swings, anxiety, ataxia, dizziness, memory impairment, somnolence, bradyphrenia, disturbance in attention, paraesthesia, diplopia, constipation, diarrhoea, dyspepsia, nausea, vomiting, rash, fatigue, pyrexia, irritability, weight decreased, blood creatinine phosphokinase increased, alanine aminotransferase increased, aspartate aminotransferase increased. Isolated cases of Sudden Unexplained Death in Epilepsy Patients (SUDEP). A pooled analysis of safety data on 95 elderly subjects has shown a relatively higher reporting frequency of oedema peripheral and pruritis compared to the adult population. Post-marketing data suggests patients aged ≥65 years report a higher frequency of Stevens-Johnson syndrome and Drug Induced Hypersensitivity syndrome. **Legal Category:** POM. **Basic UK NHS cost:** Zonegran 25 mg: packs of 14 £8.82, Zonegran 50 mg: packs of 56 £47.04, Zonegran 100 mg: packs of 56 £62.72. **Irish price to wholesaler:** Zonegran 25 mg: packs of 14 €9.20, Zonegran 50 mg: packs of 56 €48.78, Zonegran 100 mg: packs of 56 €65.18. **Marketing authorisation numbers:** Zonegran 25 mg 14 capsules: EU/1/04/307/001, Zonegran 50 mg 56 capsules: EU/1/04/307/003, Zonegran 100 mg 56 capsules: EU/1/04/307/004. **Marketing authorisation holder:** Eisai Ltd. **Further information from/Marketed by:** Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN. **Date of preparation:** August 2012.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Eisai Ltd on 0208 600 1400/0845 676 1400 or [EUMedinfo@eisai.net](mailto:EUMedinfo@eisai.net)

### References

1. Zonegran - Summary of Product Characteristics. Date: May 2012.
2. Sills GJ and Brodie MJ. *Epilepsia* 2007; 48: 435-441.
3. Baulac M et al. *Lancet Neurol* 2012; 11(7): 579-588.



# POSTERS

**MONDAY 1ST OCTOBER**

**TUESDAY 2ND OCTOBER**

**WEDNESDAY 3RD OCTOBER**

**POSTERS**

**BEST POSTERS**

**GUIDED POSTER TOURS**

## POSTERS

The Poster Area is located on Level 0 beside the Exhibition Area.

Posters will be set up on Monday 1st October – Wednesday 3rd October between 09:00 and 10:00 and taken down on Monday 1st October – Wednesday 3rd October between 17:00 and 18:00.

The Scientific Advisory Committee has chosen to organise guided poster tours (led by experts in the field), giving researchers the opportunity to present their work during the congress. Presenters will be available at their posters on their assigned day. Each presenter shall be given 3-5 minutes to outline their findings and answer questions.

The full poster abstracts are available online under “Posters” in the interactive session planner which can be found on the congress website. They also appear in an online supplement of Epilepsia.

Delegates can search abstracts by keywords and access the full papers via the mobile application which can be downloaded from the App Store or Android Market.



## BEST POSTERS

A number of posters which have been selected by the Scientific Advisory Committee based on the quality of the work presented, will be shown to the audience during the morning and afternoon coffee breaks.

These posters are signaled with a star (page 85 to 163)



## GUIDED POSTER TOURS

### TOUR LEADER

Silvia Bonelli	Basic Science 1	Mon 1st	12:30 - 14:00	P061	P069
Graeme Sills	Basic Science 2	Mon 1st	12:30 - 14:00	P070	P078
Deb Pal	Basic Science 3	Mon 1st	12:30 - 14:00	P079	P088
Ruta Mameniskiene	Basic Science 4	Mon 1st	12:30 - 14:00	P089	P098
Richard Selway	Epilepsy surgery 1	Mon 1st	12:30 - 14:00	P099	P107
Christian Elger	Epilepsy surgery 2	Mon 1st	12:30 - 14:00	P108	P117
TBC	Genetics 1	Mon 1st	12:30 - 14:00	P118	P129
Dana Craiu	Genetics 2	Mon 1st	12:30 - 14:00	P130	P141
Emilija Cvetkovska	Genetics 3	Mon 1st	12:30 - 14:00	P142	P153
Andre Palmi	Medical therapy and pharmacology 1	Mon 1st	12:30 - 14:00	P154	P164
Khalid Hamandi	Medical therapy and pharmacology 2	Mon 1st	12:30 - 14:00	P165	P174
Rajiv Mohanraj	Medical therapy and pharmacology 3	Mon 1st	12:30 - 14:00	P175	P185
Christoph Baumgartner	Neuroimaging and neurophysiology 1	Mon 1st	12:30 - 14:00	P186	P195
Catherine Chiron	Neuroimaging and neurophysiology 2	Mon 1st	12:30 - 14:00	P196	P205
Fergus Rugg-Gunn	Neuroimaging and neurophysiology 3	Mon 1st	12:30 - 14:00	P206	P215
Ronit Pressler	Paediatric epileptology	Mon 1st	12:30 - 14:00	P216	P222
Madison Berl	Semiology, aetiology and classification 1	Mon 1st	12:30 - 14:00	P223	P232
Yvonne Leavy	Semiology, aetiology and classification 2	Mon 1st	12:30 - 14:00	P233	P242
John Paul Leach	Semiology, aetiology and classification 3	Mon 1st	12:30 - 14:00	P243	P252
Dora Loszadi	Semiology, aetiology and classification 4	Mon 1st	12:30 - 14:00	P253	P262
Alexis Arzimanoglou	Semiology, aetiology and classification 5	Mon 1st	12:30 - 14:00	P263	P272
Doug McCorry	Semiology, aetiology and classification 6	Mon 1st	12:30 - 14:00	P273	P282
Bridget MacDonald	Semiology, aetiology and classification 7	Mon 1st	12:30 - 14:00	P283	P292
Sofia Eriksson	Semiology, aetiology and classification 8	Mon 1st	12:30 - 14:00	P293	P302
Rebecca Liu	Semiology, aetiology and classification 9	Mon 1st	12:30 - 14:00	P303	P312

Beate Diehl	Semiology, aetiology and classification 10	Mon 1st	12:30 - 14:00	p313	p321
Tony Marson	Basic Science 5	Tues 2nd	12:30 - 14:00	p322	p332
TBC	Basic Science 6	Tues 2nd	12:30 - 14:00	p333	p342
TBC	Basic Science 7	Tues 2nd	12:30 - 14:00	p343	p352
Matthew Walker	Basic Science 8	Tues 2nd	12:30 - 14:00	p353	p362
Charles Polkey	Epilepsy surgery 3	Tues 2nd	12:30 - 14:00	p362	p372
Martin Prevett	Epilepsy surgery 4	Tues 2nd	12:30 - 14:00	p372	p381
Torbjorn Tomson	Medical therapy and pharmacology 4	Tues 2nd	12:30 - 14:00	p382	p392
Anna Miserocchi	Medical therapy and pharmacology 5	Tues 2nd	12:30 - 14:00	p393	p403
Lucy Kinton	Medical therapy and pharmacology 6	Tues 2nd	12:30 - 14:00	p404	p414
Bosanka Jovic-Jakubi	Medical therapy and pharmacology 7	Tues 2nd	12:30 - 14:00	p415	p425
Alex Hammers	Neuroimaging and neurophysiology 4	Tues 2nd	12:30 - 14:00	p426	p435
Anja Haag	Neuroimaging and neurophysiology 5	Tues 2nd	12:30 - 14:00	p436	p445
Nandini Mullatti	Neuroimaging and neurophysiology 6	Tues 2nd	12:30 - 14:00	p446	p455
Eduard Hirsch	Semiology, aetiology and classification 11	Tues 2nd	12:30 - 14:00	p456	p464
Bernard Steinhoff	Semiology, aetiology and classification 12	Tues 2nd	12:30 - 14:00	p465	p473
Ley Sander	Semiology, aetiology and classification 13	Tues 2nd	12:30 - 14:00	p474	p483
Mark Richardson	Semiology, aetiology and classification 14	Tues 2nd	12:30 - 14:00	p484	p493
Kath Sieradzian	Semiology, aetiology and classification 15	Tues 2nd	12:30 - 14:00	p494	p503
Eugen Trink	Semiology, aetiology and classification 16	Tues 2nd	12:30 - 14:00	p504	p512
Helen Cross	Semiology, aetiology and classification 17	Tues 2nd	12:30 - 14:00	p513	p522
Philip Patsalos	Semiology, aetiology and classification 18	Tues 2nd	12:30 - 14:00	p523	p532
Vicki Myson	Semiology, aetiology and classification 19	Tues 2nd	12:30 - 14:00	p533	p542
Elaine Hughes	Semiology, aetiology and classification 20	Tues 2nd	12:30 - 14:00	p543	p552
Ann Johnston	Semiology, aetiology and classification 21	Tues 2nd	12:30 - 14:00	p553	p562
Sophia Varadkar	Semiology, aetiology and classification 22	Tues 2nd	12:30 - 14:00	p563	p572
Colin Ferrie	Semiology, aetiology and classification 23	Tues 2nd	12:30 - 14:00	p573	p582

TBC	Basic Science 9	Wed 3rd	12:30 - 14:00	p583	p591
Hermann Stefan	Basic Science 10	Wed 3rd	12:30 - 14:00	p592	p601
TBC	Basic Science 11	Wed 3rd	12:30 - 14:00	p602	p611
Dimitri Kullman	Basic Science 12	Wed 3rd	12:30 - 14:00	p612	p618
Hannah Cock	Epilepsy surgery 5	Wed 3rd	12:30 - 14:00	p619	p628
Alla Guecht	Epilepsy surgery 6	Wed 3rd	12:30 - 14:00	p629	p638
Lina Nashef	Medical therapy and pharmacology 8	Wed 3rd	12:30 - 14:00	p639	p649
Susan Duncan	Medical therapy and pharmacology 9	Wed 3rd	12:30 - 14:00	p650	p659
Sanjay Sisodiya	Medical therapy and pharmacology 10	Wed 3rd	12:30 - 14:00	p660	p669
Heather Angus-Lappan	Medical therapy and pharmacology 11	Wed 3rd	12:30 - 14:00	p670	p678
Bogdan Lorber	Neuroimaging and neurophysiology 7	Wed 3rd	12:30 - 14:00	p679	p687
Maxime Guye	Neuroimaging and neurophysiology 8	Wed 3rd	12:30 - 14:00	p688	p696
Colm Mcginnity	Neuroimaging and neurophysiology 9	Wed 3rd	12:30 - 14:00	p697	p704
TBC	Psychiatry and psychology 1	Wed 3rd	12:30 - 14:00	p705	p715
J A Witt	Psychiatry and psychology 2	Wed 3rd	12:30 - 14:00	p716	p726
Tim VonOertzen	Psychiatry and psychology 3	Wed 3rd	12:30 - 14:00	p727	p737
Sallie Baxendale	Psychiatry and psychology 4	Wed 3rd	12:30 - 14:00	p738	p747
Philippe Kahane	Semiology, aetiology and classification 24	Wed 3rd	12:30 - 14:00	p748	p757
Tejal Mitchell	Semiology, aetiology and classification 25	Wed 3rd	12:30 - 14:00	p758	p767
TBC	Semiology, aetiology and classification 26	Wed 3rd	12:30 - 14:00	p768	p777
Andrew Kelso	Semiology, aetiology and classification 27	Wed 3rd	12:30 - 14:00	p778	p787
Aileen McGonigal	Semiology, aetiology and classification 28	Wed 3rd	12:30 - 14:00	p788	p796
Niels Focke	Semiology, aetiology and classification 29	Wed 3rd	12:30 - 14:00	p797	p806
Mike Kerr	Semiology, aetiology and classification 30	Wed 3rd	12:30 - 14:00	p807	p816
Charlotte Lawthom	Semiology, aetiology and classification 31	Wed 3rd	12:30 - 14:00	p817	p825
David Smith	Semiology, aetiology and classification 32	Wed 3rd	12:30 - 14:00	p826	p835
Rhys Thomas	Semiology, aetiology and classification 33	Wed 3rd	12:30 - 14:00	p836	p846

Full abstracts, including the authors' list and affiliations can be found in the Epilepsia online supplement. Please note that abstracts number P-01 - P-60 have been selected for platform presentation.

## BASIC SCIENCE 1

MONDAY, 01 OCTOBER 2012

- P-61 Characterising seizure evolution in patients with idiopathic generalized epilepsy using a computational model  
J.R. Terry
- P-62 Computer assisted analysis of electrical stimulations during stereo-EEG recordings of pre-surgical epileptic patients  
D.F. Boido
- P-63 Partial epilepsy in children can be predicted with functional network characteristics E.G.A.L.  
Van Diessen
- P-64 Spatio-temporal models to predict and control epileptic seizure dynamics  
G. Baier
- P-65 Glutathione transferase polymorphisms in patients with progressive myoclonic epilepsy  
M. Ercegovic
- P-66 Dopamine receptors in neocortex of patients with temporal lobe epilepsy: correlations with memory disturbances  
M.P. Mata Mendoza
- P-67 Rare clinical feature of epilepsy, report of two cases  
M. Nadeem
- P-68  Up-regulation of methyl CPG binding protein-2 in intractable temporal lobe epilepsy patients and experiment animals  
Y. Chen
- P-69 Network topology and seizure initiation in idiopathic generalised epilepsy  
M.P. Richardson

**BASIC SCIENCE 2**

MONDAY, 01 OCTOBER 2012

- P-70  Significant involvement of toll-like receptor 4 (TLR4) and receptor for advanced glycation end products (RAGE) in epileptogenesis in an experimental model of mesial temporal lobe epilepsy (MTLE)  
V. Iori
- P-71 Ictal tachycardia prevalence and comparison with other factors which influence cardiac rate  
R.M. McGuire
- P-72 Characterization of multiple mitochondrial dna deletions in sclerotic hippocampus of patients with temporal lobe epilepsy  
W.S. Kunz
- P-73 Differential mrna expression of tumor necrosis factor and klotho in temporal lobe epilepsy patients with hippocampal sclerosis  
M.A. Teocchi
- P-74 Epilepsy and sleep; a perfect marriage!!!  
I.J. Poddar
- P-75 NMDAR1 expression in the temporal lobe from intractable epilepsy patients  
Z. Wang
- P-76 Are glutamine synthetase expression levels associated with mesial temporal lobe epilepsy with hippocampal sclerosis?  
A. Martins Da Silva
- P-77 Excitatory amino acid transporter – 1 expression in human mesial temporal lobe epilepsy with hippocampal sclerosis  
B. Leal
- P-78 Developing a multi-modal device for nonEEG, extramural nocturnal seizure monitoring  
J. Van Andel

**BASIC SCIENCE 3**

MONDAY, 01 OCTOBER 2012

- P-79 The risk of seizures in progressive multiple sclerosis  
O.W. Howell
- P-80 “Hercules”: Developing an integrated health care scheme, based on biomedical genetics, advanced biomedical informatics and computer vision for early diagnosis, monitoring and treatment of children with neurological disorders in Greece. Pilot application in absence like seizures  
P. Vorgia
- P-81  DNA methylation profiling reveals differential methylation patterns correlated with gene expression in human epilepsy  
L. Wang
- P-82 Evoked high frequency oscillations in the human hippocampal formation  
D. Fabo
- P-83 The expression of MIR-132 associated with CREB in epilepsy  
H. Wang
- P-84 The expression of LIM KINASE1 and associated active form in human and rat temporal lobe epilepsy  
X. Yang
- P-85 A mathematical model of epilepsy: synaptic regulation acts as an anti-epileptic regulatory mechanism  
A. Peterson
- P-86 Deep brain stimulation early during epileptogenesis modifies disease progression in the hippocampus  
B. Van Nieuwenhuyse
- P-87  Dudep following status epilepticus  
A. Lacey
- P-88 Lentiviral vector-delivered small interfering RNA targeting to HIF-1A gene effect on MDR1B gene expression in rat astrocytes model induced by coriaria lactone  
L. Chen

**BASIC SCIENCE 4**

MONDAY, 01 OCTOBER 2012

- P-89 Electrographic seizures and periodic epileptiform discharges in patients with post-anoxic coma  
E. Altindag
- P-90 Status epilepticus, a hospital based systemic cases review in Southern Taiwan  
C. Lo
- P-91 IV lacosamide as therapeutic option for refractory status epilepticus before coma induction  
E. Santamarina
- P-92 Selective lentiviral mediated targeting of glia cells in the central nervous system  
M. Fassler
- P-93 Asymmetries of sleep spindles in human epilepsy with temporal or frontotemporal focus  
A. Kyzozis
-  P-94 Wireless instantaneous adenosine recording during kainic acid-induced seizure in rat: wincs application  
Y. Shon
-  P-95 Alpha-lactoalbumin, a whey protein rich in tryptophan, is effective in rodent models of seizures and epileptogenesis  
G. De Sarro
- P-96 The CX32 gene expression in brain foci of patients with refractory epilepsy  
W. Lin
-  P-97 GABAergic excitatory mechanisms are involved in the genesis of epileptic activities in the cortex surrounding glioma in humans  
G. Huberfeld
- P-98 The outcome of antiepileptic drug therapy in benzodiazepine-resistant status epilepticus: a review of published cases and trials  
Z.S..Y. Yasiry

**EPILEPSY SURGERY 1**

MONDAY, 01 OCTOBER 2012

- P-99 Lateralization and localization of post-traumatic epilepsy with dual pathology using foramen ovale electrodes: A case report  
H. Henninger
- P-100 A prospective long-term study on the outcome after vagus nerve stimulation at maximally tolerated current intensity in a cohort of children with refractory secondary generalized epilepsy  
A. Cukiert
- P-101 The efficacy of VNS in pharmaco-resistant epilepsy of temporal versus extra-temporal lobe locations  
A. Abubakr
- P-102 Hemispherectomy: An option also for adolescent and adult patients  
A. Althausen
- P-103 Childhood temporal lobe epilepsy: beyond hippocampal sclerosis  
A. Mühlebner-Fahrngruber
- P-104 Centromedian thalamic deep brain stimulation for the treatment of refractory generalised and frontal epilepsy: A blinded controlled study  
A. Valentin
- P-105 Epilepsy surgery in neurofibromatosis type 1  
C. Barba
- P-106 Long-term outcome after callosotomy or vagus nerve stimulation (VNS) in consecutive prospective cohorts of patients with secondary generalized epilepsy  
C. Cukiert
- P-107 Belgrade epilepsy surgery program: early outcome of the first 35 operated patients  
D.V. Sokic

**EPILEPSY SURGERY 2**

MONDAY, 01 OCTOBER 2012

- P-108 Surgical and hardware complications to vagal nerve stimulation for drug resistant epilepsy. A longitudinal single centre study of 143 patients  
H. Kahlow
- P-109 Lennox-gastaut syndrome and callosotomy in adulthood  
M. Herbas Rocha
- P-110 Postoperative resolution of hypothalamic hamartoma in a patient with generalized epilepsy  
N. Cengiz
- P-111 Vagus Nerve Stimulation for medically refractory epilepsy: Our experience in a tertiary epilepsy center at the University of Seville  
P.M. Martinez
- P-112 Cavernous malformations surgical epilepsy series  
R.M. Buentello García
- P-113 Pre- and Post-Op activation of the motor cortex in epilepsy with hemiparesis and rolandic ischemia  
R.F. Severino
- P-114 Role of neuronavigation during invasive monitoring for epilepsy surgery  
R. Vazquez
- P-115 Temporal lobe epilepsy surgery results of an epilepsy surgery unit with up to ten years follow up  
S. Gatzonis
- P-116 Higher responder rates to vagal nerve stimulation: in super-selective patients  
S. Sinha
- P-117 Seizure reduction after deep brain stimulation in a patient with parkinson disease associated with idiopathic generalized epilepsy  
T. Hoshida

**GENETICS 1**

MONDAY, 01 OCTOBER 2012

- P-118 Whole exome sequencing within an Irish pedigree of idiopathic generalised epilepsy  
 M. McCormack
- P-119 Pilot study for PCDH19 gene testing in Bulgaria  
P. Dimova
- P-120 Borderline Dravet Syndrome: Broadening the phenotypic spectrum of pyridoxine-dependent epilepsy  
A. Baumgart
- P-121 Paediatric diagnosis not made until adulthood: A case of Wolf-Hirschhorn Syndrome  
A. Coppola
- P-122 Distribution of ELP4 polymorphisms in rolandic epilepsy patients in relation to clinical parameters  
A. Gkampeta
- P-123 Hippocampal sclerosis worsens adnfl phenotype related to CHRN2 mutation  
A. Labate
- P-124 Euroepinomics RES AR working group: A shared resource for the identification of risk factors in autosomal recessive epilepsies  
A. Suls
- P-125 Identification of a novel gene in a family with severe infantile-onset epilepsy  
C. Depondt
- P-126 Clinical variability resulting from the mutations at the P.ARG1596 residue in the SCN1A gene  
D. Hoffman-Zacharska
- P-127 Phenotyping drug response in epilepsy  
E. Caruana Galizia
- P-128 GLRB is the 3rd major gene-of-effect in hyperekplexia  
 S.K. Chung
- P-129 Pharmacogenomics of valporate induced weight gain  
J. Chukwu

**GENETICS 2**

MONDAY, 01 OCTOBER 2012

- P-130 Does the BDNF VAL66MET polymorphism influence cognitive function in patients with MTLE? - J. Stretton
- P-131 A compound heterozygous missense mutation and a large deletion in the KCTD7 gene presenting as an opsoclonus-myoclonus ataxia-like syndrome - L. Blumkin
- P-132 SUDEP and familial epilepsy - R.H. Thomas
- P-133 Familial Movement-Induced Reflex Epilepsy (FMIRE): A novel genetic epilepsy syndrome with possible mapping to chromosome 1P - S. Schirwani
- P-134 STXBP1 mutations as a cause of dravet syndrome - S. Weckhuysen
- P-135 Dense surface models of face shape assist in predicting pathogenic copy number variants  
K. Chinthapalli
- P-136 Alice In Wonderland Syndrome: Epilepsy, migraine or both? - W.O. Pickrell
- P-137 Effect of UGT1A6\*2 genetic polymorphism on the doses, plasma concentration and metabolism of valproic acid in patients with epilepsy from R.Macedonia - Z. Sterjev
- P-138 Pharmacogenomic testing-based personalized medicine for epilepsy. Analysis of 10 consecutive refractory epileptic patients - P.E. Bermejo
- P-139 Expanding the role of copy number variation in epilepsy pathology - L. Addis 
- P-140 Identifying genes involved in epileptic encephalopathy by whole exome sequencing in families - E.H. Brilstra
- P-141 Preliminary data on the use of MTOR inhibitors for management of refractory seizures and for the management of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex - M. Cardamone

**GENETICS 3**

MONDAY, 01 OCTOBER 2012

- P-142 Identification of a novel genetic locus for febrile seizures in a Maltese family  
C. Farrugia
- P-143 Chromosomopathies and epilepsy  
J.P. Domingos
- P-144 Targeted next generation sequencing as diagnostic tool in epileptic disorders  
 J. Lemke
- P-145 Early epileptic encephalopathy: A peculiar genetic case  
P. Guimarães
- P-146 Analysis of copy number variations affection ion channel genes in idiopathic generalized epilepsy -a case-control survey using a customized microarray-based comparative genomic hybridization (ionchannel array®)  
P. Striano
- P-147 Genetic analysis of sporadic alternating hemiplegia of childhood  
A. Ishii
- P-148 Genetics of epilepsy: A Dutch cohort study  
B. Berghuis
- P-149 Clinical features of epilepsy in dentatorubral-pallidoluyisian atrophy patients  
H. Nakano
- P-150 Effect of CYP3A4\*1G/\*18/\*19 and CYP3A5\*3 genotype on serum carbamazepine concentrations at steady-state in Han Chinese epileptic patients  
J. Wang
- P-151 Recurrent reciprocal genomic rearrangement of 17Q12 as a cause of GEFS+  
K. Hardies
- P-152 A rat model for LGI1-related epilepsy  
S. Baulac
- P-153 Epilepsy associated with 22Q11.21 microduplication  
S. Tang

**MEDICAL THERAPY AND PHARMACOLOGY 1**

MONDAY, 01 OCTOBER 2012

- P-154 Lacosamide in add-on in children and young adults affected by drug-resistant epilepsy  
D. Battaglia
- P-155 Cost utility analysis of phenobarbital as monotherapy among adult epilepsy patients in a tertiary hospital  
P.P. Pingul
- P-156 Effects of valproic acid treatment in lipid profile and HS-CRP in epileptic patients  
S. Markoula
- P-157 Rectal carbamazepine as effective treatment for escalating seizures and status epilepticus  
D.J. Cordato
- P-158 Phase III trials of adjunctive perampanel, a selective ampa receptor antagonist, in patients with treatment-resistant partial-onset seizures: analysis of patient demographics and baseline clinical characteristics  
V. Villanueva
- P-159 Efficacy and safety of lacosamide as adjunctive therapy in a cohort of children with refractory partial-onset epilepsy  
J. Kaleyias
- P-160 The effects of eslicarbazepine and r-licarbazepine on sodium currents through NAV1.7 and NAV1.8 channels  
S. Hebeisen
- P-161 Symptoms and course of intoxication with mesuximide  
C. Brandt
- P-162 Efficacy of intravenous lacosamide in patients with convulsive versus non-convulsive status Epilepticus  
E.Y. Moreno
- P-163 Response to add-on lacosamide in patients with refractory epilepsy  
J. Rodríguez Uranga
- P-164 Levetiracetam is superior to carbamazepine-SR in newly diagnosed epilepsy in the elderly: Results of the STEP-ONE Trial  
K.J. Werhahn

**MEDICAL THERAPY AND PHARMACOLOGY 2**

MONDAY, 01 OCTOBER 2012

- P-165 Zonisamide monotherapy in adult patients with partial, generalized and combined seizures: Findings of a open-label, non-comparative, observational study  
A. Dash
- P-166 Phase III, double-blind, randomised, placebo-controlled trial assessing efficacy and safety of adjunctive zonisamide therapy in paediatric patients with partial-onset seizures: preliminary analysis of effects on cognition  
A. Rosati
- P-167 Sexual hormonal profile of epileptic male patients receiving valproic acid  
D. Chatzistefanidis
- P-168 Efficacy and safety of zonisamide as first add-on therapy in adult patients with partial, generalized & combined seizures  
S.C. Mehta
- P-169 Retigabine: A challenge for therapeutic drug monitoring  
U. Juerges
- P-170 Effects of eslicarbazepine, R-Licarbazepine and oxcarbazepine on fast and slow inactivation of voltage-gated sodium channels  
C. Aires
- P-171 Rufinamide and lennox-gastaut syndrome: efficacy, tolerability and neuropsychological outcome in young patients  
C. Cerminara
- P-172 Exposure-response modeling of lacosamide in adjunctive treatment of patients with partial-onset seizures  
C. Laveille
- P-173 Quality of life in patients with medically refractory epilepsy treated with levetiracetam as a monotherapy  
D.P. Cvetkovska
- P-174  Effects of lacosamide and carbamazepine on human motor cortex excitability  
H. Peckolt

**MEDICAL THERAPY AND PHARMACOLOGY 3**

MONDAY, 01 OCTOBER 2012

- P-175 A clinical study method used to evaluate the efficacy and safety of novel antiepileptic drug eslicarbazepine acetate in epileptic children with partial-onset seizures  
F. Mota
- P-176 Drug resistance and seizure severity of patients in partial-onset seizure registration trials of perampanel compared with recently approved antiepileptic drugs  
G.L. Krauss
- P-177 Pharmacokinetics and tolerability of zonisamide in paediatric patients with epilepsy: results of a phase II, open-label study  
L. Giorgi
- P-178 Long-term tolerability of zonisamide in paediatric patients with epilepsy: results of a phase II, open-label, extension study  
I. Chouette
- P-179 Efficacy and tolerability of lamotrigin monotherapy in newly diagnosed epilepsy  
I. Marinkovic
- P-180 Antiepileptic drug use and seizure referral patterns by non-epilepsy specialists at a London regional neuroscience centre: a clinical audit  
D.P. Holland
- P-181 Slow and fast inactivation of voltage-gated sodium channels by eslicarbazepine and carbamazepine  
P. Soares-Da-Silva
- P-182 Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: A multicentre study in epilepsy clinics in the United Kingdom  
R.D. Cary Elwes
- P-183 The long-term experience of monotherapy with oxcarbazepine and levetiracetam in the tertiary epilepsy center  
J. Lim
- P-184 Generic substitution of antiepileptic drugs: A survey of the patient's perspective  
K. Hensler
- P-185 Topiramate and dyskinesia  
Y. Liang

**NEUROIMAGING AND NEUROPHYSIOLOGY 1**

MONDAY, 01 OCTOBER 2012

- P-186 ICTAL [99MTC] HMPAO spect in nonlesional extratemporal epilepsy  
E. Patarai
- P-187 Magnetoencephalographic measures of abnormal sensory oscillations: A window on photosensitive epilepsy  
G. Perry
- P-188 Comparison of EEG-FMRI data to invasive electrophysiological registration in cryptogenic focal epilepsy  
I. Pesaresi
- P-189 Stress affects emotional processing in left temporal lobe epilepsy  
J. Szaflarski
- P-190 Identification of the epileptogenic zone by EEG-FMRI: Concordance between pre-surgical EEG-FMRI and subsequent stereo-EEG data  
L. Miranda
- P-191 Unveiling the mystery of Déjà vu  
M. Brazdil
- P-192 How to improve the yield of FDG-PET in the preoperative work-up for epilepsy surgery  
M.A. Van
- P-193 Multimodal evoked potentials be useful tool in the study of encephalopathy with status epilepticus during slow sleep: Report 5 cases  
P.A. Ruiz
- P-194 Mesial temporal sclerosis with mri signals extending to the fornix  
S. Baz
- P-195 Localizing epileptic networks in tuberous sclerosis using arterial spin labeling MRI perfusion  
A. Azarion

**NEUROIMAGING AND NEUROPHYSIOLOGY 2**

MONDAY, 01 OCTOBER 2012

- P-196 The effect of generalized spike and waves discharge duration and IGE sub-syndrome on brain networks as revealed by EEG-FMRI  
M. Pugnaghi
- P-197 SPECT perfusion patterns in paediatric epilepsy of temporal lobe origin: Correlation with surgical outcome  
P.S. Lakkunta
- P-198 Functional connectivity study in patients with temporal lobe epilepsy and depressive symptoms  
R. Rocamora
- P-199 Convergent evidence of regional thalamic abnormalities in mesial temporal lobe epilepsy  
S.S. Keller
- P-200 MR Imaging in status epilepticus secondary to paraneoplastic encephalitis  
S. Sarria
- P-201 Dynamic effective connectivity of epileptic networks determined with high density EEG source analysis  
S. Vulliemoz
- P-202 Altered resting-state connectivity during interictal generalized spike-wave discharges in drug-naïve childhood absence epilepsy  
T. Yang
- P-203 Comparison of FDG-PET and ICTAL SPECT in children with focal epilepsy undergoing pre-surgical evaluation  
N. Vora
- P-204 Ex vivo high-resolution mr (7T) microscopy of the human hippocampus  
R. Coras
- P-205 Intracranial EEG-FMRI: Mapping brain networks related with alpha and beta in sensorimotor cortex  
S. Perani

**NEUROIMAGING AND NEUROPHYSIOLOGY 3**

MONDAY, 01 OCTOBER 2012

- P-206 Definition of a stereotactic 3D model of the human insula for neurosurgical approach (epilepsy and stereotaxic surgery)  
A. Aff
- P-207 Myoclonus cortical generators in unverricht-lundborg disease: An electric source imaging study  
A. Del Felice
- P-208 A novel method for the classification of interictal EEG abnormalities in partial epilepsy: An EEG-FMRI validation study  
A.E. Vaudano
- P-209 Flumazenil is a weak substrate for P-Glycoprotein in humans. A PET study in pharmacoresistant patients with unilateral MTS  
F.E. Froklage
- P-210 ICTAL PET findings in patients with refractory focal epilepsy  
G. Kuester
- P-211 Motor circuit tractography predicts motor performance in children with rolandic epilepsy  
L.M. Brindley
- P-212 Temporal pole asymmetry in temporal lobe epilepsy patients  
L. Martinkovic
- P-213 Comparative value of siscom, FDG-PET and intracranial EEG in patients with non-lesional extratemporal epilepsy  
M. Kudr
- P-214 Reliability of memory FMRI in temporal lobe epilepsy patients  
K. Towgood
- P-215 Granger causality analysis of resting-state networks in post-traumatic epilepsy patients  
H.A. Ferreira

**PAEDIATRIC EPILEPTOLOGY 1**

MONDAY, 01 OCTOBER 2012

- P-216 Seizure burden in neonatal hypoxic ischemic encephalopathy: the modifying role of phenobarbitone during therapeutic hypothermia  
N.E. Lynch
- P-217 In depth performance analysis of a novel automated seizure detection algorithm for neonatal EEG  
S. Mathieson
- P-218 Delta frequency seizures are common in sick newborns and can be easily recognised using a simple adaptation to amplitude integrated EEG  
T.V. Stanley
- P-219 Amplitude-integrated electroencephalography and electroencephalography in neonates  
W. Kim
- P-220 The application of multichannel amplitude-integrated EEG with simultaneously video EEG in neonatal seizure  
X. Zhu
- P-221 Diagnosis of neonatal seizures: effectiveness of current classification systems  
L. Menzies
- P-222  Clinical and electrographic pattern correlates in neonatal seizures  
M.M. Awadh

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 1**

MONDAY, 01 OCTOBER 2012

- P-223 Screening for symptoms of anxiety and depression in patients with psychogenic nonepileptic seizures  
A.Z. Ilic
- P-224 Psychogenic nonepileptic seizures in video-EEG monitoring unit: Spontaneous seizures and effectiveness of provocative technique  
I. Mareckova
- P-225 Cognitive and somatic symptoms of anxiety during dissociative and epileptic seizures  
L.H. Goldstein
- P-226 The role of electroencephalography in diagnostics of central nervous system (CNS) structural lesions in children with minor neurological symptoms  
O. Kozhevnikova
- P-227 Prevalence of restless legs syndrome among adult epilepsy patients is high: A preliminary screening in Armenia  
S. Khachatryan
- P-228 Co-existing psychogenic non-epileptic seizures and epileptic seizures: Determination of incidence in an epilepsy monitoring unit population  
D.F. Thomas
- P-229 Health-related quality of life in patients with epilepsy, non-epileptic attack disorder and dual diagnosis  
F. Ali
- P-230 Dissociative experiences and quality of life in patients with non-epileptic attack disorder  
J.W. Mitchell
- P-231 Mutations within the GLRA1 gene associated with hyperekplexia  
S.E. Wood
- P-232 Development of a waiting list initiative and implementation of an early intervention clinic for non-epileptic attack disorder  
G.M. Fortune

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 2**

MONDAY, 01 OCTOBER 2012

- P-233 A retrospective study of 131 patients with psychogenic non-epileptic seizures (PNES): Comorbid diagnoses and outcome after in-patient treatment  
H.C. Miersch
- P-234 Significance of activation of auras in patients with psychogenic non-epileptic seizures (PNES)  
K.N. Ramesha
- P-235 Use of anti-epileptic drugs in the setting of non-epileptic seizures  
M. Stefanidou
- P-236 Clinical and long-term videoEEG features of patients with both psychogenic non epileptic and epileptic seizures: A prospective study in a Spanish epilepsy unit  
R.M. Vivanco-Hidalgo
- P-237 "Rinch Motions" (Rhythmic ictal nonclonic hand motions) analysis: Incidence and lateralizing value  
K. Musilová
- P-238 What about a transition program on epilepsy?  
J. Carrizosa
- P-239 A review of an epilepsy nurse specialist's clinical activity & association with paediatric epilepsy admissions  
K. Johnson
- P-240 Implementing the American Academy of Neurology epilepsy quality measures: Using an epilepsy electronic patient record as a tool for change  
M. Fitzsimons
- P-241 Transition's gap from paediatric to adult system care of patients with epileptic encephalopathy: A myth or a reality?  
M. Kuchenbuch
- P-242 Audit of patient satisfaction at the Transition Adolescent Epilepsy Clinic in The Walton Centre NHS Foundation Trust, Liverpool  
M. Rodriguez

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 3**

MONDAY, 01 OCTOBER 2012

- P-243 Learning environment at a paediatric ward: A qualitative study  
T. Løvenskjold
- P-244 Can a nurse intervention promote the self-management of patients who attend emergency departments with established epilepsy? A nested qualitative study  
A.J. Noble
- P-245 Facility of epilepsy service in Thailand  
S. Towanabut
- P-246 Impact of staffing levels and training on patient safety & management on the epilepsy monitoring unit  
C.A. McLaughlin
- P-247 National audit of seizure management in hospitals: Initial findings  
A.G. Marson
- P-248 Ambuflex/epilepsy: Implementation of patient-reported outcomes in epilepsy clinics  
L.M.V. Schougaard
- P-249 Epilepsy care by rail in rural India - Thinking out of the box!  
M.B. Singh
- P-250 The development of standard operating procedures (SOPS) in epilepsy care to reduce variability and transform a national service  
M.E. White
- P-251 Late-life remission in intractable epilepsy: "Burnt out epilepsy" or natural history?  
M. Belluzzo
- P-252 Comparison of prognosis between patients with and without epileptic seizures as a first manifestation of stroke  
S.Z. Atic

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 4**

MONDAY, 01 OCTOBER 2012

- P-253 Surgical versus conservative treatment in patients with cerebral cavernomas and non refractory epilepsies  
S. Fernández
- P-254 Antiepileptic drug suspension in adult patients-assessment of risk factors  
S.M. Vujisic
- P-255 Provoked seizures and functional outcome one year after acute ischaemic stroke  
H. Senties-Madrid
- P-256 Epilepsy remission stage statement by nonlinear methods for EEG results processing.  
S. Artsiomenka
- P-257 Epilepsy as a chronic complication in cerebral venous thrombosis: A 20-year follow-up  
E. Chiquete
- P-258 Long-term outcome after cognitive and behavioral regression in non-lesional epilepsy with CSWS  
E. Roulet Perez
- P-259 Ten-year mortality among people with epilepsy (PWE) at a primary health care level: The case of the Mbam area of Cameroon  
J.Y. Fonsah
- P-260 Long-term outcome in absence epilepsies  
M. Holtkamp
- P-261 Prognostic factors for time to treatment failure and time to 12 month remission for patients with generalised epilepsy: Post hoc and subgroup analyses of sanad  
L.J. Bonnett
- P-262 Mortality and SUDEP in epilepsy patients treated with vagus nerve stimulation  
C.A. Granbichler

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 5**

MONDAY, 01 OCTOBER 2012

- P-263 Is terminal remission without therapy possible in patients with juvenile myoclonic epilepsy?  
N.J. Jovic
- P-264 Cardiac arrhythmias may be underestimated in people with chronic epilepsy  
R.J. Lamberts
- P-265 Has treatment of epilepsy improved in the past 10 years? The impact of epilepsy treatment in the past 10 years; a community-based comparison study  
M. Wassenaar
- P-266 Carbamazepine and oxcarbazepine triggered epileptic negative myoclonus aggravation in childhood  
K.Y. Mukhin
- P-267 Neonatal parameters as prognostic factors for epilepsy or cerebral palsy in infants with hypoxic-ischemic encephalopathy  
N.M. Cerovac
- P-268 Reliability and validity of a Spanish version of the impact of pediatric epilepsy scale in a Cuban population  
N. Garófalo Gómez
- P-269 Management of acute symptomatic seizures: Outline of current practice  
R. Powell
- P-270 Refractory seizures and QOL: can a patient be worse off on AEDS? 3 case studies  
S. White
- P-271 A study of standardised mortality rate in people with intellectual disability who died of sudden unexpected death in epilepsy (SUDEP)  
R. Kiani
- P-272 Epilepsy and psychiatric disorders in a "learning disability" patient's series  
V.C. Monetti

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 6**

MONDAY, 01 OCTOBER 2012

- P-273 Complex partial status epilepticus due to hippocampal sclerosis as the initial manifestation of pediatric-onset mixed connective tissue disease  
D. Athanasopoulos
- P-274 Status epilepticus and multiple sclerosis case overview  
D. Sahovic
- P-275 Generalised seizures as first clinical manifestation of different focal cerebrovascular impairment  
D.I. Cuciureanu
- P-276 Antecedents of drug resistant temporal lobe epilepsy with and without hippocampal sclerosis: A comparative study  
G. Shukla
- P-277 Treatment efficacy of symptomatic epilepsy in post stroke patients  
H.D. Hambardzumyan
- P-278 Comparison of somatic comorbidity incidence in young adults with idiopathic and symptomatic epilepsy  
L.B. Mar'Yenko
- P-279 Fibrinolysis and symptomatic epileptic seizures: Prevention or induction  
M.J. Aguilar Amat Prior
- P-280 Epilepsy associated with cerebrotendinous xanthomatosis successfully treated by chenodeoxycholic acid  
P. Vrielynck
- P-281 Epilepsy in patients with tuberous sclerosis complex  
S.T. Ristic
- P-282 Mesial temporal lobe epilepsy as a neuropsychiatric syndrome of systemic lupus erythematosus  
T. Toyota

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 7**

MONDAY, 01 OCTOBER 2012

- P-283 An assessment of the inter-observer reliability of the definition of drug-resistant epilepsy provided by the International League against Epilepsy  
L.H. Ronquillo
- P-284 Epilepsy among the students of Çanakkale Onsekiz Mart University  
H.I. Ozisik
- P-285 Knowledge and beliefs of parents of children and adolescents with epilepsy  
B. Desnous
- P-286 On the origin of Cornu Ammonis (Ammon's Horn)  
I. Iniesta
- P-287 Audit of local neuropathology practice in SUDEP autopsies  
M. Thom
- P-288 Functional asymmetry of the brain and late components of event-related potential P300  
O.S. Ivetic
- P-289 Pharmaco-resistant epilepsy: Case presentation  
C. Panea
- P-290 Anti-epileptic therapy and sleep related problems in Georgian epilepsy patients  
L. Maisuradze
- P-291 neuroaminoacids state in patients recovering from traumatic brain injury with convulsive syndrome  
I.I. Chernenko
- P-292 Epilepsy and neurocysticercosis in North West Cameroon: A serological study  
A.J. Akeneck

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 8**

MONDAY, 01 OCTOBER 2012

- P-293 Health-related quality of life of patients in the patientslikeme epilepsy community  
C. De La Loge
- P-294 Evaluating epileptic population and its cost in the South of Spain  
G. Garcia Martin
- P-295 Pseudo-refractory epilepsy: Follow up 105 patients  
G. Kutlu
- P-296 What really matters to people with epilepsy? Results from an international patient survey  
J.A. Cramer
- P-297 Somatic co-morbidities are a major issue in people with epilepsy  
J. Novy
- P-298 Development and pilot of a questionnaire for reporting epilepsy-related deaths  
L. Flores
- P-299 Place of video-EEG monitoring in diagnosis and management of idiopathic generalized epilepsy  
L. Luhtimovschi
- P-300 PGES is more frequent in convulsive seizures arising from sleep  
R.J. Lamberts
- P-301 Automatic abnormal waves detection from the electroencephalograms of epilepsy cases to sort out the spikes, the sharps, the polyphase based on wavelet transformation crosscorrelation  
S. Noertjahjani
- P-302 Reflex myoclonic epilepsy in infancy: A multicenter clinical study  
S. Matricardi

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 9**

MONDAY, 01 OCTOBER 2012

- P-303 A novel internet animation seizure survey may be an effective screening instrument for population-based research  
W.J. D'Souza
- P-304 A competency framework for adult epilepsy specialist nurses  
Y. Leavy
- P-305 Treatment gap of epilepsy in Pakistan: A population-based study  
Z. Mogal
- P-306 William Richard Gowers 1845-1915: Exploring the Victorian brain  
A. Scott
- P-307 Troponin levels after seizures and relationship to cardiovascular risk factors  
A. Fawaz
- P-308 Occurrence of ICTAL arrhythmia is associated with a first-degree family history of epilepsy  
G. O'Connor
- P-309 Association between epilepsy and cysticercosis and toxocarasis: A population-based case-control study in an urban slum in India  
G. Singh
- P-310 Acute pure red cell aplasia. rare complication of lamotrigine treatment  
H. Ikeda
- P-311 The role of minocycline on development of amygdala kindling in wistar rats  
S.M. Beheshti Nasr
- P-312 Different types of headache in patients with epilepsy: Clinical investigations  
C. Lorenzen

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 10**

MONDAY, 01 OCTOBER 2012

- P-313  Psychosocial outcome and patient satisfaction 10 years after temporal lobe resection for epilepsy  
L. Andersson-Roswall
- P-314  A comparison study of the quality of life (QOL) in epilepsy, MS, and healthy controls in Saudi Arabia  
H. Alkhamees
- P-315  Epileptic encephalopathies of the Landau-Kleffner and continuous spike and waves during slow-wave sleep types: genomic dissection makes the link with Autism  
G. Lesca
- P-316 Seizure semiology of a hot water seizure case  
O. Karadas
- P-317 Derealization disorders in epilepsy  
P. Vlasov
- P-318 Transient epileptic amnesia: Description of two cases  
S. Meregalli
- P-319 Epileptic aphasia: A description of 10 new cases  
A. López-Ferreiro
- P-320 Semiologic and EEG features of patients with temporal lobe epilepsy and hippocampal sclerosis who were seizure-free following surgery  
H. Ertaşoğlu Toydemir
- P-321 Characteristic seizure semiology in PCDH19-Related infantile epileptic encephalopathy  
H. Ikeda
- P-322 Reliability of postictal nose rubbing for localization and lateralization of epileptogenic zone in focal epilepsies  
N.M. Vojvodic

**BASIC SCIENCE 5**

TUESDAY, 02 OCTOBER 2012

- P-323 The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy  
M. Ferlisi
- P-324 EEG and MRI findings in super refractory status epilepticus due to unknown underlying etiology  
A. Ferrari
- P-325 Epileptic status in adults  
D. Ndoja
- P-326 A case of severe form of pandas-like course  
L.C. Heberle
- P-327 Efficacy of intravenous lacosamide in symptomatic focal motor status epilepticus: A clinical and video-polygraphic study  
M. Trivisano
- P-328 Convulsive status epilepticus in children-predictors of outcome  
N. Tatishvili
- P-329 Utility of one hour portable EEG recording in detection and management of non-convulsive status epilepticus in patients with altered sensorium in a rural-based ICU in resource limited settings  
S.D. Desai
- P-330 Atypical absence nonconvulsive status epilepticus in children with medulloblastoma after craniospinal irradiation; a possible Lennox-Gastaut Syndrome mimicking entity  
I. Maestro Saiz
- P-331 Non-convulsive status epilepticus: profile of patients admitted on a tertiary hospital  
M.J. Aguilar Amat Prior
- P-332 Efficacy of different therapeutic agents in status epilepticus  
J. Rösche

**BASIC SCIENCE 6**

TUESDAY, 02 OCTOBER 2012

- P-333 Non-convulsive status epilepticus: prevalence, precipitating factors, clinical manifestations, radiological, electroencephalographic findings and mortality in a tertiary care hospital in Mexico  
V. Gijón-Mitre
- P-334 Successful use of ketamine in pediatric super-refractory status epilepticus: Case report  
C. Andrade
- P-335 Delay in diagnosis: A new predictor of refractoriness and mortality in nonconvulsive status epilepticus?  
M. Sanchez
- P-336 In hospital deaths associated with status epilepticus: A Dr Foster alert  
E.F. Cant
- P-337 The impact of newer antiepileptic drugs in the treatment of status epilepticus  
A.O. Rossetti
- P-338 Corticosteroids in the treatment of non-convulsive status epilepticus (NCSE)  
D. Tsiftsis
- P-339 Nonconvulsive status epilepticus in normoglycemic diabetic patients  
J. Klem
- P-340 Focal myoclonus status is not uncommon manifestation in the patients with antifosfolipid syndrome  
L.M. Stancetic Bacvanin
- P-341 Super-refractory status-epilepticus: there is always hope  
Z. Agirre-Arrizubieta
- P-342 Use of intravenous lacosamide in status epilepticus and cluster seizures  
Y. Handouk

**BASIC SCIENCE 7**

TUESDAY, 02 OCTOBER 2012

- P-343 The effects of antiepileptic drugs on the voltage-gated sodium channels of the peripheral myelinated nerve fibers of the adult rat  
G. Zafeiridou
- P-344 A new in vitro model of high frequency electrical stimulus induced seizure and effects of standard antiepileptic drugs  
A. Wahab
- P-345 Penumbra region excitability is not enhanced acutely after cerebral ischemia in the in vitro isolated guinea pig brain  
G.L. Breschi
- P-346 Investigation of antiepileptic drug transport by solute carriers OATP-1A2 and MCT1  
H.L. Jones
- P-347 L-Type voltage gated calcium channels affect seizure-like activity in an ambivalent manner, but promote the induction of paroxysmal depolarization shifts  
H. Kubista
- P-348 Patterns of synchronous population activity in the neocortical tissue of epileptic and non-epileptic tumor patients, in vitro  
K. Tóth
- P-349 Synaptic and non-synaptic mechanisms underlying suppression of epileptiform activity in the subicular neurons of the hippocampus  
N. Sah
- P-350 Epileptiform activity in the piriform cortex after 4ap administration in the isolated guinea pig brain  
L.M. Uva
- P-351 How do changes in gabab receptor expression affect idiopathic generalised epilepsy phenotypes? (Literature Review)  
G. Summons
- P-352 The orexin pathway is not involved in the attenuation of limbic seizures by des-acyl ghrelin  
J. Coppens

**BASIC SCIENCE 8**

TUESDAY, 02 OCTOBER 2012

- P-353 Anti-seizure action of the antidepressant, sertraline  
M. Sitges
- P-354 Proteomic profiling of the hippocampus of epileptic mice with and without sclerosis  
A. Mago
- P-355 Benefits of aerobic exercise for adult rats with seizures induced by homocysteine thiolactone  
D. Hrcic
- P-356 Early and late MRI changes in rat brain after status epilepticus and behavioral impairment  
E. Suleymanova
- P-357 Brief seizures induce a severe ischemic/hypoxic episode  
G.C. Teskey
- P-358 The dynamics of cortico-thalamo-cortical network interactions at the transition to spike-wave discharges  
G. Van Luijtelaar
- P-359 Age-dependent changes in XCT and EAAC1 expression in somatosensory cortex of WAG/RIJ rats  
J. Van Liefvering
- P-360 Evaluation of novel behavioural correlates to electrographic seizure activity in mice  
J. Zelano
- P-361 Effect of low-frequency stimulation on the afterdischarge induced by acute kindling of the rabbit hippocampus  
K. Tsuchiya

**EPILEPSY SURGERY 3**

TUESDAY, 02 OCTOBER 2012

- P-362 Localizing value of ICTAL SPECT in patients with tuberous sclerosis complex and intractable epilepsy  
 A. Jahodova
- P-363 Efficacy of vagus nerve stimulation in 28 consecutive patients with treatment resistant epilepsy not eligible for epilepsy surgery  
F. Dainese
- P-364 Resective surgery for refractory structural epilepsy in infants and young children  
G. Ramantani
- P-365 Clinical features of seizures semiology and electroencephalography in young children with lesional temporal lobe epilepsy  
X. Shao
- P-366 Long-term outcome of resective surgical procedures in adult patients with refractory epilepsy: The Kork Series  
A.M. Staack
- P-367 Risk factors for epileptic seizure of cavernous malformations in the central nervous system: 52 cases  
C. Huang
- P-368 Short-term results of stereotactic anterior callosotomy in the treatment drug resistant epilepsy  
K. Kostiantyn
- P-369 Acute intralesional recording in hypothalamic hamartomas: description of 4 cases  
N. Specchio
- P-370 Vagus Nerve Stimulation decrease emergency assistance and hospitalization in drug-resistant epileptic patients  
T. García-Sobrino
- P-371 Evolution up to 18 years after surgery for temporal epilepsy with hippocampal sclerosis: impact of technique, medication management and presurgical variables  
 D. Crestani

**EPILEPSY SURGERY 4**

TUESDAY, 02 OCTOBER 2012

- P-372 Epilepsy Surgery in the United Kingdom in 2011, an update  
A. Neligan
- P-373 Long-term outcome of functional temporal lobe disconnection for non-lesional mesiotemporal epilepsy  
B. Legros
- P-374 Infantile spasms as the unique seizure type in hemispheric epilepsies related to perinatal middle cerebral artery stroke - outcome following hemispherotomy  
C. Bulteau
- P-375 Long-term outcome after multilobar epilepsy surgery  
D. Altenmüller
- P-376 Outcome of extra temporal epilepsy surgery and hemispherectomy  
D.D. Ruikar
- P-377 Seizure outcome after hemispherectomy: Data from the Swedish national epilepsy surgery register  
I. Olsson
- P-378 The contributions of meg in surgical decision making of lesional epilepsy  
J.P. Blount
- P-379 Comparative study of efficacy and safety between radiosurgical callosotomy and open callosotomy for Lennox-Gastaut Syndrome in a third-level neurological center  
J.D.D. Del Castillo Calcáneo
- P-380 Correlation of FDG-PET and voxel-based MRI morphometry with invasive EEG findings and surgical results in MRI-negative epilepsy  
J. Scholly
- P-381 Intracranial EEG ictal onset frequency: High or low?  
J. Chung

**MEDICAL THERAPY AND PHARMACOLOGY 4**

TUESDAY, 02 OCTOBER 2012

- P-382 Status dystonicus in a case of Wilson's Disease  
O. Cokar
- P-383 Early treatment with lacosamide: Results of relacova study  
M. Garcés
- P-384 On the use of intra rectal valium in patients with dravet syndrome: Families opinion  
N. Coqué
- P-385 A retrospective observational study of the use, effectiveness, tolerability, and retention of carbamazepine and valproate in children and young people  
N.P. Docheva
- P-386 Buccal pyridoxine: rescue medication for prolonged seizures in children with pyridoxine dependent epilepsy, in the community setting  
L. Christodoulou
- P-387 Cognitive effects of lacosamide  
D. Ijff
- P-388 Steady-state pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers  
A. Falcão
- P-389 Long-term efficacy and tolerability of zonisamide as adjunctive therapy in patients with refractory partial epilepsy  
A. La Neve
- P-390 The effects of eslicarbazepine on receptors, ion channels, enzymes and transporters  
A.I. Loureiro
- P-391 A case report of the safe use of levetiracetam in a patient with sickle cell disease  
A. Nitkunan
- P-392 Drug utilization study with lacosamide in daily clinical practice in Belgium: An interim analysis  
W. Van Paesschen

**MEDICAL THERAPY AND PHARMACOLOGY 5**

TUESDAY, 02 OCTOBER 2012

- P-393 A retrospective observational study of comparative lacosamide cost in a real world setting in the USA (VOYCE)  
S. Janssens
- P-394 Hepatotoxicity and anticonvulsant therapy in children and adolescents  
S. Karkelis
- P-395 Adverse effects of AEDS are related with dose and number of AEDS: Observational study with adverse event profile  
S.E. Kim
- P-396 Comparison of dried blood spots and plasma valproic acid and carbamazepine levels  
S.T. Kong
- P-397 Serum concentrations of lacosamide in patients with epilepsy: influences of dose, age, gender and comedication  
S. Markoula
- P-398 The MTLE mouse as a model of human temporal lobe epilepsy: A comparative study of the most commonly-used antiepileptic drugs  
V. Duveau
- P-399 Drug utilization study with lacosamide in daily clinical practice in Belgium: An interim analysis  
W. Van Paesschen
- P-400 Efficacy of progabide add-on for refractory epilepsy  
X. Zou
- P-401 Levetiracetam in oral solution – safety, tolerability and efficacy in paediatric patients. Single-centre clinical trial  
O. Horak
- P-402 Meta-analysis of nonpsychotic behavioral treatment emergent adverse events in brivaracetam and levetiracetam development programs  
J. D'Souza
- P-403  Evaluation of sudden unexpected death in epilepsy (sudep) occurring in lamotrigine (LTG) clinical trials  
T. Tomson

**MEDICAL THERAPY AND PHARMACOLOGY 6**

TUESDAY, 02 OCTOBER 2012

- P-404 Improving the development of promising drug candidates: Preclinical solutions in a chronic mouse model of mesial temporal lobe epilepsy  
M. Langlois
- P-405 Eslicarbazepine does not alter proliferation and cell cycle distribution of neural stem cells isolated from the rat subventricular zone  
M.I. Morte
- P-406 Steady-state pharmacokinetics and tolerability of once-daily and twice-daily regimens of eslicarbazepine acetate in healthy volunteers  
M. Vaz-Da-Silva
- P-407 Retigabine in children and adolescents with pharmacoresistant epilepsies - documentation with the electronic treatment diary Epi-Vista®  
K. Groening
- P-408 The effects of eslicarbazepine, r-licarbazepine, oxcarbazepine, and carbamazepine on sodium currents through NAV1.2 channels  
N. Pires
- P-409 Efficacy of lacosamide in drug-resistant focal epilepsy  
P. Bellas-Lamas
- P-410 Prescribing pattern of older versus newer antiepileptic drugs in patients with epilepsy attending outpatient department at a tertiary care centre in India  
R. Joshi
- P-411 Rufinamide's efficacy and safety in childhood epilepsy secondary to brain malformations  
R. Moavero
- P-412 On the use of intra rectal valium in patients with Dravet Syndrome: Families' experience  
R. Nabbout
- P-413 Comparative bioavailability study of two different sources of eslicarbazepine acetate in healthy subjects  
R.P. Sousa
- P-414 Modelling the cognitive effects of common antiepileptic drugs: A cross sectional head-to-head comparison using the epitrack  
C. Helmstaedter

**MEDICAL THERAPY AND PHARMACOLOGY 7**

TUESDAY, 02 OCTOBER 2012

- P-415 Design of a phase III, double-dummy, active-controlled, multi-national non-inferiority monotherapy trial of eslicarbazepine acetate versus controlled-release carbamazepine in adults with partial-onset seizures  
J. Moreira
- P-416 Zonisamide as add-on treatment does not affect nocturnal sleep and vigilance in patients affected by focal epilepsy: A polysomnographic study  
A. Romigi
- P-417 Efficacy of perampanel, a selective ampa antagonist, in complex partial and secondarily generalized seizures: A pooled analysis of phase III studies in patients with treatment-resistant partial-onset seizures  
B.J. Steinhoff
- P-418 Long-term cognitive effects of treatment with monotherapy carbamazepine (CBZ) and valproate (VPA)  
★ D. Ijff
- P-419 Implantation of phenytoin-loaded polycaprolactone microspheres in a rat model of temporal lobe epilepsy  
★ J. Sui
- P-420 Seizure freedom on antiepileptic monotherapy  
L.J. Stephen
- P-421 \* will be presented on Wednesday – see Medical Therapy and Pharmacology 8  
Eslicarbazepine acetate and plasma levels of combined antiepileptic drugs: a population pharmacokinetics evaluation based on double-blind phase III clinical studies  
M. Bialer
- P-422 Effects of eslicarbazepine and lacosamide on slow and fast inactivation of voltage-gated sodium channels  
M.J. Bonifácio
- P-423 Outcomes in newly diagnosed epilepsy: Why do patients remain uncontrolled?  
M. Brodie
- P-424 The direct costs of treatment with antiepileptic drugs in Balearic Islands  
M. Massot Cladera
- P-425 Assessment of adherence to medication in refractory partial epilepsy  
N. Carpentier

**NEUROIMAGING AND NEUROPHYSIOLOGY 4**

TUESDAY, 02 OCTOBER 2012

- P-426 Human herpes 6, 7-DNAS (PCR) in CSF of convulsive children  
H.R. Monavari
- P-427 Effect of interictal epileptiform activities and subclinical electroencephalographic seizure patterns on heart rate variability in temporal lobe epilepsy  
M. Kinoshita
- P-428 Epilepsia partialis continua in chronic and acute cerebral disease: report of two patients  
J.M. Pinzon
- P-429 The role of streptococcal infection in children with neuropsychiatric manifestations (PANDAS): A case control study  
E. Shirazi
- P-430 Cognitive functions in patients with frontal lobe epilepsy during topiramate or depakine therapy  
G.V. Selitskii
- P-431 Differences of intracerebral electrical stimulation thresholds in the human brain  
C. Stephani
- P-432 Thalamocortical dysrhythmia in photosensitive epilepsy  
D. Brazzo
- P-433 Imaging dynamic memory encoding network plasticity post anterior temporal lobe resection for refractory temporal lobe epilepsy  
★ M.K. Sidhu
- P-434 Functional and structural connectivity of working memory networks in temporal lobe epilepsy  
★ G.P. Winston
- P-435 Mechanism of action of vagal nerve stimulation; evidence for acute anti-seizure affect  
★ C. Mcgrane

**NEUROIMAGING AND NEUROPHYSIOLOGY 5**

TUESDAY, 02 OCTOBER 2012

- P-436 The significance of intra-stimulation discharges during neurophysiologic language mapping for epilepsy surgery  
I. Karakis
- P-437 Sleep in partial epilepsy (pe) as compared to idiopathic generalised epilepsy (IGE)  
J.M. Boserio
- P-438 After-discharge generation and termination during functional stimulation in children  
J. Pocock
- P-439 How frequent are additional epileptogenic abnormalities detected? Inpatient long-term EEG monitoring VS. out-patient EEG  
K.A. Siddiqui
- P-440 The postictal state in daytime frontal lobe seizures: EEG and behavioural characteristics  
K. Whitehead
- P-441 Preliminary results of video-EEG findings in the neuro-intensive care unit: Is there a prognostic significance in acute stroke?  
N. Dericioglu
- P-442 Noonan's Syndrome and epilepsy. Neurophysiological findings  
N. Torres Caño
- P-443  Inter- and intra-rater reliability of EEG interpretation: A large, single-center study  
S.G. Abdel-Baki
- P-444 Vagus nerve evoked potential in vagus nerve stimulation therapy -method and clinical application  
K. Usami
- P-445 Virtual human physiology: A simulation technique to visualise ictal cardiac rhythm  
S. Narula

**NEUROIMAGING AND NEUROPHYSIOLOGY 6**

TUESDAY, 02 OCTOBER 2012

- P-446 DTI-based evidence for impaired integrity of major white matter tracts in non-lesional temporal lobe epilepsy  
C. Whelan
- P-447 The iowa gambling task in juvenile myoclonic epilepsy  
B. Wandschneider
- P-448 Non-invasive language mapping in epileptics and in brain tumor patients  
M. Genetti
- P-449 Brain P-Glycoprotein function studied in rats with two novel pet radiotracers: [11C]quinidine and [11C]laniquidar. Differences between controls and epileptic responders and non-responders  
R.A. Voskuyl
- P-450 Assessment of naming in temporal lobe epilepsy patients: A comparison of auditory and visual confrontation tests  
M. Elisak
- P-451 Seizures captured with video-electroencephalogram in infants with epilepsy  
J. Liao
- P-452 Analysis of temporal lobe epilepsy pathogenesis using dipole source imaging  
L.E. Betting
- P-453 Blink reflex at anticonvulsive therapy efficacy estimation  
V. Semashko
- P-454 The SCN1A-ploymorphism and carbamazepine - effects on cortical excitability in healthy adults in a TMS-study in the epicure-consortium  
A. Hermsen
- P-455 Seizure propagation analysis via segmentation of ICTAL electrocorticography  
S. Pirker

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 11**

TUESDAY, 02 OCTOBER 2012

P-456 Long-lasting epilepsy induces progressive changes in the brain: evidence from type II FCD patients



A. Finardi

P-457 Refractory convulsive status epilepticus as the first manifestation of systemic lupus erythematosus



I. Unterberger

P-458 Sexual disfunctions, AEDS and seric hormonal profile in epileptic men

L. Zummo

P-459 Medical treatment of focal cortical dysplasia: A case series of 11 patients

S.H. Kim

P-460 GAD65 - GAD67 MRNA and PV expression in human focal cortical dysplasia

V. Medici

P-461 The clinical spectrum of hemimegalencephaly in children

F.X. Sanmarti

P-462 M. Pneumoniae in cerebrospinal fluids of children with neurological manifestations :A case/control study; Tehran, Iran

S. Noorbakhsh

P-463 Data-driven phenomic analysis of epileptic encephalopathy phenotypes using an ontology-based phenotype database

J.A. Albers

P-464 A decade of experience with deep brain stimulation for patients with refractory medial temporal lobe epilepsy

M. Sprengers

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 12**

TUESDAY, 02 OCTOBER 2012

P-465 Innovated surgical treatment of epileptic syndrome in patients with brain arteriovenous malformations

V. Panuntsev

P-466 High-resolution EEG electrical source imaging contributes to localize the epileptogenic zone in malformations of cortical development



E. Rikir

P-467 Sensitivity of a 256 channel EEG recording in temporal mesial sclerosis patients and temporal neocortical patients



C. Arcaro

P-468 The evaluation of sexual functions and sex hormones in male and female epilepsy patients who are on valproic acid and carbamazepine monotherapy

A. Erdal

P-469 Epilepsy and reproductive disorders

I.A. Zhidkova

P-470 Tissue doppler evaluation of diastolic functions in patients with newly diagnosed and untreated patients with generalized epilepsy

M. Bilgi

P-471 Burns: A lesion underestimated in intractable temporal lobe epilepsy

E. Quintero López

P-472 Women with epilepsy in perimenopause and menopause

G. Luef

P-473 A decision support model of preconception counselling for women with epilepsy

J. Winterbottom

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 13**

TUESDAY, 02 OCTOBER 2012

- P-474 Long term prognosis of children with epilepsy in rural India  
D.K. Pal
-  P-475 Towards predicting individual outcome in patients after temporal lobe surgery for hippocampal sclerosis: white matter fdg and [11C]flumazenil binding  
J. Yankam Njiwa
-  P-476 Mortality risk in people with convulsive epilepsy: 8 years' follow-up of a cohort in rural China  
D. Ding
- P-477 Primary reading epilepsy: case report  
H.L. Gul
- P-478 Silent strokes is a risk for epilepsy in elderly population  
I.K. Abdulzahra
- P-479 Prediction of effectiveness of the first antiepileptic drug in the elderly patients with epilepsy  
S. Lukic
- P-480 Comparison of seizure distribution and EEG recordings of epilepsy patients  
I. Ipekdal
- P-481 Coexisting seizures in patients with infantile spasms confirmed by long-term video-electroencephalography monitoring  
H. Kim
- P-482 Survey on the management of epilepsy by geriatricians  
S.L. Jones
- P-483 Incidence of first acute symptomatic seizures and unprovoked seizures in adult: A prospective, epidemiological study based in captive population in Argentina  
L. Romano

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 14**

TUESDAY, 02 OCTOBER 2012

- P-484 State of blood-brain barrier and nitric oxide metabolism in patients with post-traumatic epilepsy early after generalized seizure  
 O. Kukhlenko
- P-485 Analysis of a group of patients with post-stroke acute and remote epileptic seizures  
 I. Chmielewska
- P-486 Unusually high incidence of intracranial arachnoid cysts among patients with epilepsy unrelated to seizure etiology  
 D.J. Milivojevic
- P-487 Comprehensive information imparted to patients with epilepsy and comorbidity and decreased prevalence of adverse treatment effects. The edu-com study  
S. Beretta
- P-488 Insomnia in epilepsy patients. Clinical and polysomnographic characteristics. A retrospective study  
A. Rodriguez
- P-489 3D-television and the risk of seizures in children  
L. Navarro-Ramirez
- P-490 Screening of sleep disorders in the epilepsy patients  
M.E. Contreras Pinto
- P-491 Seizures and alcohol  
S. Grabova
- P-492 Are benzodiazepines protective against propoxyphene abuse associated seizures  
S. Kaushal
- P-493 Does atmospheric pressure correlates with seizure frequency in epilepsy monitoring unit and emergency department?  
A.J. Ristic

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 15**

TUESDAY, 02 OCTOBER 2012

- P-494 Factors influencing quality of life in 160 subjects with epilepsy and their caregivers  
A. Alam
- P-495 Employment of people with epilepsy from the perspective of patients, neurologists and the general population  
B. Majkowska-Zwolińska
- P-496 Epilepsy-associated stigma in Bolivia: A community based study among Guaraní population. An ILAE/IBE/WHO global campaign against epilepsy regional project  
E. Bruno
- P-497 Impact of stigma on quality of life of patients with refractory epilepsy  
E.I. Viteva-Velkova
- P-498 Experience of epilepsy in a Senegalese series of patients  
L.B. Seck
- P-499 A survey of medical association members in the San-In region on the medical treatment of people with epilepsy  
S. Yoshioka
- P-500 Exploring quality of life in Slovak epilepsy patients: A focus group study  
V. Donáth
- P-501 Perception of epilepsy-related handicap is greater in "naïve" population according to a French web-based survey involving more than 2000 persons  
S. Hamelin
- P-502 Can social support serve as a mediator between illness perception and quality of life in patients with epilepsy?  
T. Bar-Adon
- P-503 Investigation into representation in film of first person subjective experience of a group of people with epilepsy  
S. Anderson

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 16**

TUESDAY, 02 OCTOBER 2012

- P-504 ICTAL kissing with complex partial epilepsy and inferior frontal gliosis  
A. Alsemari
- P-505 Variants of transformation of epileptic seizures  
A. Dubenko
- P-506 Clinical, video-EEG and neuroimaging study of drug-resistant focal epilepsy associated with hamartoma of the floor of the fourth ventricle  
G. Rubboli
- P-507 Tubulin genes in human disorders of cerebral cortex development  
 T.D. Cushion
- P-508 A portable device for investigating automated seizure abatement in humans using electrical stimulation  
 A. Lai
- P-509 Focal cortical dysplasia type IA and parvalbumin staining in temporal lobe epilepsy  
G. Kuchukhidze
- P-510 Layer specific genes expression in patients with focal cortical dysplasia type II  
L. Rossini
- P-511 Epilepsy and developmental outcome in infants and children with Sturge-Weber Syndrome (SWS)  
S.E. Aylett
- P-512 Fatal post-ICTAL ventricular fibrillation in a patient with complex partial seizures: A case report  
 L. Leung

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 17**

TUESDAY, 02 OCTOBER 2012

- P-513 Impact of peri-ictal interventions on respiratory impairment and post-ICTAL generalized EEG attenuation  
M. Seyal
- P-514 Study of pregnant women with epilepsy in Brazil: Initial results  
C.S.M.G. Miziara
- P-515 Women's epilepsy and antiepileptic drugs side effects on reproductive health  
G.V. Odintsova
- P-516 'Option grid' decision-support intervention for women taking sodium valproate and planning pregnancy  
P. Smith
-  P-517 Glutamic acid decarboxylase antibody: a link for localisation related epilepsy, stiff-person syndrome and type 1 diabetes mellitus? Report of two cases  
G. Barcs
- P-518 The aim of work was to study the content neuroaminoacids (NAC) in whey of blood patients with Traumatic Brain Injury (TBI) with a convulsive syndrome  
I.I. Chernenko
-  P-519 Epilepsy in Prader-Willi Syndrome; the Israeli experience  
T. Gilboa
- P-520 Cardiac asystole with syncope as a first manifestation of epilepsy  
A. Rakitin
- P-521 Quality of life in older adults with epilepsy  
A. Velez-Van-Meerbeke
- P-522 Diagnosing and treatment of epilepsy in the elderly  
G.A. Kiteva-Trencevska

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 18**

TUESDAY, 02 OCTOBER 2012

- P-523  Optimizing patient care and medical education through AAN epilepsy quality measures in a University Hospital  
J.M. Cisneros-Franco
- P-524 Longterm outcome beyond 20 years in 66 patients with juvenile myoclonic epilepsy  
P. Senf
- P-525  Electroclinical features in epilepsy caused by voltage gated potassium channel antibodies  
N. Mullatti
- P-526  Feature comparison for real-time detection of nocturnal seizures using accelerometry  
C. Ungureanu
- P-527 Acute Encephalitis with Refractory Repetitive Partial Seizures (AERRPS): Presentation of 3 Chilean cases  
V.I. Venegas
- P-528 Autoimmune mediated seizures with encephalopathy: A review of clinical and electrophysiological features  
Y. Hacohen
- P-529 The current treatment of infantile spasms among members of The Child Neurology Society  
S.M. Joshi
- P-530 Repetitive transcranial magnetic stimulation can be adjunctive method to low anticonvulsants doses  
V. Kistsen
- P-531 Effect of physical exercise during adolescence on behavioral changes in rats submitted to pilocarpine model of epilepsy in immature brain  
R.M. Arida
- P-532 Whole vibration therapy in persons with epilepsy and additional handicaps: A feasibility study  
I. Smolenaers

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 19**

TUESDAY, 02 OCTOBER 2012

- P-533 Local specialists' knowledge of plants within barguna district of bangladesh: A safe alternative therapy for epilepsy in patients with brain insufficiency  
M..A.H. Mollik
- P-534 Successful plasma exchange treatment of multifocal myoclonus. Two case histories  
I. Gati
- P-535 Worsening of seizures following abrupt discontinuation of marijuana in an epilepsy monitoring unit  
A. Kabir
- P-536 The ketogenic diet in children with Dravet Syndrome: The Austrian experience  
A. Dressler
- P-537 Cessation of refractory convulsive status epilepticus after implantation of Vagus Nerve Stimulation (VNS) therapy  
A. Soto
- P-538 Electrolyte hydration therapy in control of spike and wave discharges in the WAG/RIJ rat model of absence epilepsy  
D. Isaev
- P-539 Temporal versus frontal lobe seizures with automatisms in children with surgically verified epileptogenic zone  
O. Grinenko
- P-540 Effectiveness of the use of an omega 3/6 combination in paediatric patients with refractory epilepsy  
E.J. Barragán Pérez
- P-541 Effects of vagus nerve stimulation on seizures and cardiovascular responses in patients with drug-resistant epilepsy  
I. Naldi
- P-542 Has transcranial dc stimulation prolonged after effects on absences?  
M. Zobeiri

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 20**

TUESDAY, 02 OCTOBER 2012

- P-543 Optimized individual treatment protocols in patients with Dravet- Syndrome using electronic documentation with Epivista®  
R. Boor
- P-544 Refractory epileptic encephalopathy related to mycoplasma pneumoniae infection  
R. Buenache
- P-545 Description of clinical case of Febrile Infection-Related Epilepsy Syndrome (FIRES)  
S.N. Sivkova
- P-546 Clinical profile and treatment outcome in Febrile Infection-Related Epilepsy Syndrome (FIRES) in South Indian children  
V. Kollencheri Puthenveetil
- P-547 Concordance between history and epilepsy monitoring unit evaluation for diagnosing seizures  
E. Khalid
- P-548  Secondly generalized seizures in temporal lobe epilepsy  
B. Bóné
- P-549 The spectrum of frontal seizures: anatomo-electro-clinical correlations using SEEG  
A. McGonigal
- P-550  Is there clinical evidence for differences related to the new classification of temporal lobe cortical dysplasia?  
S. Fauser
- P-551 Epilepsy and speech-related protein SRPX2 controls neuronal migration in the developing rat brain cortex  
M. Salmi
- P-552  IGE of late onset versus IGE of "classical onset"  
A. Valavanis

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 21**

TUESDAY, 02 OCTOBER 2012

- P-553 Natural prognosis of EEG abnormalities and intellectual functions in children with ADHD and/or LD  
D. Turkdogan
- P-554 The clinical value of the incomplete hippocampal inversion in epileptic and nonepileptic patients  
E. Sasso
- P-555 Predictors of neurodevelopmental outcome following epilepsy onset in infancy  
H. O'Reilly
- P-556 Development and behavior of children aged 2 to 5 years after exposure to antiepileptic monotherapy in utero  
N. Cossa
- P-557 Motor impairment during the formation of benign epileptiform discharges of childhood. True or false?  
D. Zaytsev
- P-558 Seizure occurrence during pediatric EEG  
R. Gandelman-Marton
- P-559 Misleading generalized refractory epilepsy in young children "evolving" to symptomatic or probably-symptomatic focal epilepsy; epilepsy surgery candidates late detection possible reason to be considered  
A. Dalla-Porta
- P-560 The risk factors of recurrent febrile convulsion  
B.H. Cha
- P-561 A girl with Dravet Syndrome and immunoglobulin G subclasses deficiency  
D.A. Hasbini
- P-562 Atypical for rolandic epilepsy  
D. Musralina

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 22**

TUESDAY, 02 OCTOBER 2012

- P-563 Recovery in child with acquired aphasia and epilepsy  
S.M. Golubovic
- P-564 Correlations of clinical and radiologic features in pediatric patients with schizencephaly  
I. Kopyta
- P-565 Analysis of the effectiveness polytherapy in children with pharmaco-resistant epilepsy  
N. Mendigaliyeva
- P-566 Double cortex syndrome and epilepsy  
R.I. Teleanu
- P-567 The results of night sleep electroencephalography and MRI in children with epilepsy  
O. Klochkova
- P-568 Features of the pituitary hormonal regulation in children and adolescents with epilepsy  
Z. Viksna
- P-569 Epileptogenic potential of supratentorial brain tumors in children  
A.A. Kholin
- P-570 Seizure outcome after serial aeds have failed for lack of efficacy in focal epilepsy in children without an electroclinical syndrome  
E. Wirrell
- P-571 Cytokine levels in children with idiopathic partial and generalized epilepsy treated with topiramate and valproic acid  
F.M. Sonmez
- P-572 Cognitive impairment and cortical reorganisation in children with Benign Epilepsy with Centro-Temporal Spikes (BECTS)  
A.N. Datta

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 23**

TUESDAY, 02 OCTOBER 2012

- P-573 The effectiveness of the carbamazepine treatment in the juvenile myoclonic epilepsy  
B. Lorber
- P-574 An exploration of prescribing practice and parental use of emergency rescue medication to prevent status epilepticus in children  
C.M. Brand
- P-575 Blink related temporal spikes in benign rolandic epilepsy  
D. Allen
- P-576 Sensory processing disabilities in childhood-onset generalized epilepsy  
E. Shahar
- P-577 Sudden unexpected death in children and teenagers with epilepsy: An epidemiological study  
F.M. Besag
- P-578 Evaluation of efficacy of vagus nerve stimulation in children. Prospective results from a single center in Lebanon  
G.A. Hmaimess
- P-579 A short course of acth regimen for treating refractory childhood seizures  
H.H. Abdeldayem
- P-580 Continuous interictal epileptiform activity and its effect on cognition and behavior of children  
I.S. Ivanov
- P-581 Photosensitivity at different forms of epilepsy and therapy features  
I. Schederkina
- P-582 Cognitive function in childhood epilepsy: A single center study  
J. Park

**BASIC SCIENCE 9**

WEDNESDAY, 03 OCTOBER 2012

- P-583 What is an attack (seizure)?  
V. Karlov
- P-584 Granule cell dispersion is associated with more severe neuronal loss in mesial temporal lobe epilepsy with mesial temporal sclerosis  
 L.O.S.F. Caboclo
- P-585 What is the role of neuromedin n during seizures?  
K. Maes
- P-586 Indian herbal drugs in experimental models of epilepsy  
Y.K. Gupta
- P-587 Electrophysiological responses to vagus nerve stimulation in rats  
L. Mollet
- P-588 Convulsant activity of pilocarpine in mice is limited by multidrug-transporters at the blood-brain barrier  
M. Bankstahl
- P-589 Rutin reduces neuroinflammation and neuronal degeneration in the rat brain after kainic acid-induced status epilepticus  
M. Golechha
- P-590 Does feeding behaviour of genetic absence epilepsy rats differ from control wistar rats?  
M. Gulcebi Idriz Oglu
- P-591 Effect of anacyclus pyrethrum on pentylentetrazole-induced kindling, cognition, oxidative stress and rho-kinase II expression in mice  
M. Pahuja

**BASIC SCIENCE 10**

WEDNESDAY, 03 OCTOBER 2012

- P-592 The presence of the CAV3.2 R1584P mutation is associated with resistance to kindling induced change in the TRN neuron firing pattern  
N. Carcak
- P-593 An antagonist of GABAB receptors exhibits proconvulsant action in both age- and model-dependent manner  
P. Mareš
- P-594 The antidepressants citalopram and reboxetine reduce seizure frequency in chronic epileptic rats  
R. Clinckers
- P-595 Antiepileptic effect of tianeptine in pentylenetetrazole induced seizures in rats: Possible role of NMDA receptor  
R. Kh
- P-596 Sucrose preference test reveals depression-associated anhedonic behaviour in epileptic mice  
S. Klein
- P-597 Modulation of C-FOS and BDNF proteins expression in PTZ-kindled mice following the treatment with novel anti-epileptic compound 2-Acetyl-3-(2-Hexanoylamidoethyl)-7-methoxyindole: An immunohistochemical analysis  
S.M. Malhi
- P-598 Targeting epilepsy: molecular markers of epileptogenesis and its modulation by isoxylitones [E/Z Isomeric mixture]  
S.U. Simjee
- P-599 Central and obstructive apnea and cardiac arrhythmia during seizures all play roles in sudden death in a dravet syndrome mouse model  
Y. Horigome
- P-600 Transplantation of embryonic stem cells to dorsal hippocampus of epileptic mutant el mice  
Y.L. Murashima
- P-601 C-Fos expression after hippocampal deep brain stimulation in rats  
J. Silva

**BASIC SCIENCE 11**

WEDNESDAY, 03 OCTOBER 2012

- P-602 High frequency hippocampal deep brain stimulation (HIP-DBS) did not enhance inflammatory mediators in the rat hippocampus  
S. Perosa
- P-603 The effect of high frequency, poisson distributed cortical stimulation on cortical excitability in rats  
I. Buffel
- P-604 Are astrocytes involved in the epileptogenesis? The effects of thrombospondin receptor blockage in a model temporal lobe epilepsy  
A.J. Ramos
- P-605 Identification of kinase inhibitors that protect against seizures in zebrafish and rodent models of epilepsy  
N. Aourz
- P-606 Electrographic but not behavioural measures of epileptic activity are reliable indicators of the efficacy of ketogenic diet in pentylenetetrazol acute seizure model  
D. She
- P-607 Blood-brain barrier integrity and pentylenetetrazole-induced seizure severity in septic rats  
M.B. Bahceci
- P-608 Various kinds of hyperpolarizing afterpotentials in neocortical neurons during epileptic discharges  
V. Tsomaia
- P-609 Effect of mild hypothermia on glutamate receptor expression after status epilepticus  
L. Yu
- P-610 Epilepsy-dependent architectural and nmda abnormalities in mam-pilocarpine rat brain  
F. Colciaghi
- P-611 Inactivation of the constitutively active ghrelin receptor attenuates limbic seizure activity in rodents  
J. Portelli

**BASIC SCIENCE 12**

WEDNESDAY, 03 OCTOBER 2012

- P-612 Effects of N-Methyl-D-Aspartic acid-induced spasms on the brain: In vivo magnetic resonance spectroscopy  
M. Yum
- P-613 Seizure activity generates calcium-independent reactive oxygen species via nadph oxidase and xanthine oxidase  
S. Kovac
- P-614 The efficacy of intravenous valproate compared to intravenous phenobarbital in controlling seizures among pediatric patients with benzodiazepine- refractory status epilepticus: A randomized controlled trial  
L.K.F. Banta- Banzali
- P-615 Refractory status epilepticus in children: Lacosamide efficacy and safety  
S. Grosso
- P-616 Stimulus-induced ictal EEG patterns in comatose and non-comatose adult patients with nonconvulsive status epilepticus  
S. Marca
-  P-617 Intravenous sodium valproate for status epilepticus  
Y. Wu
-  P-618 Treatment of status epilepticus in the elderly with intravenous levetiracetam  
S. Eue

**EPILEPSY SURGERY 5**

WEDNESDAY, 03 OCTOBER 2012

- P-619 Mnestic performance after selective transcortical amygdalohippocampectomy in patients with temporal mesial sclerosis  
R.L. Aguilar-Estrada
- P-620 Epilepsy surgery: Leaving the lesion behind?  
S. Chinnasami
- P-621 Clinical characteristics and outcome of surgery for children and adolescents  
S.J. Sattaluri
- P-622 Epilepsy Surgery in children with difficult-to-treat epilepsy in the south region of Sweden: Long-term follow-up  
T.C. Hallböök
- P-623 Resective surgery by intracranial monitoring immediately after corpus callosotomy in adult non-lesional frontal lobe epilepsies  
Y. Cho
- P-624 Results of epilepsy surgery with non invasive methods Moroccan experience:51 cases  
A. Mrani
- P-625 Complications of epilepsy surgery in Sweden 1996-2010: Results from the Swedish national epilepsy surgery register  
J. Bjellvi
- P-626 Surgical excision of temporal glioneuronal tumours: Risk factors for psychiatric sequelae?  
O. Solanke
- P-627 MEG versus EEG localization for presurgical evaluation of the intractable epilepsy  
A. Koptelova
- P-628 Epilepsy surgery for refractory extratemporal epilepsies. Up to ten years follow up  
A. Siatouni

**EPILEPSY SURGERY 6**

WEDNESDAY, 03 OCTOBER 2012

- P-629 Basal temporal language testing in patients undergoing invasive EEG studies  
C. Scott
- P-630 Surgery for temporal lobe epilepsy with normal MR Imaging: seizure outcome, yield of re-evaluation and outcome following reoperation  
M.M. Ali
- P-631 Long-term outcome of surgery in patients with extratemporal epilepsy  
P. Hanakova
- P-632 Practical value of intraoperative electrocorticography in children  
P. Krsek
- P-633 Multimodal 3D visualisation for placement of intracranial EEG electrodes  
R. Rodionov
- P-634 Chronotopology of neurophysiologic markers for early and late epileptogenesis and surgery of drug-resistant temporal lobe epilepsy  
S. Kravtsova
- P-635 Current status and pharmacoconomics of Epilepsy Surgery in developing countries like India  
M.M. Mehndiratta
-  P-636 Mitochondrial disorders in the neocortex of patients with refractory epilepsy  
M.A. Alonso Vanegas
-  P-637 Seizure outcome and etiologies in frontal lobe Epilepsy Surgery in Sweden 1990-2009  
B. Rydenhag
- P-638 Functional hemispherectomy for Continuous Spike Wave in Slow Wave Sleep (CSWS) in patients with early vascular insult: Further evidence of the role of the thalamus in pathogenesis  
H. Cross

**MEDICAL THERAPY AND PHARMACOLOGY 8**

WEDNESDAY, 03 OCTOBER 2012

- P-639 Lacosamide as add-on to monotherapy in patients with partial-onset seizures: interim results of the post-marketing VITObA study (Vimpat added to one baseline AED)  
M. Noack-Rink
- P-640 Chronic valproate encephalopathy with reversible cognitive impairment and brain atrophy  
A.G. Caicoa
- P-641 Eslicarbazepine use in mentally retarded and refractory epileptic patients  
A. Fraile
- P-642 Vagus nerve stimulation for drug resistant epilepsy in children: Gazi University experience  
A. Serdaroglu
- P-643 Experience with lacosamide in a series of adults with drug-resistant focal epilepsy  
A. Verentzioti
- P-644 Effectiveness of lamotrigine and levetiracetam in clinical practice: retrospective chart review  
C. Deckers
- P-645 Costs, work absence, and adherence in patients with partial onset seizures taking gabapentin or pregabalin  
D. Labiner
- P-646 Increased levetiracetam clearance in pregnancy: Is seizure frequency affected?  
E. Mawhinney
- P-647 Retention of lacosamide in an third-line referral epilepsy centre  
E.V. Van Beijeren
- P-648 The experience of therapeutic new antiepileptic drug monitoring (Pregabalin) in the tertiary epilepsy center  
J. Byun
- P-649 Hypothermia in two patients with refractory epilepsy  
J. Raymackers
- P-421 Eslicarbazepine acetate and plasma levels of combined antiepileptic drugs: a population pharmacokinetics evaluation based on double-blind phase III clinical studies  
M. Bialer

**MEDICAL THERAPY AND PHARMACOLOGY 9**

WEDNESDAY, 03 OCTOBER 2012

- P-650 Vigabatrin associated movement disorder with MRI scan changes: an under-recognised complication  
M. Kaliakatsos
- P-651 Effects of valproate and oxcarbazepine on neutrophils' oxidative metabolism and oxidative stress in epileptic children  
Y. Zhang
-  P-652 External Trigeminal Nerve Stimulation (ETNS™) for the treatment of drug resistant epilepsy: a phase II randomized control trial  
C. Degiorgio
-  P-653 Clinical profiles and outcome of patients with antiepileptic drug-induced Steven Johnson Syndrome/Toxic Epidermal Necrosis  
G.V.L. Hamoy
- P-654 The consensus on using AEDS after cranio-cerebral operation  
S. Li
- P-655 The comparison of EEG patterns at the background of AEP drugs in epileptic patients  
I. Khachidze
- P-656 Efficacy and safety of once-daily adjunctive perampanel, a selective AMPA antagonist: a pooled analysis of three phase III trials in patients with treatment-resistant partial-onset seizures  
E. Ben-Menachem
- P-657 Effectiveness and tolerability of levetiracetam in children under 2 years of age  
G.A. Ramos-Rivera
- P-658 A novel anticonvulsant isoxylitones [e/z] suppresses sodium currents in NAV 1.2 and NAV1.3, and prolongs inactivation development and recovery from inactivation in voltage-gated sodium channels  
M.N. Ashraf
- P-659 Efficacy of different lamotrigine dosage regimens in epileptic patients' –clinical experience  
R. Gilad

**MEDICAL THERAPY AND PHARMACOLOGY 10**

WEDNESDAY, 03 OCTOBER 2012

- P-660 Low dose lacosamide-induced atrial fibrillation: Case analysis with literature review  
K.R. Kaufman
- P-661 Adjunctive lacosamide in patients with uncontrolled focal epilepsy: Interim analysis of a prospective audit  
K. Kelly
- P-662 Diagnostics and therapeutic aspects of resistant epileptic seizures in children of early age with a tuberous sclerosis  
L.G. Kirillova
- P-663 Design of an open-label, multicentre, non-interventional study of zonisamide as first-line adjunctive treatment in adults with partial epilepsy: The zoom study  
M. Baulac
- P-664 Hyperhomocysteinemia in epileptic patients  
M. Candric
- P-665 Design of the EPOS study: An open-label, multicentre, non-interventional study to evaluate eslicarbazepine acetate as adjunctive treatment to one baseline antiepileptic drug in adults with partial-onset seizures  
M. Holtkamp
- P-666 Comparative efficacy of combination drug therapy in refractory epilepsy  
N.P. Poolos
- P-667 Lacosamide in add on therapy to treat partial epilepsies  
O. Daniele
- P-668 Cost of antiepileptic drug monotherapies and combination therapies at a tertiary referral hospital in Singapore  
S. Lim
- P-669 Analysis of seizure frequency reduction by concomitant antiepileptic drug (AED) use with adjunctive perampanel: Pooled phase III results  
E. Trinka

**MEDICAL THERAPY AND PHARMACOLOGY 11**

WEDNESDAY, 03 OCTOBER 2012

- P-670 Event-related potentials in patients with epilepsy treated with levetiracetam  
W.J. Derkowski
- P-671 Steady-state plasma and cerebrospinal fluid pharmacokinetics of eslicarbazepine acetate and oxcarbazepine in healthy volunteers  
T. Nunes
- P-672 Evaluation of the tolerability of adjunctive retigabine/ezogabine during the recommended titration schedule in adults with partial-onset seizures  
N. Brickel
- P-673 Spironucleus linked gaba derivatives as potential antiepileptic agents acting through GABA mediation and inhibiting nitric oxide and free radicals  
Y. Perumal
-  P-674 Intense pharmacovigilance in pediatric patients with focal epilepsy treated with carbamazepine monotherapy  
B. Rodriguez
- P-675 Tolerability, safety, and side-effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen amongst craniotomy patients: A prospective randomised study  
K.L. Fuller
- P-676 The effects of eslicarbazepine, r-licarbazepine, oxcarbazepine and carbamazepine on sodium currents through NAV1.3 channels  
L. Wright
-  P-677 First experience with retigabine in a highly drug resistant population of 29 epileptic patients  
C. Kurth
-  P-678 The effects of morphine and naloxon on spontaneuse seizure activity in hippocamopal slices  
A. Alijarahi

**NEUROIMAGING AND NEUROPHYSIOLOGY 7**

WEDNESDAY, 03 OCTOBER 2012

- P-679  The utility of high frequency oscillations on meg and intracranial EEG in localising seizure foci in patients with refractory epilepsy undergoing presurgical evaluation  
A. Lemesiou
- P-680  Structural and functional changes in thalamo-cortical connectivity reflect a specific impaired network in juvenile myoclonic epilepsy  
J. O'Muirheartaigh
- P-681 The location of fast ripples is stationary as focal seizures evolve  
T. Nowacki
- P-682 Inferring patient-specific physiological parameters from intracranial EEG: Application to clinical data  
S. Shmuely
- P-683 The event related potential P-300 and reaction time in epilepsy  
V.P. Ivetic
- P-684 Electrophysiological features in progressive myoclonic epilepsy  
Z. Matur
- P-685 Neuroprotective potential of stiripentol against oxygen and glucose deprivation or glutamate exposure in cultured rat cortical neurons  
V. Riban
- P-686 Visual cortex hyperexcitability in idiopathic generalized epilepsies with photosensitivity: A TMS study  
F. Brigo
- P-687 Stability of synchronization clusters and ictogenicity in temporal lobe epilepsy  
G. Ortega

**NEUROIMAGING AND NEUROPHYSIOLOGY 8**

WEDNESDAY, 03 OCTOBER 2012

- P-688  Highly focal bold activation on fmri in patients with progressive myoclonic epilepsy and diffuse giant somatosensory evoked potentials  
P. Manganotti
- P-689  Intracranial EEG-fMRI in epilepsy: A preliminary approach to modeling very frequent spike discharges  
D.W. Carmichael
- P-690  Volumes of subcortical structures in idiopathic generalised epilepsy and unaffected family members  
F.A. Chowdhury
- P-691 Inferring patient-specific physiological parameters from intracranial EEG: Theoretical studies  
D.R. Freestone
- P-692 Effects of vagal nerve stimulation on vocal functions  
E. Gardella
- P-693 Localising and lateralising value of ictal EEG patterns in mesial and neocortical temporal lobe epilepsy  
E.T. Lim
- P-694 Video-electroencephalogram monitoring in a pediatric epilepsy unit  
P. Giner-Bayarri
- P-695 EEG findings and treatment in juvenile myoclonic and juvenile absence epilepsies  
S.V. Kasradze
- P-696 Towards guidelines for the rational use of the prolonged EEG  
F.Z. Javaid

**NEUROIMAGING AND NEUROPHYSIOLOGY 9**

WEDNESDAY, 03 OCTOBER 2012

- P-697 Intracranial EEG seizure-onset patterns in temporal lobe epilepsy and their association with outcome, localization, and histopathology  
I. Dolezalova
- P-698 Evaluation of the utility of long term video-EEG monitoring  
M. Caballero
- P-699  Application of diffusion tensor imaging in drug-resistant extra-temporal epilepsy with focal cortical dysplasia in mri: correlation with FDG-PET hypometabolic area  
J. Aparicio
- P-700  Diagnostic accuracy of [11C]-Methionine pet for the differentiation between dysembryoplastic neuroepithelial tumour and other epileptogenic brain neoplasms  
S. Rheims
- P-701  Fiber density asymmetry in temporal lobe epilepsy  
M. Okujava
- P-702  Subtraction Ictal Spect Co-Registered to Mri (SISCOM) in children with epileptic spasms  
L. Wong-Kisiel
- P-703  Contributions of EEG/fMRI to localizing focal cortical dysplasia  
F. Pittau
- P-704  How much language is in picture and face processing?  
A. Haag

**PSYCHIATRY AND PSYCHOLOGY 1**

WEDNESDAY, 03 OCTOBER 2012

- P-705 Psychosocial and psychopharmacological aspects of refractory psychogenic nonepileptic seizures  
A. Rodriguez-Urrutia
- P-706 Use of methylphenidate for attention-deficit/hyperactivity disorder in children with and without epileptiform abnormalities  
D. Socanski
- P-707 Perception of side-effects in epilepsy patients and depression  
J. Amlerova
- P-708 Duration of interictal psychotic episodes by antipsychotic drug treatments  
K. Hara
- P-709 Comorbid depression in epilepsy: Sociodemographic and clinical correlates and impact on quality of life  
K.S. Todorova
- P-710 Pshychiatric features in families with autosomal dominant cortical tremor, myoclonus and epilepsy  
L. Santulli
- P-711 Influence of psychopathologic symptoms on quality of life in patients with epilepsy  
M. Milovanovic
- P-712 Forced normalization in post-surgical patients of temporal lobectomy and medically intractable epilepsy. Colombian foundation center for epilepsy and neurological diseases – FIRE  
M. Torres
- P-713 Are psychiatric disorders exclusion criteria for video EEG monitoring and epilepsy surgery in patients with mesial temporal sclerosis?  
P.O. Da Conceição
- P-714 Mood dysfunction in epilepsy patients in Kosovo  
V. Govori
- P-715 Memory development in children with a history of prolonged febrile seizures  
M. Martinos

**PSYCHIATRY AND PSYCHOLOGY 2**

WEDNESDAY, 03 OCTOBER 2012

- P-716 Rhythmic tremor artifact mimicking ictal epileptiform pattern on EEG of non-epileptic psychogenic seizures  
T. Tombul
- P-717 Do antipsychotic drugs increase seizure frequency in epilepsy patients?  
M. Okazaki
- P-718 Psychogenic non epileptic seizures: the nidus may lie somewhere else  
S. Kumar
- P-719 Interictal dysphoric disorder in Japanese patients with localization-related epilepsy: prevalence and clinical characteristics  
A. Yoshino
- P-720 Prevalence of symptoms of interictal dysphoric disorder: results of a survey conducted at the Welsh epilepsy unit  
C.B. Kuloor
- P-721 Quality of life in childhood epilepsy and parental and paediatric anxiety: The role of a structured education program  
G. Serdaroglu
- P-722 A longitudinal study of psychological features in patients before and two years after epilepsy surgery  
K. Malmgren
- P-723 The effects of support group on self-esteem in people with epilepsy  
S. Tiamkao
- P-724 Cognitive retraining among children with epilepsy at a tertiary care hospital in Delhi, India  
K. Bala
- P-725 Online assessment of remote and semantic memory in epilepsy by using daily news questionnaires  
M. Hendriks
- P-726  Long term memory outcome after selective amygdalohippocampectomy versus standard temporal lobectomy in temporal lobe epilepsy  
A. Wendling

**PSYCHIATRY AND PSYCHOLOGY 3**

WEDNESDAY, 03 OCTOBER 2012

- P-727 Types of coping strategies for epileptic patients  
L. Lipatova
- P-728 Cognitive impairment and cognitive evoked potentials in patients with partial symptomatic epilepsy  
A. Kostylev
- P-729 Neurological and psychiatric analysis of ictal kissing automatism  
E. Taskiran
- P-730 Is propofol tolerable during wada?  
F. Alsallom
- P-731 Perceptions of stress in left temporal lobe epilepsy and differences in response to acute stress  
J. Allendorfer
- P-732 Illness perception, quality of life and coping styles in patients admitted to an epilepsy monitoring unit  
J.A. Magee
- P-733 Do brain lesions increase the risk of depression in epilepsy?  
N. Cinar
- P-734 Fear-specific modulation of tactile perception is disrupted after amygdala lesions  
C. Bertini
- P-735 Facial identity and emotion recognition in patients with mesial temporal lobe epilepsy  
A. Gomez-Ibañez
- P-736 Neuropsychological outcomes in adults with tuberous sclerosis complex  
A. Vignoli
-  P-737 Quantitative method for identification of the language eloquent areas during presurgical SEEG recordings  
C. Pastori

**PSYCHIATRY AND PSYCHOLOGY 4**

WEDNESDAY, 03 OCTOBER 2012

- P-738 Long-term evolution of different neuropsychological phenotypes in SCN1A spectrum  
C. Passamonti
- P-739 Stereotactic radiofrequency amygdalohippocampectomy for the treatment of temporal lobe epilepsy: Do good neuropsychological and seizure outcomes correlate with hippocampal volume reduction?  
H. Malikova
- P-740 Montreal cognitive assessment performance in patients with epilepsy  
J. Ding
- P-741 Changes in neurocognition and quality of life after bilateral electrical stimulation of the anterior thalamic nuclei in 7 patients with refractory epilepsy  
M. Milian
- P-742 Accelerated long-term forgetting, subjective memory complaints and depression in medial temporal lobe epilepsy  
S. Yagci
- P-743 Neuropsychological outcome after epilepsy surgery in patients with bilateral ammon's horn sclerosis  
V.L. Vogt
- P-744 Applicability of a memory association task for fmri in epilepsy surgery  
N.L. Frankenmolen
- P-745 Language after temporal lobe epilepsy surgery  
A.R. Giovagnoli
- P-746 Temporal lobe epilepsy impairs advanced cognitive estimation abilities  
A. Parente
- P-747 The DMS-48 as a visual recognition memory task for cognitive epilepsy evaluation  
I. Wisniewski

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 24**

WEDNESDAY, 03 OCTOBER 2012

- P-748 Epilepsy children support camp  
L. Cvitanovic-Sojat
- P-749 Inflammatory temporal lobe epilepsy: Focal Rasmussen encephalitis?  
L. De Palma
- P-750 A novel internet animation seizure survey may be an effective screening instrument for population-based research  
W.J. D'Souza
- P-751 The influence of antiepileptic drug therapy on bone mineral density and serum total and ionized calcium levels in children and adolescents  
M.D. Dimic
- P-752 Importance of subtle clinical features associated to the motor phenomenon of epileptic spasms for differential diagnosis  
M. Eisermann
- P-753 School years for children with epilepsy in Greece: A voice coming from parents and children  
M. Kampra
- P-754 Study of the executive function in children with benign focal epilepsy with centrotemporal spikes  
M.L.G. Manreza
- P-755 An ongoing European non-interventional registry study of patients with Lennox-Gastaut Syndrome: Interim analysis  
M. Nikanorova
- P-756 Long term efficacy and hospitalization rate in children with refractory focal epilepsy treated by vagus nerve stimulation  
M. Ryzí
- P-757 Diagnostic challenges in a patient with focal cortical dysplasia type IIB and Benign Focal Epileptiform Discharges of Childhood (BFEDC) in addition  
N. Barišić

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 25**

WEDNESDAY, 03 OCTOBER 2012

- P-758 Dravet Syndrome and other genetic and structural causes of post-vaccination epilepsy: A nation-wide ten-year cohort study  
N.E. Verbeek
- P-759 Epilepsy in children with cerebral palsy  
O. Jotovska
- P-760 Response to intravenous immunoglobulins in malignant migrating partial seizures in infancy: One case report  
P. Morillo
- P-761 Clinical and EEG characteristics of epilepsy in patients with neuronal ceroid lipofuscinosis  
R. Kravljanc
- P-762 Behavioural problems and EEG characteristics of children with benign childhood epilepsy with centrotemporal spikes  
R. Samaitiene
- P-763 Yield of brain imaging of children with seizure following referral  
S. Al - Ani
- P-764 Comparative embedded case study to explore experiences of young people with epilepsy and their parents during transition from children to adult epilepsy services  
S.A. Lewis
- P-765 A pilot study investigating the effect of childhood epilepsy on siblings' quality of life.  
S. Memon
- P-766 Parental reactions in benign childhood focal seizures  
T. Valeta
- P-767 Video-EEG monitoring in diagnostics of epileptic and non-epileptic paroxysmal conditions in children  
V.I. Guzeva

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 26**

WEDNESDAY, 03 OCTOBER 2012

- P-768 Vagus nerve stimulation in pediatric epilepsy patients: Is this really worthwhile?  
V.C. Terra
- P-769 The effect of body temperature in seizures associated with rotavirus gastroenteritis  
Y.S. Kwon
- P-770 Electro-clinical aspects of focal symptomatic epilepsy of childhood with secondary bilateral synchrony phenomenon on EEG  
A. Bunduchi
- P-771 Carbon monoxide and seizures in children  
A. Gniatkowska-Nowakowska
- P-772 Autoantibody to glutamic acid decarboxylase in a 2-year old girl with therapy-resistant epilepsy  
S. Saltik
- P-773 Atypical evolution of panayiotopoulos syndrome into childhood absence epilepsy: A case report  
K. Skiadas
- P-774 Clinical and electrophysiological characteristics of patients with paroxysmal disorders. clinical-electrophysiological characteristic of patient with paroxysmal disorders  
M.Y. Fomina
- P-775 Clinical features and outcomes in febrile infection-related acute epileptic encephalopathy  
J. García-Peñas
- P-776 Early onset of cortical thinning in children with rolandic epilepsy  
G.M. Overvliet
- P-777 But... does my daughter not suffer a mitochondrial disease? Co-Morbid Dravet Syndrome  
M. Ruíz-Falcó-Rojas

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 27**

WEDNESDAY, 03 OCTOBER 2012

- P-778 A clinical audit of process and outcome of emergency treatment for prolonged epileptic seizures in children attending an emergency department  
E. Joslin
- P-779 Application of new ILAE criteria for drug resistant epilepsy in children in clinical practice M.A. De La Morena Vicente
- P-780 Vagus Nerve Stimulation in a new pathway with anti-inflammatory cytokines  
V. Cantarin-Extremera
- P-781 The prognostic factors of acute encephalitis in children  
J.S. Lee
- P-782 Stress sensitivity of childhood epilepsy: which children seize under stress?  
J.S. Van Campen
- P-783 Absence seizures during awake and sleep: What is the difference?  
B. Jovic-Jakubi
- P-784 Epilepsy of infancy with migrating focal seizures- expanding the phenotype and exploring the aetiology  
A. Mctague
- P-785 Aberrant functional connectivity between sensorimotor and prefrontal cortex regions in rolandic epilepsy  
G.M. Overvliet
- P-786 Clinical profile of psychogenic nonepileptic seizures in children and adolescents: a study of 37 cases  
M. Gupta
- P-787 Epilepsy and the immune system "... is there anybody there?"  
S. Wright

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 28**

WEDNESDAY, 03 OCTOBER 2012

- P-788 Prevalence and associations of ADHD in rolandic epilepsy  
B. Mukhtyar
- P-789 Juvenile myoclonic epilepsy: A family study  
E. Cvetkovska
- P-790 Levetiracetam monotherapy in patients with juvenile myoclonic epilepsy  
J. Kim
- P-791 Temporal lobe epilepsy  
T. Chepreganova-Changovska
- P-792 Bathing epilepsy triggered by emersion from water and towel wrapping: A case with ictal video-electroencephalographic recording  
C. Aguiar
- P-793 Clinical heterogeneity in familial partial epilepsy with auditory features negative for LGI1 and with matrilineal inheritance  
C. Leta
- P-794 Rare copy number variants in Lennox-Gastaut-like epilepsy  
C. Lund
- P-795 Clinical and video-polygraphic features of "senile progressive myoclonic epilepsy": A distinctive progressive myoclonic epilepsy of adult down patients  
G. D'Orsi
- P-796 Idiopathic occipital lobe epilepsy and absence epilepsy in the same patient?  
H.P. Grebe

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 29**

WEDNESDAY, 03 OCTOBER 2012

- P-797 Does photoparoxysmal EEG response predict seizures control in patients with juvenile myoclonic epilepsy?  
M.P. Borkovic
- P-798 Nocturnal frontal lobe epilepsy and parasomnias differential diagnosis: accuracy of two different clinical diagnostic tools  
M. Broli
- P-799 Focal EEG abnormalities in childhood absence epilepsy - any prognostic value?  
M. Mazurkiewicz-Beldzinska
- P-800 Clinical, genetic, and EEG features of turkish progressive myoclonic epilepsy patients  
O.E. Ore
- P-801 "Delayed" diagnosis of coeliac disease in adult patients with posterior partial epilepsy: Searching for a possible link  
S. Casciato
- P-802 An epilepsy bedside diagnosis by doing logical task in form ad hoc full-text database of working knowledge  
V.M. Andreev
- P-803 Autosomal Recessive Partial Epilepsy with Intellectual Disability (ARPEID) – A novel epilepsy syndrome?  
Z. Afawi
- P-804 SLC2A1 mutations are cause of infantile drug resistant seizures and paroxysmal exercise induced dyskinesia  
M.K. Jurek
- P-805 Magnetoencephalography findings in two cases of idiopathic generalized epilepsies  
S. Carrasco García De León
- P-806 Outcome and prognostic features in SCN1A positive Dravet Syndrome from infancy to adult life  
A. Brunklaus

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 30**

WEDNESDAY, 03 OCTOBER 2012

- P-807 ESES (CSWS) in a middle-aged man  
M. Arvio
- P-808 Can neonatal electroclinical findings guide towards an early diagnosis of neonatal encephalopathy? A case report  
B. Scelsa
- P-809 Neurological aspects of dialysis patients  
S.M. Vujisić
- P-810 Neuropsychological aspects of dialysis patients  
D.B. Milikic
- P-811 EEG evolution in children with west syndrome  
D.M. Nikolic
- P-812 Severe pattern-sensitivity in a girl with Dravet Syndrome, due to microdeletion in locus 2Q24.3. A case report  
E. Szczepanik
- P-813 Neonatal Cerebral Sinovenous Thrombosis (CSVT) with thalamic haemorrhage is strongly related to Electrical Status Epilepticus in Sleep (ESES)  
F.E. Jansen
- P-814 Early epileptic encephalopathies associated with stxbP-1 mutations: could we better define the phenotype?  
G. Barcia
- P-815 A role for the CXCR3/CXCL10 axis in Rasmussen encephalitis. a new target for immunotherapy?  
M. Pérez-Jiménez
- P-816 Absence of thalamic metabolic change in epilepsies with continuous spike-waves during sleep  
N. Ligtot

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 31**

WEDNESDAY, 03 OCTOBER 2012

- P-817 Persistent connectivity during awake and sleep of brain locations generating Continuous Spike and Waves during Slow Sleep (CSWS)  
P.G. Larsson
- P-818 A SLC2A1 mutation in a boy with childhood absence epilepsy, alternating hemiplegia and ataxia  
H. Muhle
- P-819 Eyelid myoclonia with absences (Jeavons Syndrome): A life long disorder with mild cognitive impairment?  
H.T. Ong
- P-820 Results of the study of hormones in blood of girls with epilepsy  
V.I. Guzeva
- P-821 Long term outcomes of epilepsy surgery in school-age children with partial epilepsy  
S. Liang
- P-822 Detection of epileptic seizure in children using non-linear analysis is HRV  
V. Kharytonov
- P-823 The spectrum of benign infantile seizures including benign infantile seizures with mild gastroenteritis, benign infantile focal epilepsy with midline spikes and waves during sleep and others  
I.Y. Saadeldin
- P-824 Potentially seizure provoking video sequences in Spanish TV: The smoking gun  
J. Parra
- P-825 Thrombin facilitates seizures through activation of neuronal persistent sodium current: A new mechanism of seizure developed during intracerebral hemorrhage  
O. Isaeva

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 32**

WEDNESDAY, 03 OCTOBER 2012

- P-826 Partial posterior epilepsies with persistent fixation off sensitivity in adult life: electro-Clinical evaluation, neuroimaging features and epileptic syndrome definition  
J. Fattouch
- P-827 Distribution of progressive myoclonus epilepsies in Italy; positively diagnosed and unclassified patients  
L. Canafoglia
- P-828 Comorbidities in rolandic epilepsy  
Y.A. Hernandez Vega
- P-829 Electroencephalographic focal discharges with or without clinical manifestations in children with childhood absence epilepsy  
Z. Sabol
- P-830 Epilepsy and PCDH19 mutation clinical and electrophysiological features in 13 patients  
N. Chemaly
- P-831 Fear towards the antiepileptic therapy withdrawal  
M.F. Knezevic-Pogancev
- P-832 Focal epileptiform discharges in pediatric patients with idiopathic generalized epileptic syndromes  
N. Ermolenko
- P-833 Epilepsy in patients with cerebral palsy is not always lifelong condition  
P. Ignjatovic
- P-834 Comorbidity in childhood epilepsy in clinical practice  
A. Garcia Ron
- P-835 A genomic deletion encompassing KCNQ2 causes infantile epilepsy: A further example of genotype and phenotype correlation  
A.P. Parker
- P-847 Anthropological and epidemiological study of epilepsy in the region of Tangier  
Y Bahbiti

**SEMIOLOGY, AETIOLOGY AND CLASSIFICATION 33**

WEDNESDAY, 03 OCTOBER 2012

- P-836 Evaluation of health care utilisation among adult patients with epilepsy in the district of Marburg-Biedenkopf in Germany  
A. Strzelczyk
- P-837 The knowledge about epilepsy has significant impact on quality of life in people with epilepsy  
S. Lee
- P-838 The uptake and knowledge of the uk epilepsy and pregnancy registry amongst healthcare professionals and patients  
J.R. Howells
- P-839 Health related quality of life and social stigma in patients with epilepsy  
M. Prieschl
- P-840 Health-related quality of life (HRQOL) in Russian adult patients with epilepsy  
A. Guekht
- P-841 Knowledge and attitude of Nigerian adults in an urban center  
B. Ezeala-Adikaibe
- P-842 Risk factors of epilepsy and clinical-electroencephalographical correlation in children with pervasive developmental disorders  
K.A. Polatynska
- P-843 Ictal unilateral hyperkinetic proximal lower limb movements: An independent lateralising sign suggesting ipsilateral seizure onset  
R. Teotonio
- P-844 Ictal and postictal speech impairment in temporobasal epilepsy: An underrecognized clinical manifestation  
R. Toledano Delgado
- P-845 Seizure response dogs for children's nocturnal seizures: update on consumer involvement and feasibility study  
K. Jeavons
- P-846 An unusually severe phenotype in a family with a novel scn1a mutation: from gefs+ to Dravet Syndrome  
H. Goldberg-Stern



Download the  
10th ECE  
mobile app  
(free)

Free WiFi is available in the  
Boulevard of ICC London ExCeL.



Congress App supported by:



Join the Conversation - Are you on Twitter? 

To join the online conversation you can follow the Epilepsy Congress on Twitter by following @EpilepsyCongres. The official hashtag (#) for the 10th European Congress on Epileptology on Twitter is #ece2012

---



# OTHER INFORMATION

---



**BURSARIES**

**SPEAKERS LIST**

**LIST OF EXHIBITORS**

**AND FLOORPLAN**

## BURSARIES

NAME	COUNTRY
Ashraf, M	CANADA
Awadh, M	EGYPT
Baulac, S	FRANCE
Beretta, S	ITALY
Brunklaus, A	UNITED KINGDOM
Caboclo, L O	BRAZIL
Chan, J	AUSTRALIA
Chatzistefanidis, D	GREECE
Chen, L	CHINA
Chen, L	CHINA
Chowdhury, F	UNITED KINGDOM
Cisneros-Franco, J	MEXICO
Djémié, T	BELGIUM
Dolezalova, I	CZECH REPUBLIC
Ezeala-Adikaibe, B	NIGERIA
Fabo, D	HUNGARY
Fassler, M	ISRAEL
Faure, J B	FRANCE
Finardi, A	ITALY
Fonsah, J	CAMEROON
Fuller, K	AUSTRALIA
Gilboa, T	ISRAEL
Haag, A	UNITED KINGDOM
Hamoy, G V	PHILIPPINES
Hardies, K	BELGIUM
Hermesen, A	GERMANY
Howells, J	UNITED KINGDOM
Iori, V	ITALY
Isaeva, O	UKRAINE
Ishii, A	JAPAN
Jahodova, A	CZECH REPUBLIC
Javaid, F	UNITED KINGDOM
Kharatishvili, I	AUSTRALIA
Kondekar, S	INDIA
Koptelova, A	RUSSIAN FEDERATION
Kukhlenko, O	UKRAINE
Lai, A	AUSTRALIA

NAME	COUNTRY
Lemesiou, A	UNITED KINGDOM
Lopes, A F	PORTUGAL
Lorenzen, C	AUSTRIA
Major, P	CANADA
Maljevic, S	GERMANY
Matricardi, S	ITALY
Mcgonigal, A	FRANCE
Mollik, M A H	BANGLADESH
Okujava, M	GEORGIA
O'Muircheartaigh, J	USA
Overvliet, G M	NETHERLANDS
Pahuja, M	INDIA
Parente, A	ITALY
Pastori, C	ITALY
Patel, V	AUSTRALIA
Perumal, Y	INDIA
Pingul, P	PHILIPPINES
Pittau, F	ITALY
Pujar, S	UNITED KINGDOM
Ramesha, K	UNITED KINGDOM
Ramos-Rivera, G	SLOVAK REPUBLIC
Rathore, C	INDIA
Rheims, S	FRANCE
Rodionov, R	UNITED KINGDOM
Roth, C	GERMANY
Sidhu, M	UNITED KINGDOM
Singh, M	INDIA
Strzelczyk, A	GERMANY
Sui, J	AUSTRALIA
Tsiptsios, D	GREECE
Unnwongse, K	THAILAND
Wandschneider, B	UNITED KINGDOM
Wang, L	CHINA
Wisniewski, I	GERMANY
Witt, J A	GERMANY
Yankam Njiwa, J	FRANCE
Zummo, L	ITALY

## SPEAKERS LIST

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Afif	A. France	Platform Session	01-Oct	11:30 - 12:30	Hall E	Speaker
Äikiä	M. Finland	Platform Session	02-Oct	11:30 - 12:30	Hall E	Speaker
Alexopoulos	A. Greece	Session	03-Oct	07:45 - 09:00	Hall D	Speaker
Al-Shahi Salman	R. UK	Epilepsy Course	04-Oct	09:15 - 11:15	Hall C	Speaker
Andermann	F. Canada	Debate	02-Oct	11:30 - 12:30	Hall B	Chair
Anderson	S. UK	Session	02-Oct	09:00 - 10:30	Hall F	Speaker
Andersson-Roswall	L. Sweden	Session	02-Oct	14:30 - 16:00	Hall D	Speaker
Andrzejak	R. Spain	ECE Forum	04-Oct	11:00 - 12:30	Hall H	Speaker
Aronica	E. Netherlands	ECE Forum	30-Sep	11:30 - 13:00	Hall G	Speaker
Arzimanoglou	A. France	Satellite Symposium	30-Sep	16:30 - 18:00	Auditorium	Speaker
Arzimanoglou	A. France	Session	03-Oct	14:30 - 16:00	Hall C	Speaker
Arzimanoglou	A. France	Session	03-Oct	07:45 - 09:00	Hall D	Speaker
Arzimanoglou	A. France	Special Session	03-Oct	11:30 - 12:30	Hall F	Chair/Spkr
Aurlien	H. Norway	ECE Forum	01-Oct	09:00 - 10:30	Hall F	Speaker
Avoli	M. Canada	ECE Forum	30-Sep	11:30 - 13:00	Hall G	Speaker
Avoli	M. Canada	ECE Forum	04-Oct	13:30 - 15:00	Hall H	Speaker
Baker	M. UK	Session	01-Oct	07:45 - 09:00	Hall B	Speaker
Bankstahl	J. Germany	Session	01-Oct	07:45 - 09:00	Hall F	Speaker
Bartolomei	F. France	Session	30-Sep	13:30 - 15:00	Hall E	Speaker
Bartolomei	F. France	Session	03-Oct	07:45 - 09:00	Hall E	Speaker
Barucha	N. India	Session	03-Oct	14:30 - 16:00	Hall D	Chair
Bateman	L. USA	ECE Forum	04-Oct	11:00 - 12:30	Hall D	Speaker
Battaglia	D. Italy	ECE Forum	04-Oct	13:30 - 15:00	Hall G	Speaker
Battino	D. Italy	Session	03-Oct	16:30 - 18:00	Hall C	Speaker
Baulac	M. France	Satellite Symposium	01-Oct	16:30 - 18:00	Auditorium	Speaker
Baulac	M. France	Main Session	03-Oct	09:00 - 11:00	Auditorium	Chair
Baumgartner	C. Austria	Session	30-Sep	15:00 - 16:30	Hall E	Speaker
Baxendale	S. UK	Platform Session	02-Oct	11:30 - 12:30	Hall E	Chair
Baxendale	S. UK	Session	02-Oct	09:00 - 10:30	Hall F	Chair
Baxendale	S. UK	Session	02-Oct	14:30 - 16:00	Hall D	Speaker
Becker	A. Germany	Session	30-Sep	15:00 - 16:30	Hall G	Speaker
Beghi	E. Italy	ECE Forum	02-Oct	09:00 - 10:30	Hall G	Speaker
Bell	G. UK	Session	02-Oct	14:30 - 16:00	Hall D	Speaker
Benachi	A. France	Session	03-Oct	16:30 - 18:00	Hall C	Speaker
Beniczky	S. Denmark	ECE Forum	01-Oct	09:00 - 10:30	Hall F	Speaker
Beniczky	S. Denmark	Platform Session	02-Oct	11:30 - 12:30	Hall G	Chair/Spkr
Bergin	P. New Zealand	ECE Forum	02-Oct	10:30 - 11:30	Hall E	Chair/Spkr
Berl	M. USA	ECE Forum	04-Oct	13:30 - 15:00	Hall J	Chair/Spkr
Bernard	C. France	Session	30-Sep	15:00 - 16:30	Hall G	Speaker
Bernard	C. France	Platform Session	01-Oct	11:30 - 12:30	Hall D	Chair
Bernard	C. France	Session	03-Oct	16:30 - 18:00	Hall F	Speaker

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Besag	F. UK	ECE Forum	04-Oct	09:00 - 10:30	Hall D	Speaker
Beyenburg	S. Luxembourg	Session	02-Oct	07:45 - 09:00	Hall D	Speaker
Bialer	M. Israel	Special Session	01-Oct	14:30 - 16:00	Auditorium	Speaker
Bialer	M. Israel	Chairs Symposium	01-Oct	09:00 - 11:00	Auditorium	Chair/Spkr
Bialer	M. Israel	Special Session	02-Oct	14:30 - 16:00	Auditorium	Chair
Bindoff	L. Norway	Epilepsy Course	04-Oct	13:30 - 14:50	Hall C	Speaker
Blatt	I. Israel	Session	02-Oct	14:30 - 16:00	Hall E	Chair
Blümcke	I. Germany	Session	01-Oct	07:45 - 09:00	Auditorium	Chair
Blümcke	I. Germany	Session	02-Oct	07:45 - 09:00	Hall E	Speaker
Blümcke	I. Germany	Session	03-Oct	07:45 - 09:00	Hall E	Speaker
Bodenreider	O. USA	ECE Forum	04-Oct	11:00 - 12:30	Hall E	Speaker
Boison	D. USA	Session	02-Oct	07:45 - 09:00	Hall F	Speaker
Bonelli	S. Austria	Main Session	03-Oct	09:00 - 11:00	Hall B	Speaker
Bonelli	S. Austria	Platform Session	03-Oct	11:30 - 12:30	Auditorium	Chair/Spkr
Bonilha	L. USA	Session	01-Oct	07:45 - 09:00	Hall D	Speaker
Boon	P. Belgium	Session	30-Sep	13:30 - 15:00	Hall D	Speaker
Boon	P. Belgium	How to do it course	03-Oct	07:45 - 09:00	Hall G	Speaker
Boon	P. Belgium	Session	03-Oct	14:30 - 16:00	Hall B	Speaker
Boon	P. Belgium	ECE Forum	04-Oct	09:00 - 10:30	Hall H	Speaker
Borthen	I. Norway	Session	03-Oct	16:30 - 18:00	Hall C	Speaker
Boylan	G. Ireland	Session	03-Oct	07:45 - 09:00	Hall B	Speaker
Braakman	H. Netherlands	Platform Session	03-Oct	11:30 - 12:30	Hall B	Speaker
Braun	K. Netherlands	Session	30-Sep	13:30 - 15:00	Auditorium	Speaker
Brodie	M. UK	Special Session	01-Oct	14:30 - 16:00	Auditorium	Speaker
Brodie	M. UK	Main Session	02-Oct	09:00 - 11:00	Auditorium	Speaker
Brodie	M. UK	Satellite Symposium	02-Oct	16:30 - 18:00	Auditorium	Speaker
Brodie	M. UK	ECE Forum	04-Oct	13:30 - 15:00	Hall E	Speaker
Brodtkorb	E. Norway	Session	03-Oct	14:30 - 16:00	Hall C	Chair/Spkr
Brunnhuber	F. UK	Platform Session	02-Oct	11:30 - 12:30	Hall G	Speaker
Campo	P. Spain	Platform Session	03-Oct	11:30 - 12:30	Hall B	Speaker
Canevini	M. Italy	ECE Forum	04-Oct	09:00 - 10:30	Hall F	Speaker
Capovilla	G. Italy	Session	30-Sep	15:00 - 16:30	Hall F	Speaker
Carreño	M. Spain	How to do it course	02-Oct	07:45 - 09:00	Hall G	Speaker
Carreño	M. Spain	Main Session	03-Oct	09:00 - 11:00	Hall B	Chair
Carreño	M. Spain	Platform Session	03-Oct	11:30 - 12:30	Hall B	Chair
Cash	S. USA	Session	02-Oct	07:45 - 09:00	Auditorium	Speaker
Cavanna	A. UK	Session	30-Sep	13:30 - 15:00	Hall E	Chair
Cavanna	A. UK	Platform Session	01-Oct	11:30 - 12:30	Hall E	Speaker
Cavanna	A. UK	Session	01-Oct	07:45 - 09:00	Hall E	Speaker
Centeno	M. UK	Session	30-Sep	13:30 - 15:00	Hall D	Speaker
Chan	J. Australia	Platform Session	02-Oct	11:30 - 12:30	Hall G	Speaker
Chaudhary	U. UK	Platform Session	03-Oct	11:30 - 12:30	Auditorium	Speaker
Chauvel	P. France	Session	03-Oct	07:45 - 09:00	Hall F	Chair

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Chaves	J. Portugal	Platform Session	02-Oct	11:30 - 12:30	Hall D	Speaker
Chelly	J. France	Session	01-Oct	14:30 - 16:00	Hall C	Speaker
Chen	L. China	Platform Session	03-Oct	11:30 - 12:30	Hall C	Speaker
Chepreganova	T. Macedonia	Epilepsy Course	04-Oct	13:30 - 14:50	Hall C	Chair
Chin	R. UK	ECE Forum	02-Oct	10:30 - 11:30	Hall G	Speaker
Chowdhury	F. UK	Platform Session	02-Oct	11:30 - 12:30	Hall E	Speaker
Christensen	J. Denmark	Epilepsy Course	04-Oct	09:15 - 11:15	Hall C	Speaker
Cleary	R. UK	Platform Session	01-Oct	11:30 - 12:30	Hall F	Speaker
Cloarec	R. France	Platform Session	02-Oct	11:30 - 12:30	Hall D	Speaker
Cock	H. UK	ECE Forum	03-Oct	09:30 - 11:00	Hall G	Chair
Cock	H. UK	Session	03-Oct	14:30 - 16:00	Auditorium	Chair
Cook	M. Australia	Session	03-Oct	14:30 - 16:00	Hall B	Chair/Spkr
Cook	M. Australia	Special Session	03-Oct	13:30 - 14:30	Auditorium	Speaker
Cook	I. USA	Satellite Symposium	30-Sep	14:00 - 15:00	Hall C	Speaker
Cooper	P. UK	ECE Forum	04-Oct	13:30 - 15:00	Hall D	Chair
Correia	F. Portugal	Platform Session	02-Oct	11:30 - 12:30	Hall C	Speaker
Covanis	A. Greece	Session	30-Sep	15:00 - 16:30	Hall F	Speaker
Covanis	A. Greece	Epilepsy Course	04-Oct	17:15 - 18:45	Hall C	Speaker
Croft	L. UK	ECE Forum	04-Oct	13:30 - 15:00	Hall J	Chair/ Spkr
Cross	H. UK	Session	30-Sep	13:30 - 15:00	Auditorium	Speaker
Cross	H. UK	Session	01-Oct	14:30 - 16:00	Hall D	Chair
Cross	H. UK	Session	02-Oct	14:30 - 16:00	Hall C	Speaker
Cross	H. UK	ECE Forum	04-Oct	11:00 - 12:30	Hall F	Speaker
Cross	H. UK	Epilepsy Course	04-Oct	15:15 - 16:35	Hall C	Speaker
Cross	H. UK	Epilepsy Course	04-Oct	07:45 - 09:00	Hall C	Speaker
Cunningham	M. UK	ECE Forum	04-Oct	13:30 - 15:00	Hall H	Speaker
Cupers	P. Belgium	Session	02-Oct	14:30 - 16:00	Hall G	Speaker
Curatolo	P. Italy	Session	03-Oct	14:30 - 16:00	Hall C	Speaker
Cvetkovska	E. Macedonia	Platform Session	01-Oct	11:30 - 12:30	Hall C	Chair
Dalla Bernardina	B. Italy	Session	30-Sep	13:30 - 15:00	Auditorium	Chair
Dalla Bernardina	B. Italy	ECE Forum	04-Oct	13:30 - 15:00	Hall G	Speaker
Danielsson	S. Sweden	Platform Session	01-Oct	11:30 - 12:30	Hall F	Chair
Danielsson	S. Sweden	Main Session	02-Oct	09:00 - 11:00	Hall B	Speaker
David	O. France	ECE Forum	04-Oct	11:00 - 12:30	Hall H	Speaker
DCruz	N. USA	Platform Session	01-Oct	11:30 - 12:30	Hall G	Speaker
De Curtis	M. Italy	ECE Forum	30-Sep	11:30 - 13:00	Hall D	Speaker
De Curtis	M. Italy	Debate	03-Oct	11:30 - 13:00	Hall D	Speaker
De Curtis	M. Italy	ECE Forum	04-Oct	11:00 - 12:30	Hall H	Chair
De Jonghe	P. Belgium	Session	02-Oct	14:30 - 16:00	Hall C	Speaker
De Jonghe	P. Belgium	Session	03-Oct	16:30 - 18:00	Hall D	Chair/Spkr
De Kovel	C. Netherlands	Session	01-Oct	14:30 - 16:00	Hall C	Speaker
De Mey	C. Germany	Satellite Symposium	02-Oct	10:30 - 11:30	Hall C	Speaker
De Vries	L. Netherlands	Session	03-Oct	07:45 - 09:00	Hall B	Speaker

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
DeGiorgio	C. USA	Satellite Symposium	30-Sep	14:00 - 15:00	Hall C	Chair/ Spk
DeGiorgio	C. USA	Session	03-Oct	14:30 - 16:00	Hall B	Speaker
Delanty	N. Ireland	Platform Session	01-Oct	11:30 - 12:30	Hall C	Chair
Delanty	N. Ireland	Session	01-Oct	07:45 - 09:00	Hall F	Chair
Delanty	N. Ireland	Session	01-Oct	14:30 - 16:00	Hall E	Chair/Spkr
Delanty	N. Ireland	Epilepsy Course	04-Oct	13:30 - 14:50	Hall C	Speaker
Depaulis	A. France	Session	01-Oct	14:30 - 16:00	Hall B	Chair
Deppe	M. Germany	Platform Session	03-Oct	11:30 - 12:30	Hall B	Speaker
Detyniecki	K. USA	Session	30-Sep	13:30 - 15:00	Hall E	Speaker
Deva	N. Belgium	Session	02-Oct	14:30 - 16:00	Hall G	Speaker
Diehl	B. UK	Session	30-Sep	15:00 - 16:30	Hall D	Chair
DiFrancesco	J. Italy	ECE Forum	30-Sep	11:30 - 13:00	Hall C	Speaker
Djémié	T. Belgium	Platform Session	01-Oct	11:30 - 12:30	Hall C	Speaker
Dobesberger	J. Austria	Platform Session	01-Oct	11:30 - 12:30	Hall E	Speaker
Dravet	C. France	Session	30-Sep	15:00 - 16:30	Hall F	Chair
Dravet	C. France	ECE Forum	04-Oct	13:30 - 15:00	Hall G	Chair
Dulac	O. France	ECE Forum	04-Oct	11:00 - 12:30	Hall F	Chair
Duncan	J. UK	Debate	01-Oct	11:30 - 12:30	Auditorium	Chair
Duncan	J. UK	Satellite Symposium	01-Oct	16:30 - 18:00	Auditorium	Chair/Spkr
Duncan	J. UK	Satellite Symposium	02-Oct	16:30 - 18:00	Auditorium	Chair
Duncan	J. UK	Main Session	03-Oct	09:00 - 11:00	Hall B	Chair
Duncan	J. UK	Session	03-Oct	14:30 - 16:00	Hall E	Chair
Dunkley	C. UK	ECE Forum	02-Oct	10:30 - 11:30	Hall G	Speaker
Dunkley	C. UK	Platform Session	03-Oct	11:30 - 12:30	Hall C	Speaker
Edelvik	A. Sweden	Platform Session	02-Oct	11:30 - 12:30	Hall F	Speaker
Elger	C. Germany	How to do it course	01-Oct	07:45 - 09:00	Hall G	Chair/Spkr
Elger	C. Germany	How to do it course	02-Oct	07:45 - 09:00	Hall G	Chair
Elger	C. Germany	Special Session	02-Oct	14:30 - 16:00	Auditorium	Speaker
Elger	C. Germany	How to do it course	03-Oct	07:45 - 09:00	Hall G	Chair/Spkr
Endziniene	M. Lithuania	Platform Session	03-Oct	11:30 - 12:30	Hall C	Chair
Engel	J. USA	Session	30-Sep	13:30 - 15:00	Hall F	Chair
Engelsen	B. Norway	Session	03-Oct	14:30 - 16:00	Hall C	Speaker
Eriksson	S. UK	Session	02-Oct	07:45 - 09:00	Hall B	Chair
Evangeliou	A. Greece	Session	03-Oct	16:30 - 18:00	Hall E	Chair
Fabene	P. Italy	ECE Forum	30-Sep	11:30 - 13:00	Hall E	Speaker
Fabricius	M. Denmark	ECE Forum	01-Oct	09:00 - 10:30	Hall F	Speaker
Faure	J. France	Platform Session	03-Oct	11:30 - 12:30	Hall G	Speaker
Fejerman	N. Argentina	Session	30-Sep	15:00 - 16:30	Hall F	Chair
Feldmann	M. UK	Session	01-Oct	07:45 - 09:00	Hall F	Speaker
Ferrie	C. UK	ECE Forum	02-Oct	10:30 - 11:30	Hall G	Speaker
Ferrie	C. UK	Session	02-Oct	14:30 - 16:00	Hall C	Chair
Fischer	A. Germany	Session	01-Oct	07:45 - 09:00	Auditorium	Speaker
Fisher	R. USA	Session	03-Oct	14:30 - 16:00	Hall B	Speaker

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Focke	N. Germany	Session	01-Oct	07:45 - 09:00	Hall D	Chair
Focke	N. Germany	Main Session	03-Oct	09:00 - 11:00	Hall B	Speaker
Fogarasi	A. Hungary	ECE Forum	04-Oct	11:00 - 12:30	Hall J	Chair/Spkr
Freiman	T. Germany	Platform Session	03-Oct	11:30 - 12:30	Hall G	Speaker
French	J. USA	Debate	01-Oct	11:30 - 12:30	Auditorium	Speaker
French	J. USA	Platform Session	01-Oct	11:30 - 12:30	Hall F	Speaker
Fried	I. USA	Session	02-Oct	07:45 - 09:00	Auditorium	Speaker
Fusco	L. Italy	ECE Forum	04-Oct	11:00 - 12:30	Hall F	Speaker
Gaily	E. Finland	Session	30-Sep	15:00 - 16:30	Hall E	Chair
Galanopoulou	A. USA	Session	30-Sep	13:30 - 15:00	Hall G	Speaker
Garganis	K. Greece	Session	03-Oct	07:45 - 09:00	Hall D	Chair
Gélisse	P. France	Session	02-Oct	07:45 - 09:00	Hall B	Speaker
Genton	P. France	ECE Forum	04-Oct	09:00 - 10:30	Hall F	Speaker
Ghali	N. UK	Session	03-Oct	14:30 - 16:00	Hall D	Speaker
Gil-Nagel	A. Spain	Session	02-Oct	07:45 - 09:00	Hall E	Chair/Spkr
Gil-Nagel	A. Spain	ECE Forum	04-Oct	09:00 - 10:30	Hall E	Speaker
Glynn	M. Ireland	Session	02-Oct	14:30 - 16:00	Hall G	Chair
Gnatkovsky	V. Italy	ECE Forum	04-Oct	11:00 - 12:30	Hall H	Speaker
Goodkin	H. USA	Session	03-Oct	14:30 - 16:00	Auditorium	Speaker
Gos	M. Poland	Platform Session	01-Oct	11:30 - 12:30	Hall C	Speaker
Gotman	J. Canada	Session	01-Oct	07:45 - 09:00	Hall D	Chair
Gowers	T. UK	Special Session	01-Oct	13:30 - 14:30	Auditorium	Speaker
Granata	T. Italy	ECE Forum	30-Sep	11:30 - 13:00	Hall E	Speaker
Granata	T. Italy	ECE Forum	04-Oct	11:00 - 12:30	Hall F	Chair
Grant	A. USA	Platform Session	02-Oct	11:30 - 12:30	Hall G	Speaker
Gray	S. USA	Session	02-Oct	11:30 - 13:00	Auditorium	Speaker
Greenberg	D. USA	Epilepsy Course	04-Oct	13:30 - 14:50	Hall C	Speaker
Guekht	A. Russian Fed	Session	01-Oct	07:45 - 09:00	Hall B	Chair
Guekht	A. Russian Fed	ECE Forum	02-Oct	09:00 - 10:30	Hall G	Chair/Spkr
Guerrini	R. Italy	Session	01-Oct	14:30 - 16:00	Hall C	Speaker
Guerrini	R. Italy	Session	02-Oct	14:30 - 16:00	Hall C	Speaker
Guerrini	R. Italy	Epilepsy Course	04-Oct	07:45 - 09:00	Hall C	Speaker
Guye	M. France	Main Session	03-Oct	09:00 - 11:00	Hall B	Speaker
Guye	M. France	Platform Session	03-Oct	11:30 - 12:30	Auditorium	Chair
Halasz	P. Hungary	ECE Forum	04-Oct	11:00 - 12:30	Hall J	Speaker
Hamandi	K. UK	Session	30-Sep	13:30 - 15:00	Hall F	Speaker
Hamer	H. Germany	Session	30-Sep	15:00 - 16:30	Hall D	Speaker
Hamer	H. Germany	Satellite Symposium	01-Oct	18:30 - 20:00	Auditorium	Speaker
Hammers	A. France	Session	01-Oct	07:45 - 09:00	Hall D	Speaker
Hecimovic	H. Croatia	Epilepsy Course	04-Oct	09:15 - 11:15	Hall C	Chair
Heinemann	U. Germany	Session	30-Sep	15:00 - 16:30	Hall G	Chair
Heinemann	U. Germany	ECE Forum	04-Oct	13:30 - 15:00	Hall H	Speaker
Heiner	S. Germany	ECE Forum	02-Oct	10:30 - 11:30	Hall F	Chair/Spkr

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Helbig	I. Germany	Session	03-Oct	16:30 - 18:00	Hall D	Speaker
Helmstaedter	C. Germany	Platform Session	02-Oct	11:30 - 12:30	Hall E	Chair
Helmstaedter	C. Germany	ECE Forum	04-Oct	13:30 - 15:00	Hall J	Speaker
Henshall	D. Ireland	Session	30-Sep	15:00 - 16:30	Hall G	Chair/Spkr
Hesdorffer	D. USA	ECE Forum	04-Oct	11:00 - 12:30	Hall D	Speaker
Hirsch	E. France	ECE Forum	01-Oct	09:00 - 10:30	Hall D	Speaker
Hirsch	E. France	Session	01-Oct	14:30 - 16:00	Hall F	Chair
Hirsch	E. France	ECE Forum	04-Oct	13:30 - 15:00	Hall F	Chair/Spkr
Holmes	G. USA	Session	30-Sep	15:00 - 16:30	Hall C	Speaker
Huber	R. Switzerland	Session	01-Oct	14:30 - 16:00	Hall F	Speaker
Huppertz	H. Switzerland	Session	01-Oct	07:45 - 09:00	Hall D	Speaker
Huppertz	H. Switzerland	Platform Session	03-Oct	11:30 - 12:30	Hall B	Chair
Husain	M. UK	Session	30-Sep	15:00 - 16:30	Hall D	Speaker
Ikonomidou	C. USA	Session	30-Sep	15:00 - 16:30	Hall C	Speaker
Itoh	M. Japan	Platform Session	01-Oct	11:30 - 12:30	Hall D	Speaker
Jacques	T. UK	Epilepsy Course	04-Oct	15:15 - 16:35	Hall C	Speaker
Janigro	D. USA	ECE Forum	30-Sep	11:30 - 13:00	Hall E	Speaker
Jefferys	J. UK	ECE Forum	30-Sep	11:30 - 13:00	Hall D	Chair
Jefferys	J. UK	ECE Forum	04-Oct	09:00 - 10:30	Hall H	Speaker
Jensen	F. USA	Session	30-Sep	15:00 - 16:30	Hall C	Chair
Jerney	J. Hungary	Session	03-Oct	14:30 - 16:00	Hall C	Chair
Jette	N. Canada	Session	01-Oct	14:30 - 16:00	Hall D	Speaker
Jiruska	P. UK	ECE Forum	30-Sep	11:30 - 13:00	Hall D	Chair
Joels	M. Netherlands	Session	01-Oct	14:30 - 16:00	Hall E	Speaker
Johannessen	S. Norway	Main Session	03-Oct	09:00 - 11:00	Auditorium	Chair/Spkr
Johannessen L.	C. Norway	Session	01-Oct	14:30 - 16:00	Hall D	Speaker
Jokeit	H. Switzerland	Session	30-Sep	15:00 - 16:30	Hall E	Chair/Spkr
Kahane	P. France	Session	30-Sep	15:00 - 16:30	Hall D	Speaker
Kahane	P. France	ECE Forum	01-Oct	09:00 - 10:30	Hall E	Speaker
Kahane	P. France	Platform Session	02-Oct	11:30 - 12:30	Hall F	Chair
Kahane	P. France	Session	03-Oct	07:45 - 09:00	Hall D	Speaker
Kahane	P. France	ECE Forum	04-Oct	11:00 - 12:30	Hall G	Speaker
Kaila	K. Finland	ECE Forum	30-Sep	11:30 - 13:00	Hall G	Speaker
Kälviäinen	R. Finland	Platform Session	02-Oct	11:30 - 12:30	Hall D	Chair
Kälviäinen	R. Finland	Session	02-Oct	07:45 - 09:00	Hall E	Chair
Kanner	A. USA	Main Session	02-Oct	09:00 - 11:00	Hall B	Speaker
Kanner	A. USA	Session	02-Oct	14:30 - 16:00	Hall E	Speaker
Kanner	A. USA	ECE Forum	04-Oct	09:00 - 10:30	Hall D	Speaker
Kapidzic	A. Bosnia&Herzegovina	Epilepsy Course	04-Oct	17:15 - 18:45	Hall C	Chair
Kapur	J. USA	Session	03-Oct	14:30 - 16:00	Auditorium	Speaker
Kasteleijn-N.T.	D. Netherlands/Italy	Chairs Symposium	01-Oct	09:00 - 11:00	Auditorium	Speaker
Kasteleijn-N.T.	D. Netherlands/Italy	Epilepsy Course	04-Oct	17:15 - 18:45	Hall C	Speaker
Kealey	C. USA	Satellite Symposium	30-Sep	14:00 - 15:00	Hall C	Speaker

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Kelemen	A. Hungary	Session	02-Oct	07:45 - 09:00	Hall B	Speaker
Kelemen	A. Hungary	ECE Forum	04-Oct	09:00 - 10:30	Hall F	Speaker
Kempermann	G. Germany	Session	01-Oct	14:30 - 16:00	Hall B	Speaker
Kerr	M. UK	Satellite Symposium	01-Oct	08:00 - 09:00	Hall C	Speaker
Kerr	M. UK	ECE Forum	04-Oct	09:00 - 10:30	Hall D	Chair/Spkr
Kharatishvili	I. Australia	Platform Session	01-Oct	11:30 - 12:30	Hall D	Speaker
Kholin	A. Russian Fed	Platform Session	01-Oct	11:30 - 12:30	Hall G	Speaker
Kimiskidis	V. Greece	Session	02-Oct	07:45 - 09:00	Auditorium	Chair
Kittler	J. UK	Platform Session	03-Oct	11:30 - 12:30	Hall G	Chair
Kittler	J. UK	Special Session	03-Oct	13:30 - 14:30	Auditorium	Speaker
Klepper	J. Germany	Session	03-Oct	16:30 - 18:00	Hall E	Speaker
Klitgaard	H. Belgium	Satellite Symposium	02-Oct	16:30 - 18:00	Auditorium	Speaker
Kobow	K. Germany	Session	01-Oct	07:45 - 09:00	Auditorium	Speaker
Koch-Stoecker	S. Germany	Platform Session	01-Oct	11:30 - 12:30	Hall F	Chair
Koch-Stoecker	S. Germany	Main Session	02-Oct	09:00 - 11:00	Hall B	Speaker
Koch-Stoecker	S. Germany	Session	02-Oct	14:30 - 16:00	Hall E	Speaker
Koeleman	B. Netherlands	Session	03-Oct	16:30 - 18:00	Hall D	Speaker
Koepp	M. UK	ECE Forum	30-Sep	11:30 - 13:00	Hall E	Speaker
Koepp	M. UK	Session	30-Sep	13:30 - 15:00	Hall D	Chair
Koepp	M. UK	Debate	03-Oct	11:30 - 13:00	Hall D	Speaker
Köhling	R. Germany	ECE Forum	30-Sep	11:30 - 13:00	Hall G	Chair/Spkr
Köhling	R. Germany	Session	02-Oct	07:45 - 09:00	Hall F	Chair
Kokaia	M. Sweden	Session	30-Sep	15:00 - 16:30	Hall G	Speaker
Kokaia	M. Sweden	Platform Session	01-Oct	11:30 - 12:30	Hall D	Chair
Kokaia	M. Sweden	Session	01-Oct	14:30 - 16:00	Hall B	Speaker
Komarek	V. Czech Republic	Main Session	02-Oct	09:00 - 11:00	Hall B	Chair
Koutroumanidis	M. UK	Session	30-Sep	15:00 - 16:30	Hall F	Speaker
Kovac	S. Croatia	Session	30-Sep	15:00 - 16:30	Hall D	Speaker
Kramer	U. Israel	Session	02-Oct	14:30 - 16:00	Hall C	Chair
Kramer	U. Israel	Platform Session	03-Oct	11:30 - 12:30	Hall C	Chair
Kramer	G. Switzerland	ECE Forum	02-Oct	10:30 - 11:30	Hall F	Speaker
Kramer	G. Switzerland	Session	02-Oct	07:45 - 09:00	Auditorium	Chair
Krishnamoorthy	E. India	ECE Forum	04-Oct	09:00 - 10:30	Hall D	Chair/Spkr
Kubova	H. Czech Republic	Session	30-Sep	15:00 - 16:30	Hall C	Chair/Spkr
Kullmann	D. UK	Session	02-Oct	07:45 - 09:00	Hall F	Chair
Kullmann	D. UK	Session	02-Oct	11:30 - 13:00	Auditorium	Speaker
Kurian	M. UK	Session	03-Oct	16:30 - 18:00	Hall E	Speaker
Lagae	L. Belgium	Satellite Symposium	30-Sep	16:30 - 18:00	Auditorium	Chair/Spkr
Lagae	L. Belgium	ECE Forum	04-Oct	13:30 - 15:00	Hall G	Speaker
Larsson	P. Norway	Platform Session	02-Oct	11:30 - 12:30	Hall G	Chair
Laufs	H. Germany	Session	03-Oct	14:30 - 16:00	Hall E	Speaker
Leach	J. UK	Satellite Symposium	01-Oct	18:30 - 20:00	Auditorium	Speaker
Leach	J. UK	ECE Forum	04-Oct	13:30 - 15:00	Hall D	Chair

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Leach	J. UK	Epilepsy Course	04-Oct	11:15 - 12:45	Hall C	Speaker
Lehesjoki	A. Finland	Session	30-Sep	13:30 - 15:00	Hall G	Speaker
Lehesjoki	A. Finland	Session	02-Oct	14:30 - 16:00	Hall F	Speaker
Lemieux	L. UK	Session	03-Oct	14:30 - 16:00	Hall E	Speaker
Leonard	B. Ireland	Session	01-Oct	14:30 - 16:00	Hall B	Speaker
Lerche	H. Germany	Session	01-Oct	07:45 - 09:00	Auditorium	Chair
Lhatoo	S. USA	Session	30-Sep	15:00 - 16:30	Hall D	Chair
Lhatoo	S. USA	ECE Forum	04-Oct	11:00 - 12:30	Hall E	Chair/Spkr
Li	S. China	Special Session	02-Oct	14:30 - 16:00	Auditorium	Chair
Librizzi	L. Italy	Platform Session	01-Oct	11:30 - 12:30	Hall D	Speaker
Lilleker	J. UK	Platform Session	03-Oct	11:30 - 12:30	Hall E	Speaker
Lopes	A. Portugal	Platform Session	02-Oct	11:30 - 12:30	Hall E	Speaker
Lopes Lima	J. Portugal	Debate	03-Oct	11:30 - 13:00	Hall D	Chair
Löscher	W. Germany	Special Session	01-Oct	14:30 - 16:00	Auditorium	Speaker
Löscher	W. Germany	Session	01-Oct	07:45 - 09:00	Hall F	Speaker
Löscher	W. Germany	Main Session	02-Oct	09:00 - 11:00	Auditorium	Chair/Spkr
Lowenstein	D. USA	ECE Forum	03-Oct	09:30 - 11:00	Hall G	Speaker
Luef	G. Austria	Main Session	03-Oct	09:00 - 11:00	Auditorium	Speaker
MacDonald	B. UK	Session	02-Oct	09:00 - 10:30	Hall F	Chair/Spkr
Mahler	B. Sweden	Platform Session	03-Oct	11:30 - 12:30	Hall E	Speaker
Majkowski	J. Poland	ECE Forum	04-Oct	11:00 - 12:30	Hall J	Speaker
Major	P. Canada	Platform Session	03-Oct	11:30 - 12:30	Hall E	Speaker
Maljevic	S. Germany	Platform Session	01-Oct	11:30 - 12:30	Hall D	Speaker
Malmgren	K. Sweden	Session	01-Oct	14:30 - 16:00	Hall B	Chair
Malmgren	K. Sweden	Main Session	02-Oct	09:00 - 11:00	Hall B	Chair
Malmgren	K. Sweden	Session	02-Oct	14:30 - 16:00	Hall D	Speaker
Malmgren	K. Sweden	Epilepsy Course	04-Oct	09:15 - 11:15	Hall C	Speaker
Mameniski	R. Lithuania	Platform Session	01-Oct	11:30 - 12:30	Hall E	Chair
Man	S. UK	Platform Session	01-Oct	11:30 - 12:30	Hall G	Speaker
Mansfield	P. UK	Special Session	02-Oct	13:30 - 14:30	Auditorium	Speaker
Mantegazza	M. France	Session	30-Sep	13:30 - 15:00	Hall G	Speaker
Marchi	N. USA	ECE Forum	30-Sep	11:30 - 13:00	Hall E	Chair
Mares	P. Czech Republic	Session	01-Oct	07:45 - 09:00	Hall F	Chair
Marek	M. UK	ECE Forum	04-Oct	13:30 - 15:00	Hall D	Speaker
Marini	C. Italy	Session	01-Oct	14:30 - 16:00	Hall C	Chair
Marini	C. Italy	Session	02-Oct	14:30 - 16:00	Hall F	Speaker
Maroso	M. Italy	Session	03-Oct	16:30 - 18:00	Hall F	Speaker
Marras	C. Italy	ECE Forum	04-Oct	11:00 - 12:30	Hall F	Speaker
Marsh	M. UK	Session	03-Oct	16:30 - 18:00	Hall C	Chair
Marson	T. UK	Debate	01-Oct	11:30 - 12:30	Auditorium	Speaker
Marson	T. UK	Session	01-Oct	07:45 - 09:00	Hall B	Chair/Spkr
Martland	T. UK	Session	03-Oct	16:30 - 18:00	Hall E	Chair
Marusic	P. Czech Republic	ECE Forum	30-Sep	11:30 - 13:00	Hall D	Speaker

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Mathern	G. USA	Epilepsy Course	04-Oct	15:15 - 16:35	Hall C	Speaker
McEvoy	A. UK	Session	03-Oct	07:45 - 09:00	Hall F	Chair/Spkr
Meletti	S. Italy	Session	30-Sep	15:00 - 16:30	Hall E	Speaker
Meyer	T. Germany	ECE Forum	02-Oct	10:30 - 11:30	Hall F	Speaker
Michelucci	R. Italy	Session	02-Oct	14:30 - 16:00	Hall F	Speaker
Michelucci	R. Italy	Platform Session	03-Oct	11:30 - 12:30	Hall E	Speaker
Michoulas	A. Canada	Platform Session	01-Oct	11:30 - 12:30	Hall F	Speaker
Mifsud	J. Malta	Platform Session	01-Oct	11:30 - 12:30	Hall G	Chair
Miller-Delaney	S. Ireland	Session	01-Oct	07:45 - 09:00	Auditorium	Speaker
Miserocchi	A. Italy	Platform Session	02-Oct	11:30 - 12:30	Hall F	Chair
Miserocchi	A. Italy	Session	03-Oct	07:45 - 09:00	Hall F	Speaker
Moeddel	G. Germany	Satellite Symposium	03-Oct	08:00 - 09:00	Hall C	Speaker
Moldrich	R. Australia	Platform Session	01-Oct	11:30 - 12:30	Hall F	Speaker
Möller	F. Germany	Debate	03-Oct	11:30 - 13:00	Hall D	Speaker
Møller	R. Denmark	Platform Session	01-Oct	11:30 - 12:30	Hall C	Speaker
Monzoni	C. UK	Session	02-Oct	07:45 - 09:00	Hall D	Speaker
Moran	N. UK	Session	03-Oct	14:30 - 16:00	Hall D	Speaker
Mormann	F. Germany	Session	02-Oct	07:45 - 09:00	Auditorium	Speaker
Morrell	M. USA	ECE Forum	04-Oct	09:00 - 10:30	Hall H	Speaker
Moshe	N. USA	Debate	03-Oct	11:30 - 13:00	Hall D	Chair
Mukhin	K. Russian Fed	Epilepsy Course	04-Oct	15:15 - 16:35	Hall C	Chair
Mula	M. Italy	Session	30-Sep	13:30 - 15:00	Hall E	Chair
Mula	M. Italy	Session	01-Oct	07:45 - 09:00	Hall E	Speaker
Mula	M. Italy	Main Session	02-Oct	09:00 - 11:00	Hall B	Speaker
Mula	M. Italy	ECE Forum	04-Oct	09:00 - 10:30	Hall D	Speaker
Nabbout	R. France	ECE Forum	30-Sep	10:00 - 11:30	Hall D	Speaker
Nabbout	R. France	Session	01-Oct	14:30 - 16:00	Hall B	Speaker
Nabbout	R. France	Session	03-Oct	14:30 - 16:00	Hall D	Speaker
Nabbout	R. France	ECE Forum	04-Oct	13:30 - 15:00	Hall G	Speaker
Nabbout	R. France	Epilepsy Course	04-Oct	11:15 - 12:45	Hall C	Speaker
Najm	I. USA	ECE Forum	04-Oct	09:00 - 10:30	Hall G	Speaker
Nashef	L. UK	Session	03-Oct	14:30 - 16:00	Hall D	Speaker
Nashef	L. UK	ECE Forum	04-Oct	13:30 - 15:00	Hall D	Speaker
Nashef	L. UK	ECE Forum	04-Oct	11:00 - 12:30	Hall D	Chair
Natoli	M. France	ECE Forum	30-Sep	11:30 - 13:00	Hall E	Speaker
Nehlig	A. France	Session	30-Sep	15:00 - 16:30	Hall C	Speaker
Nehlig	A. France	Session	30-Sep	13:30 - 15:00	Hall G	Chair
Nehlig	A. France	Platform Session	03-Oct	11:30 - 12:30	Hall G	Chair
Neufeld	M. Israel	ECE Forum	01-Oct	09:00 - 10:30	Hall F	Speaker
Neufeld	M. Israel	Platform Session	03-Oct	11:30 - 12:30	Hall E	Chair
Noebels	J. USA	Session	30-Sep	13:30 - 15:00	Hall G	Chair
O'Brien	T. Australia	Session	30-Sep	13:30 - 15:00	Hall D	Chair
O'Brien	D. Ireland	Session	01-Oct	14:30 - 16:00	Hall E	Chair

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
O'Callaghan	P. UK	Chairs Symposium	01-Oct	09:00 - 11:00	Auditorium	Speaker
Oguni	H. Japan	ECE Forum	01-Oct	09:00 - 10:30	Hall E	Speaker
Okujava	N. Georgia	Session	01-Oct	14:30 - 16:00	Hall D	Speaker
Onat	F. Turkey	Platform Session	01-Oct	11:30 - 12:30	Hall G	Chair
Onat	F. Turkey	Platform Session	03-Oct	11:30 - 12:30	Hall G	Speaker
Otsuki	T. Japan	Platform Session	02-Oct	11:30 - 12:30	Hall F	Speaker
Özkara	C. Turkey	Session	01-Oct	07:45 - 09:00	Hall E	Chair
Özkara	C. Turkey	ECE Forum	04-Oct	09:00 - 10:30	Hall F	Chair/ Spkr
Palmini	A. Brazil	ECE Forum	01-Oct	09:00 - 10:30	Hall E	Chair/ Spkr
Panayiotopoulos	T. UK	Special Session	02-Oct	14:30 - 16:00	Auditorium	Speaker
Papacostas	S. Cyprus	Platform Session	03-Oct	11:30 - 12:30	Hall E	Chair
Papathanasiou	E. Greece	ECE Forum	04-Oct	09:00 - 10:30	Hall G	Chair/ Spkr
Parko	K. USA	Session	01-Oct	14:30 - 16:00	Hall D	Speaker
Patel	V. Australia	Platform Session	02-Oct	11:30 - 12:30	Hall C	Speaker
Patsalos	P. UK	Platform Session	02-Oct	11:30 - 12:30	Hall C	Chair
Pavlov	I. UK	ECE Forum	04-Oct	13:30 - 15:00	Hall H	Chair
Perakyla	A. Finland	Session	02-Oct	07:45 - 09:00	Hall D	Speaker
Perucca	E. Italy	Special Session	01-Oct	14:30 - 16:00	Auditorium	Chair
Perucca	E. Italy	Session	01-Oct	07:45 - 09:00	Hall B	Speaker
Perucca	E. Italy	Main Session	02-Oct	09:00 - 11:00	Auditorium	Chair
Perucca	E. Italy	Session	02-Oct	14:30 - 16:00	Hall G	Chair
Pirmohamed	M. UK	Main Session	03-Oct	09:00 - 11:00	Auditorium	Speaker
Pitkänen	A. Finland	Session	02-Oct	07:45 - 09:00	Hall F	Speaker
Pittman	Q. Canada	Session	03-Oct	16:30 - 18:00	Hall F	Speaker
Plouin	P. France	Session	03-Oct	07:45 - 09:00	Hall B	Chair
Pollard	J. USA	ECE Forum	04-Oct	13:30 - 15:00	Hall E	Speaker
Polster	T. Germany	Session	30-Sep	13:30 - 15:00	Auditorium	Speaker
Poolos	N. USA	ECE Forum	30-Sep	11:30 - 13:00	Hall C	Chair/ Spkr
Potschka	H. Germany	ECE Forum	30-Sep	11:30 - 13:00	Hall E	Speaker
Potschka	H. Germany	Session	02-Oct	11:30 - 13:00	Auditorium	Chair
Pressler	R. UK	ECE Forum	01-Oct	09:00 - 10:30	Hall F	Speaker
Pressler	R. UK	Session	03-Oct	07:45 - 09:00	Hall B	Chair/ Spkr
Privitera	M. USA	Session	01-Oct	14:30 - 16:00	Hall E	Speaker
Pujar	S. UK	Platform Session	01-Oct	11:30 - 12:30	Hall E	Speaker
Rabinstein	A. USA	ECE Forum	04-Oct	09:00 - 10:30	Hall J	Speaker
Rabinstein	A. USA	ECE Forum	04-Oct	09:00 - 10:30	Hall J	Chair
Rahman	Y. UK	Session	03-Oct	14:30 - 16:00	Hall D	Speaker
Rajna	P. Hungary	ECE Forum	04-Oct	11:00 - 12:30	Hall J	Chair/ Spkr
Rampp	S. Germany	Session	30-Sep	13:30 - 15:00	Hall F	Speaker
Ranmal	R. UK	ECE Forum	02-Oct	10:30 - 11:30	Hall G	Speaker
Rathore	C. India	Platform Session	02-Oct	11:30 - 12:30	Hall F	Speaker
Rector	A. UK	ECE Forum	04-Oct	11:00 - 12:30	Hall E	Speaker
Rektor	I. Czech Republic	ECE Forum	04-Oct	11:00 - 12:30	Hall G	Chair/ Spkr

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Reuber	M. UK	Session	02-Oct	07:45 - 09:00	Hall D	Chair
Reuber	M. UK	Special Session	03-Oct	11:30 - 12:30	Hall F	Chair/ Spkr
Reuber	M. UK	ECE Forum	04-Oct	13:30 - 15:00	Hall D	Speaker
Reynolds	E. UK	Special Session	01-Oct	14:30 - 16:00	Auditorium	Chair
Richardson	M. UK	ECE Forum	02-Oct	10:30 - 11:30	Hall E	Chair/ Spkr
Roessler	K. Germany	Platform Session	02-Oct	11:30 - 12:30	Hall F	Speaker
Rogawski	M. USA	Satellite Symposium	01-Oct	16:30 - 18:00	Auditorium	Speaker
Roivainen	R. Finland	Platform Session	03-Oct	11:30 - 12:30	Hall C	Speaker
Rossetti	A. Switzerland	Platform Session	01-Oct	11:30 - 12:30	Hall E	Chair
Rossetti	A. Switzerland	ECE Forum	04-Oct	09:00 - 10:30	Hall J	Chair/ Spkr
Roth	C. Germany	Platform Session	03-Oct	11:30 - 12:30	Hall B	Speaker
Rubboli	G. Italy	ECE Forum	01-Oct	09:00 - 10:30	Hall F	Speaker
Rubboli	G. Italy	ECE Forum	04-Oct	09:00 - 10:30	Hall E	Chair/ Spkrr
Rugg-Gunn	F. UK	Session	30-Sep	13:30 - 15:00	Hall F	Chair/ Spkrr
Russo	E. Italy	Platform Session	03-Oct	11:30 - 12:30	Hall G	Speaker
Rydenhag	B. Sweden	Session	30-Sep	13:30 - 15:00	Auditorium	Chair
Ryvlin	P. France	Satellite Symposium	01-Oct	08:00 - 09:00	Hall C	Speaker
Ryvlin	P. France	Session	01-Oct	07:45 - 09:00	Hall B	Speaker
Ryvlin	P. France	Satellite Symposium	02-Oct	16:30 - 18:00	Auditorium	Speaker
Ryvlin	P. France	Session	02-Oct	07:45 - 09:00	Hall E	Speaker
Ryvlin	P. France	ECE Forum	04-Oct	13:30 - 15:00	Hall F	Speaker
Ryvlin	P. France	ECE Forum	04-Oct	09:00 - 10:30	Hall E	Chair/ Spkrr
Ryvlin	P. France	ECE Forum	04-Oct	11:00 - 12:30	Hall D	Speaker
Sabers	A. Denmark	Session	03-Oct	16:30 - 18:00	Hall C	Chair
Sahoo	S. USA	ECE Forum	04-Oct	11:00 - 12:30	Hall E	Speaker
Sander	J. UK	Satellite Symposium	01-Oct	18:30 - 20:00	Auditorium	Chair
Sander	J. UK	ECE Forum	02-Oct	10:30 - 11:30	Hall G	Chair
Sander	J. UK	How to do it course	02-Oct	07:45 - 09:00	Hall G	Speaker
Saxena	V. India	Epilepsy Course	04-Oct	11:15 - 12:45	Hall C	Chair
Scharfman	H. USA	Session	03-Oct	16:30 - 18:00	Hall F	Chair
Scheffer	I. Australia	Platform Session	02-Oct	11:30 - 12:30	Hall D	Speaker
Scheffer	I. Australia	ECE Forum	03-Oct	09:30 - 11:00	Hall G	Chair
Scheffer	I. Australia	Epilepsy Course	04-Oct	15:15 - 16:35	Hall C	Speaker
Schmidt	D. Germany	How to do it course	01-Oct	07:45 - 09:00	Hall G	Chair/ Spkr
Schmidt	D. Germany	How to do it course	02-Oct	07:45 - 09:00	Hall G	Chair/ Spkr
Schmidt	D. Germany	Main Session	02-Oct	09:00 - 11:00	Auditorium	Speaker
Schmidt	D. Germany	How to do it course	03-Oct	07:45 - 09:00	Hall G	Chair/ Spkr
Schmitt	F. Germany	ECE Forum	02-Oct	10:30 - 11:30	Hall F	Speaker
Schmitz	B. Germany	Debate	03-Oct	11:30 - 13:00	Hall D	Speaker
Schoendienst	M. Germany	Session	02-Oct	07:45 - 09:00	Hall D	Speaker
Schomer	D. USA	ECE Forum	04-Oct	09:00 - 10:30	Hall G	Speaker
Schuchmann	S. Germany	Special Session	02-Oct	14:30 - 16:00	Auditorium	Speaker
Schulze-Bonhage	A. Germany	Platform Session	02-Oct	11:30 - 12:30	Hall G	Speaker

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Schulze-Bonhage	A. Germany	Session	02-Oct	14:30 - 16:00	Hall E	Chair
Schulze-Bonhage	A. Germany	ECE Forum	04-Oct	09:00 - 10:30	Hall H	Chair/ Spkr
Schwartzkroin	P. USA	Special Session	03-Oct	11:30 - 12:30	Hall F	Chair/ Spkr
Seeck	M. Switzerland	How to do it course	01-Oct	07:45 - 09:00	Hall G	Speaker
Seri	S. UK	Session	30-Sep	13:30 - 15:00	Hall E	Speaker
Seri	S. UK	Satellite Symposium	02-Oct	08:00 - 09:00	Hall C	Speaker
Serratos	J. Spain	Platform Session	02-Oct	11:30 - 12:30	Hall D	Chair
Serratos	J. Spain	Session	02-Oct	14:30 - 16:00	Hall F	Chair/ Spkr
Shah	M. UK	ECE Forum	30-Sep	11:30 - 13:00	Hall C	Speaker
Shinnar	S. USA	ECE Forum	03-Oct	09:30 - 11:00	Hall G	Speaker
Shmuel	A. Canada	Session	03-Oct	14:30 - 16:00	Hall E	Speaker
Shorvon	S. UK	Special Session	01-Oct	14:30 - 16:00	Auditorium	Speaker
Shorvon	S. UK	Session	02-Oct	14:30 - 16:00	Hall E	Speaker
Shorvon	S. UK	Special Session	02-Oct	13:30 - 14:30	Auditorium	Chair/ Spkr
Shorvon	S. UK	ECE Forum	03-Oct	09:30 - 11:00	Hall G	Speaker
Shorvon	S. UK	Session	03-Oct	14:30 - 16:00	Auditorium	Speaker
Shorvon	S. UK	Special Session	03-Oct	11:30 - 12:30	Hall F	Chair/ Spkr
Sills	G. UK	Debate	02-Oct	11:30 - 12:30	Hall B	Speaker
Simonato	M. Italy	Session	02-Oct	11:30 - 13:00	Auditorium	Speaker
Singh	G. India	Session	01-Oct	07:45 - 09:00	Hall E	Chair
Siniatchkin	M. Germany	Satellite Symposium	03-Oct	08:00 - 09:00	Hall C	Speaker
Sisodiya	S. UK	Session	03-Oct	16:30 - 18:00	Hall D	Chair
Smith	P. UK	Chairs Symposium	01-Oct	09:00 - 11:00	Auditorium	Chair
Smith	P. UK	Olympiad	01-Oct	11:30 - 12:30	Hall B	Chair
Smith	P. UK	Debate	02-Oct	11:30 - 12:30	Hall B	Chair
Smith	P. UK	Olympiad	02-Oct	14:30 - 16:00	Hall B	Chair
Smith	P. UK	Olympiad	03-Oct	16:30 - 18:00	Hall B	Chair
Smith	P. UK	Epilepsy Course	04-Oct	15:15 - 16:35	Hall C	Chair
Smith	P. UK	Epilepsy Course	04-Oct	07:45 - 09:00	Hall C	Chair/ Spkr
Smith	P. UK	Epilepsy Course	04-Oct	13:30 - 14:50	Hall C	Chair
Smith	P. UK	Epilepsy Course	04-Oct	11:15 - 12:45	Hall C	Chair
Smith	P. UK	Epilepsy Course	04-Oct	17:15 - 18:45	Hall C	Chair
Smith	P. UK	Epilepsy Course	04-Oct	09:15 - 11:15	Hall C	Chair
So	E. USA	ECE Forum	04-Oct	09:00 - 10:30	Hall G	Speaker
Soares-da-Silva	P. Portugal	Platform Session	02-Oct	11:30 - 12:30	Hall C	Chair
Solomon	T. UK	Epilepsy Course	04-Oct	11:15 - 12:45	Hall C	Speaker
Somale	A. India	Platform Session	03-Oct	11:30 - 12:30	Hall C	Speaker
Specchio	N. Italy	ECE Forum	30-Sep	10:00 - 11:30	Hall D	Speaker
Spreafico	R. Italy	Session	03-Oct	07:45 - 09:00	Hall E	Chair/ Spkr
Staack	A. Germany	ECE Forum	01-Oct	09:00 - 10:30	Hall D	Speaker
Staba	R. USA	ECE Forum	30-Sep	11:30 - 13:00	Hall D	Speaker
Stead	M. USA	ECE Forum	30-Sep	11:30 - 13:00	Hall D	Speaker
Stefan	H. Germany	Satellite Symposium	02-Oct	10:30 - 11:30	Hall C	Speaker

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Stefan	H. Germany	Satellite Symposium	02-Oct	08:00 - 09:00	Hall C	Chair/ Spkr
Stefan	H. Germany	Session	02-Oct	07:45 - 09:00	Hall D	Chair
Steinhoff	B. Germany	ECE Forum	01-Oct	09:00 - 10:30	Hall D	Chair/ Spkr
Steinhoff	B. Germany	Satellite Symposium	01-Oct	16:30 - 18:00	Auditorium	Speaker
Steinhoff	B. Germany	ECE Forum	04-Oct	11:00 - 12:30	Hall G	Speaker
Steinhoff	B. Germany	ECE Forum	04-Oct	13:30 - 15:00	Hall F	Speaker
Steinhoff	B. Germany	ECE Forum	04-Oct	09:00 - 10:30	Hall E	Speaker
Steinlein	O. Germany	Debate	03-Oct	11:30 - 13:00	Hall D	Speaker
Stepanyan	T. Georgia	ECE Forum	04-Oct	13:30 - 15:00	Hall E	Chair
Stephani	U. Germany	Session	01-Oct	14:30 - 16:00	Hall F	Speaker
Striano	P. Italy	Special Session	02-Oct	14:30 - 16:00	Auditorium	Speaker
Tallis	R. UK	Olympiad	01-Oct	11:30 - 12:30	Hall B	Chair
Tallis	R. UK	Special Session	01-Oct	13:30 - 14:30	Auditorium	Chair/ Spkr
Tallis	R. UK	Olympiad	03-Oct	16:30 - 18:00	Hall B	Chair
Tan	I. Netherlands	Platform Session	02-Oct	11:30 - 12:30	Hall C	Speaker
Tassinari	C. Italy	Session	01-Oct	14:30 - 16:00	Hall F	Chair/ Spkr
Theodore	W. USA	Session	01-Oct	14:30 - 16:00	Hall D	Chair
Thomas	R. UK	Olympiad	01-Oct	11:30 - 12:30	Hall B	Chair
Tijssen	M. Netherlands	Chairs Symposium	01-Oct	09:00 - 11:00	Auditorium	Speaker
Tinuper	P. Italy	Chairs Symposium	01-Oct	09:00 - 11:00	Auditorium	Speaker
Tinuper	P. Italy	Session	02-Oct	07:45 - 09:00	Hall B	Speaker
Tomson	T. Sweden	Main Session	03-Oct	09:00 - 11:00	Auditorium	Speaker
Tomson	T. Sweden	ECE Forum	04-Oct	11:00 - 12:30	Hall D	Speaker
Tousseyn	S. Belgium	Platform Session	03-Oct	11:30 - 12:30	Auditorium	Speaker
Trevelyan	A. UK	ECE Forum	30-Sep	11:30 - 13:00	Hall G	Chair/ Spkr
Trinka	E. Austria	ECE Forum	30-Sep	10:00 - 11:30	Hall D	Speaker
Trinka	E. Austria	Platform Session	01-Oct	11:30 - 12:30	Hall G	Speaker
Trinka	E. Austria	Satellite Symposium	01-Oct	08:00 - 09:00	Hall C	Chair/ Spkr
Trinka	E. Austria	Debate	02-Oct	11:30 - 12:30	Hall B	Speaker
Trinka	E. Austria	ECE Forum	02-Oct	09:00 - 10:30	Hall G	Speaker
Trinka	E. Austria	ECE Forum	03-Oct	09:30 - 11:00	Hall G	Speaker
Trinka	E. Austria	Satellite Symposium	03-Oct	08:00 - 09:00	Hall C	Chair
Trinka	E. Austria	Session	03-Oct	14:30 - 16:00	Auditorium	Chair
Trinka	E. Austria	ECE Forum	04-Oct	09:00 - 10:30	Hall E	Speaker
Trinka	E. Austria	ECE Forum	04-Oct	11:00 - 12:30	Hall D	Speaker
Trinka	E. Austria	Epilepsy Course	04-Oct	17:15 - 18:45	Hall C	Speaker
Uusimaa	J. UK	Platform Session	02-Oct	11:30 - 12:30	Hall D	Speaker
Valenti	M. France	ECE Forum	04-Oct	13:30 - 15:00	Hall F	Speaker
Valenti	M. France	ECE Forum	01-Oct	09:00 - 10:30	Hall D	Speaker
Van Bogaert	P. Belgium	Session	01-Oct	14:30 - 16:00	Hall C	Chair
Van Nieuwenhuiz	O. Netherlands	Session	03-Oct	07:45 - 09:00	Hall D	Chair
Van Paesschen	W. Belgium	Satellite Symposium	01-Oct	18:30 - 20:00	Auditorium	Speaker
Vezzani	A. Italy	ECE Forum	30-Sep	11:30 - 13:00	Hall E	Speaker

SURNAME	COUNTRY	SESSION TYPE	DATE	TIME	HALL	ROLE
Vezzani	A. Italy	Session	02-Oct	07:45 - 09:00	Hall F	Speaker
Vezzani	A. Italy	Session	03-Oct	16:30 - 18:00	Hall F	Chair
Vigevano	F. Italy	ECE Forum	30-Sep	10:00 - 11:30	Hall D	Chair
Vigevano	F. Italy	Debate	01-Oct	11:30 - 12:30	Auditorium	Chair
Villani	F. Italy	Platform Session	03-Oct	11:30 - 12:30	Auditorium	Speaker
Villanueva	V. Spain	Satellite Symposium	02-Oct	16:30 - 18:00	Auditorium	Speaker
Vollmar	C. UK	Session	30-Sep	13:30 - 15:00	Hall D	Speaker
Vollmar	C. UK	Session	03-Oct	07:45 - 09:00	Hall F	Speaker
Vulliamoz	S. Switzerland	Satellite Symposium	03-Oct	08:00 - 09:00	Hall C	Speaker
Wagner	K. Germany	ECE Forum	04-Oct	13:30 - 15:00	Hall J	Speaker
Walker	M. UK	ECE Forum	30-Sep	11:30 - 13:00	Hall G	Speaker
Walker	M. UK	Session	02-Oct	11:30 - 13:00	Auditorium	Chair
Walker	M. UK	Special Session	03-Oct	13:30 - 14:30	Auditorium	Chair
Wang	Y. China	Epilepsy Course	04-Oct	07:45 - 09:00	Hall C	Chair
Weber	Y. Germany	Genetics 1	01-Oct	11:30 - 12:30	Hall C	Speaker
Wendling	F. France	ECE Forum	04-Oct	11:00 - 12:30	Hall H	Speaker
Wendling	F. France	ECE Forum	30-Sep	11:30 - 13:00	Hall G	Speaker
Wevers	R. Netherlands	Session	03-Oct	14:30 - 16:00	Hall D	Chair
White	S. USA	Main Session	02-Oct	09:00 - 11:00	Auditorium	Speaker
Whitehouse	W. UK	ECE Forum	02-Oct	10:30 - 11:30	Hall G	Speaker
Wiebe	S. Canada	Session	02-Oct	14:30 - 16:00	Hall D	Chair
Winston	G. UK	Main Session	03-Oct	09:00 - 11:00	Hall B	Speaker
Witt	J. Germany	Platform Session	02-Oct	11:30 - 12:30	Hall E	Speaker
Wolf	P. Denmark	Debate	03-Oct	11:30 - 13:00	Hall D	Speaker
Wolf	N. Netherlands	Session	03-Oct	16:30 - 18:00	Hall E	Speaker
Yadee	T. Thailand	Platform Session	02-Oct	11:30 - 12:30	Hall C	Speaker
Zara	F. Italy	Session	03-Oct	16:30 - 18:00	Hall D	Speaker
Zeman	A. UK	Session	01-Oct	07:45 - 09:00	Hall E	Speaker
Zhang	G. USA	ECE Forum	04-Oct	11:00 - 12:30	Hall E	Speaker
Zuberi	S. UK	Session	02-Oct	14:30 - 16:00	Hall F	Chair
Zuberi	S. UK	ECE Forum	04-Oct	13:30 - 15:00	Hall F	Speaker

## SPONSORS

The 10<sup>th</sup> European Congress on Epileptology acknowledges the support of the following companies

### PLATINUM SPONSOR



Eisai Europe Ltd.

### SPONSORS



Cyberonics



Electrical Geodesics, Inc.



Elekta



GlaxoSmithKline



NeuroSigma

### GOLD SPONSOR



UCB Pharma S.A.

### SILVER SPONSOR



ViroPharma

## SCIENTIFIC EXHIBIT


Eisai Europe Ltd. will hold a sponsored Scientific Exhibit of posters in the Capital Suite Room 13, near Halls C to G, for the duration of the congress.

## LIST OF EXHIBITORS

EXHIBITOR	STAND NUMBER
Ad-Tech Medical	94
Biocodex	112/118
Ciros Centrum	table
Compumedics Ltd	110
Cyberonics	90
Danish Care Technology	6
Desitin Pharma Ltd.	24
Dravet Syndrome UK	table
EB Neuro SpA	12
Eisai Europe Ltd	30 & 38 & 65 & 98
Electrical Geodesics, Inc.	70
Elekta	14
Epilepsy Action	82
Epilepsy Society	84
EURAP	102
GlaxoSmithKline	50
Grass-Technologies	26
Holberg EEG	22
International Bureau for Epilepsy	45
International League Against Epilepsy	45
John Libbey Eurotext	106
Lifelines	104
Matthew's Friends	83
Medtronic	35
Micromed	8
NeuroSigma	74
Neurotech	60
Nihon Kohden	2
Optima (Natus)	10
OSG-BrainRT	16
Qatar Airways	Registration
Special Products Ltd	4
The EMPIRE Collaboration	100
The Lancet/The Lancet Neurology	108
Tourisme Montréal	81
UCB Pharma sa	40
ViroPharma	85
Wiley-Blackwell	20
Wisepress Bookshop	32

### EXHIBITION OPENING HOURS

Monday 1st Oct	09:00 – 17:00
Tuesday 2nd Oct	09:00 – 17:00
Wednesday 3rd Oct	09:00 – 17:00
Thursday 4th Oct	09:00 – 12:00



# European Forum on Epilepsy Research

## DUBLIN 2013



Info: [Dublin@epilepsycongress.org](mailto:Dublin@epilepsycongress.org)

*An activity of Epilepsy Advocacy Europe,  
Joint European Task Force of ILAE and IBE.*



[www.EpilepsyResearchEurope.org](http://www.EpilepsyResearchEurope.org)



**PRESCRIBING INFORMATION**

Please refer to the SPC before prescribing.

**Presentation:** Film-coated tablets: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg perampanel.

**Indication:** Adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

**Dose and administration:** Adults and Adolescents: Starting dose is 2 mg daily. Dose should be titrated based on clinical response and tolerability by increments of 2 mg/day to a maintenance dose of between 4 mg/day to 12 mg/day. Dose should be taken orally once daily before bedtime. Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel should be titrated no more frequently than at 1-week intervals. Withdraw gradually.

**Elderly and patients with renal or hepatic impairment:** Dosage adjustments not required in elderly patients. Dosage adjustments not required in mild renal impairment, not recommended in patients with moderate or severe renal impairment or patients undergoing haemodialysis. Caution in mild or moderate hepatic impairment, titration should not be faster than every 2 weeks and maximum daily dosage not exceeding 8 mg. Not recommended in severe hepatic impairment.

**Children and adolescents under 12 years:** No data available.

**Contra-indications:** Hypersensitivity to perampanel or any excipient.

**Pregnancy:** Not recommended.

**Lactation:** Unknown if excreted into breast milk. A decision whether to discontinue breastfeeding or to discontinue/abstain from Fycompa therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

**Warnings and Precautions:** Monitor for signs of suicidal ideation and behaviours and consider appropriate treatment. Perampanel may cause dizziness and somnolence and therefore may influence the ability to drive or use machines. At doses of 12 mg/day, Fycompa may decrease the effectiveness of progestative-containing hormonal contraceptives. There appears to be an increased risk of falls, particularly in the elderly. Cases of aggression have been reported and dose titration should be followed; a dose reduction should be considered in case of persistence of aggressive symptoms. Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of perampanel abuse. Patients should be closely monitored for tolerability and clinical response when adding or removing cytochrome P450 inducers or inhibitors, or switching from concomitant non-inducer anti-epileptic medicinal products to enzyme inducing medicinal products and vice versa, since perampanel plasma levels can be decreased or increased; the dose of perampanel may need to be adjusted accordingly. There are no data regarding the effects of withdrawal of concomitant anti-epileptic medicinal products to achieve monotherapy with perampanel. Fycompa contains lactose, therefore patients with rare hereditary problems of galactose intolerance, the Lapp

lactase deficiency or glucose-galactose malabsorption should not take this medicine.

**Drug Interactions:** The possibility of decreased efficacy of progestative-containing oral contraceptives should be considered for women needing Fycompa 12 mg/day and an additional reliable method (intra-uterine device (IUD), condom) is to be used. Carbamazepine, phenytoin, oxcarbazepine and topiramate have been shown to increase perampanel clearance and consequently to decrease plasma concentrations of perampanel. Fycompa did not affect in a clinically relevant manner the clearance of clobazepam, levetiracetam, phenobarbital, phenytoin, topiramate, zonisamide, carbamazepine, clobazam, lamotrigine and valproic acid. The effect of perampanel on monohydroxycarbamazepine concentrations is not known. Fycompa (6 mg once daily for 20 days) decreased midazolam AUC by 13% in healthy subjects. Strong inducers of cytochrome P450, such as rifampicin and hypericum, are expected to decrease perampanel concentrations. Felbamate has been shown to decrease the concentrations of some drugs and may also reduce perampanel concentrations. Ketoconazole, a CYP3A4 inhibitor, increased perampanel AUC by 20% and prolonged perampanel half-life by 15%. Strong inhibitors of other cytochrome P450 isoforms could potentially also increase perampanel concentrations. Fycompa, used in combination with other central nervous system (CNS) depressants such as alcohol, can increase levels of anger, confusion, and depression. The effects of perampanel on tasks involving alertness and vigilance, such as driving ability, were additive or supra-additive to the effects of alcohol. **Side effects:** Adverse reactions most commonly lead to discontinuation of perampanel were dizziness and somnolence. Refer to SPC for all side effects. Very common effects ( $\geq 1/10$ ): dizziness, somnolence. Common effects ( $\geq 1/100$ ,  $< 1/10$ ): decreased appetite, increased appetite, aggression, anger, anxiety, confusional state, ataxia, dysarthria, balance disorder, irritability, diplopia, vision blurred, vertigo, nausea, back pain, gait disturbance, fatigue, weight increased, falls. Based on the clinical trial database of 143 adolescents, the frequency, type, and severity of adverse reactions in adolescents are expected to be the same as in adults.

**Legal Category:** POM **Basic UK NHS cost:** Fycompa 2 mg, packs of 7 £35.00, Fycompa 4 mg, packs of 7 £35.00, packs of 28 £140.00, Fycompa 6 mg, packs of 28 £140.00, Fycompa 8 mg, packs of 28 £140.00, Fycompa 10 mg, packs of 28 £140.00, Fycompa 12 mg, packs of 28 £140.00

**Marketing authorisation numbers:** Fycompa 2 mg 7 tablets: EU/1/12/776/001, Fycompa 4 mg 7 tablets: EU/1/12/776/002, Fycompa 4 mg 28 tablets: EU/1/12/776/003, Fycompa 6 mg 28 tablets: EU/1/12/776/006, Fycompa 8 mg 28 tablets: EU/1/12/776/009, Fycompa 10 mg 28 tablets: EU/1/12/776/012, Fycompa 12 mg 28 tablets: EU/1/12/776/015. **Marketing authorisation holder:** Eisai Ltd. **Further information from/Marketed by:** Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN

Adverse events should be reported. Reporting forms and information can be found at <http://www.mhra.gov.uk/yellowcard>. Adverse events should also be reported to Eisai Ltd on 0208 600 1400/0845 676 1400 or EUmedinfo@eisai.net